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1.1 Central nervous system development 
 
 The development of the nervous system during the evolutionary 
process was fundamental for the emergence of organisms with better adaptive 
capacity of perception and interaction with the environment1. The increase of 
somatosensory, visual and auditory information led to the development of a 
neocortex containing increasingly efficient neural sensory and motor 
maps1,2,3. Intelligence brought the need for increased energy and a bigger 
brain. However, an advanced brain required more time to develop and the 
organism needed prolonged maternal care4.  
 The early development of the central nervous system (CNS) in 
humans consists of two stages: (1) the embryonic period, which comprises 
the first eight weeks after ovulation, and (2) the fetal period, which extends 
from the ninth week until birth3. Rodents, such as mice and rats, have a shorter 
gestational period, between 19 and 21 days6. For this reason, the term 
"embryo" is used to define all prenatal stages of rodent development between 
fertilization and birth, with the embryonic (E) stage of development indicated 
by gestational age, and with fertilization counted as E0, approximately 0.5 
day after mating7. Compared with human staging, the first two-trimesters of 
gestational development extend from embryonic day (E) 0 to E14.5 in mice 
and E16.5 in rats, whereas the last fetal trimester ranges from E15-17 to 
postnatal day (P) 10 in mice6,7. 
 The CNS arises with the formation of the neural tube during the third 
week of gestation, between E20-28 in humans8 and E8 in mice1. The neural 
tube is the structure that gives rise to the brain and spinal cord1,9. The neural 
tube grows, contorts and transforms into a structure composed of three 
dilatations (known as primary brain vesicles: prosencephalon, 
mesencephalon and rhombencephalon) and these expansions will give rise to 
the main anatomical structures of the adult individual9 (Fig. 1A). The rostral 
vesicle is called the forebrain and gives rise to the telencephalon and 
diencephalon, and these, in turn, will give rise to the cerebral cortex, 
thalamus, hypothalamus and neurohypophysis10. The middle vesicle, the 
midbrain, will give rise to the cerebral peduncles and the quadrigeminal 
blade. Finally, the hindbrain will give rise to the metencephalon and 
myelencephalon, which in turn will form the cerebellum, pons, and medulla 
oblongata11 (Fig. 1B). The development of the brain continues after the 
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postnatal period with an increase in size and also connectivity, and these 
changes in functional organization are reflected in behavior12,13,14,15.  
Fig. 1. Embryonic brain development. (A) Following neural tube closure, the 
embryo begins to expand anteriorly, and the primary vesicles appear in human 
around E28. These include the Prosencephalon, Mesencephalon, and 
Rhombencephalon. (B) Around E49 secondary vesicles start to emerge. The 
Prosencephalon is differentiated into the Telencephalon and the Diencephalon, and 
the Rhombencephalon into the Metencephalon and Myelencephalon. Adapted from 
Biga et al.214. 
  
 The cerebral cortex is derived from the embryonic telencephalon and 
consists of a layer of gray matter, which forms a complex pattern of grooves 
and turns. This is to maximize the surface area of the cerebral cortex, of which 
70% is hidden in the furrow depth16,17. The cerebral cortex is largely 
responsible for conscious information, thought, memory, and intellect19. It is 
also related to the organization of movement and to the strategic orientation 
of complex behaviors over time20. The growth of the neocortex during 
evolution can be characterized as a true phylogenetic explosion, because its 
neural architecture is different and probably more sophisticated or organized 
to accommodate more elaborate cognitive functions, which are higher in 
humans than in any other animal species18,19. 
 
1.1.1 Corticogenesis 
 
 The laminar organization of the neocortex is formed during embryonic 
development21. The neurons destined for different layers of the cerebral 
cortex are generated from progenitors located in the ventricular (VZ) and 
subventricular (SVZ) zones of the dorsal telencephalon, being excitatory21, or 
from progenitors located in the ganglionic eminence (GE) of ventral 
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telencephalon which are inhibitory neurons22. The neural progenitors can 
divide to form two other progenitor cells (symmetric cell division), or a 
progenitor cell and a neuron (asymmetric cell division)25,26,27. The shift from 
symmetric to asymmetric cell division is gradual until the end of 
neurogenesis21,23,24, and controlled by intrinsic and extrinsic cell signaling 
pathways28,29,30. In contrast, the glial progenitor cells proliferate in the SVZ 
of the forebrain and migrate into the white matter and cortex, striatum and 
hippocampus, where they differentiate into oligodendrocytes and 
astrocytes31. 
 Distinctly organized migratory movements are responsible for the 
proper positioning of the neurons in the correct cortical layer. There are two 
types of migration in the cortex: radial and tangential31,32,33. In radial 
migration, the neurons produced in the cortical VZ and SVZ move radially 
from the progenitor zone to the surface of the brain with a scaffold of radial 
glial cells32,33. The radial glial cells are a special and transient progenitor cell 
population that can support the migration of many neurons as well as give rise 
to neurons34. In contrast, cortical inhibitory interneurons cross long distances 
using a tangential migration mode33. This route of migration crosses the 
contour of the development of the cortical mantle tangentially and originates 
in the GE35,36. Tangential migration involves a variety of signaling pathways 
not seen in radial migration, but both migratory movements are also guided 
by Cajal-Retzius (CR) cells, situated in the outer marginal zone (MZ), 
through reelin glycoprotein signaling36,37. 
 Neurons use a series of guidance molecules produced locally along 
their migratory route to direct their movements to the cortex, resulting in an 
organized six-layered structure (Fig. 2)38. The neuronal cortical stratification 
occurs via the inside-out principle and the first layer to emerge is the deepest 
layer VI39. In mice, the generation of deep cortical neurons of layer VI has its 
peak around E12, whereas those of layer V have their peak at E13. Neurons 
of the granular layer IV arise mainly on E14 and the superficial cortical 
neurons of layers II and III arise around E15-1621,40. Around P4 in rodents, 
all six cortical layers have been formed40. 
 The first layer, known as the molecular layer, consists of apical 
dendrites of pyramidal cells from other layers and CR cells, which are largely 
derived from the pallium and septum41. The superficial layers II/III contain 
small dense clusters of pyramidal neurons and receive afferents from other 
cortical layers21. Layer IV tends to be thick in the primary sensory cortex and 
becomes thin in the motor cortex and prefrontal cortex (PFC)42, being a 
granular layer rich in interneurons that extend their projections locally to the 
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cortex and receive thalamic afferents43. Layer V contains a large number of 
pyramidal neurons and is the main source of subcortical efferent fibers and 
especially well developed in the motor cortex43,44,45. The axons of pyramidal 
neurons exit the cortex and descend through the internal capsule to targets in 
the brainstem and spinal cord and extend to the contralateral hemisphere44. 
Finally, layer VI is considered the most morphologically diverse as it receives 
thalamic and cortical afferents46 (Fig. 2 and 3). 
Fig. 2. Stages of corticogenesis. Progenitors generate neurons destined for different 
cortical layers over time. The newborn cells migrate radially and tangentially guided 
by soluble factors, such as reelin, to the appropriate cortical position where they 
undergo differentiation and maturation forming a complex stratified neural network 
and express different combinations of transcriptional factors. Adapted from Mukhtar 
and Taylor215. 
 
 Cortical specification is determined by a combinatorial code of gene 
expression profiles that will result in distinct cortical regions, such as frontal, 
motor, sensory or visual21. Molecular mechanisms, each involving a 
combination of proteins at varying concentrations, control the regional 
differentiation of neuronal populations40,47. For example, in the proliferative 
zones a combination of the transcription factors Emx2, Pax6, Coup-TF1 and 
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SP8 is dynamically expressed49,51,52,53. In the normal mouse brain, Emx2 is 
expressed at high concentrations in the caudal-medial areas, while Pax6 is 
highly expressed in rostral-lateral areas49,50 (Fig. 4A). The combination of low 
levels of Emx2 and high levels of Pax6 induces the motor cortex, while the 
opposite combination of concentrations induces the visual cortex, and equal 
levels of both proteins induce the somatosensory cortex49,50. In Emx2-/- mutant 
mice, the Pax6 concentration gradient extends more dorsally. Due to this, the 
visual areas shrink and the motor areas expand51 (Fig. 4B). The opposite effect 
is found when Pax6 expression is suppressed, in response to this the gradual 
Emx2 expression extends frontally, the visual areas expand and the areas of 
the motor cortex shrink50,51 (Fig. 4C). 
Fig. 3. Prefrontal cortex connections and projections. Layer I: Molecular layer 
contains few neurons and extensions of apical dendritic tufts of pyramidal neurons 
and horizontally oriented axons that project locally, as well as glial and CR cells, 
and receive inputs from thalamus. Layer II: External granular layer contains stellates 
neurons and small pyramidal neurons that project locally. Layer III: External 
pyramidal layer with small and medium pyramidal neurons projecting inter-
hemispheric corticocortical. Layer IV layer, Internal granular layer, contains 
different types of stellates and pyramidal cells and receives thalamic projections. 
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Layer V, Internal pyramidal layer contains large pyramidal neurons and connects 
with subcortical structures as internal capsule, basal ganglia, thalamus, brain stem 
and spinal cord. Layer VI layer: Multiform layer contains pyramidal and multiform 
neurons that project to the thalamus, establishing a very precise reciprocal 
interconnection between the cortex and the thalamus. Adapted from DeBoer et al.216.  
 
 In cortical layers, dynamic expression of transcription factors is again 
implicated, in this case in determining the neuronal phenotype. For example, 
Tbr1, Fezf2 and Ctip2 are involved in the specification of deep layer 
neurons45. Tbr1 specifically regulates the differentiation of layer VI and 
subplate, and its absence induces cell loss in this layer55. Mutant Fezf2-/- and 
Ctip2-/- animals show a depletion in motor neurons and axon loss in frontal 
neurons in layer V, respectively56,45. On the other hand, the transcription 
factors Cux1, Cux2, Brn1 and Satb2 are expressed in the initial stages of 
neuron specification of superficial layers54,57. Satb2 confers characteristics to 
subcerebral, corticothalamic and callosal projection neurons, while the 
soluble morphogens Fgf8 and Wnt control the relative size and position of 
these cells58. Furthermore, the depletion of Pax6 or Brn1 causes a reduction 
in neuron generation in the cortical superficial layers59. In turn, interneurons 
can fill all cortical layers depending on chemotactic stimuli, and the final 
location and specification in parvalbumin, somatostatin and vasoactive 
intestinal peptide (VIP) interneurons are defined by Dlx1/2, Nkx2.1 and 
Lhx662. 
 
Fig. 4. The effects of different 
concentrations of Emx2 and 
Pax6 on the development of 
cortical areas. (A) Normal 
patterns of frontal and dorsal 
gradual expression of Emx2 
and Pax6. (B) Effects of a 
mutation of Emx2 causing 
expansion of the sensorimotor 
areas and shrinkage of the 
visual area. (C) Effects of a 
Pax6 mutation demonstrating 
sensorimotor area shrinkage 
and visual area expansion. 
Adapted from Bishop et 
al.49,50. 
 
 
 
19 
 
 The next stages of corticogenesis involve the non-pathological loss of 
neural elements, through naturally occurring programmed cell death and 
synaptic pruning, which eliminate transient cell populations such as MZ or 
SP cells, promote synaptic refinement and correct possible errors in the 
cortical organization63,64,65. Naturally occurring cell death arises in neuronal 
populations even during the prenatal period and extends to the end of 
corticogenesis, whereby about 70% of neuronal loss can occur in cortical 
regions66. Pruning of extra connections occurs predominantly postnatally65. 
Both processes are controlled by neurotrophic factors derived from neurons 
or other brain cell types such as microglia, astrocytes and oligodendrocytes, 
and represent axonal integrity and neural survival signals67. 
 Finally, the last stage of corticogenesis involves neuronal myelination 
that begins around E19 in mice, when the oligodendrocyte begins to 
differentiate and increases the expression of myelin extending its processes 
towards the neuronal axon68. The increase in axonal conduction velocity and 
synaptic refinement is indicative of neuronal maturation69.  
 In summary, the dynamic processes of proliferation, glial and 
neuronal specification and migration, followed by differentiation, cell death, 
and maturation are largely prenatal (except for synaptic pruning and neuronal 
myelination) and essential for the correct cortical organization21,70 (Fig. 2). 
These cortical events are controlled by intrinsic factors consisting of a 
complex program of expression of transcription factors and neurotrophic 
factors, combined with extrinsic factors that involve signaling of afferents 
from other noncortical regions as well as local guidance. 
 
1.1.2 PFC development 
 
 From an evolutionary point of view, the PFC is the most recent brain 
structure. In human, the PFC comprises 29% of the cortical surface, consists 
of a large variety of cells, and is conventionally divided into six layers3,4,6,17. 
The relatively large size of the human PFC presumably indicates that the 
cortex is the substrate for higher-order cognitive functions6. In rodents, a 
major division of the PFC involves the ventromedial area, which can be 
subdivided into the cingulate, prelimbic and infralimbic cortex71,72,72. The 
PFC receives projections from cortical, sensory, motor and limbic areas74. 
The connections with temporal and parietal areas are associated with 
cognitive functions, whereas connections with the amygdala and 
hippocampus are linked to emotions and memory72. Most prefrontal areas 
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have six layers, including a granular IV layer, except for the orbitofrontal and 
posterior mediastinal areas, and belong to the cortical-limbic system1. 
 Magnetic resonance imaging has shown that human PFC development 
is characterized by growth in early childhood, a decrease in size in 
adolescence, and then a slight increase and stabilization in adulthood84, 
followed by a decline in the volume of gray matter and an increase in white 
matter volume81,82. Cortical gray matter reaches its maximum volume in the 
frontal lobe between the ages of 11 and 12 years, being lately in the 
chronological development, when compared to other areas87,86. This contrasts 
with the cortex as a whole, where gray matter increases mainly from infancy 
to age 6 to 9 years86. During this period of brain development, the dorsolateral 
and medial PFC expands almost twice as much as some other dorsal regions, 
but mature late in relation to a large part of the remaining cortex of the 
sensory-motor regions and other81. It is believed that this pattern is linked to 
the maturation of cortical circuits underlying complex frontal lobe 
functioning, including language, decision making, attention control, and 
memory84,85,86. 
 
1.2 Serotonergic and dopaminergic system development 
 
1.2.1 Serotonergic system development and impact on mPFC 
development 
 
 Serotonin (5-hydroxytryptamine or 5-HT) is a monoamine 
neurotransmitter and neurotrophic factor that affects brain functioning from 
emotions to motor skills88. In animals, 5-HT is synthesized from the amino 
acid L-tryptophan by a metabolic pathway consisting of the enzymes 
tryptophan hydroxylase (TH), aromatic amino acid decarboxylase (AADC) 
and pyridoxal phosphate coenzyme88,89, and was isolated from serum for the 
first time in 194890.   
 During brain development, the serotonergic system emerges in the 
brainstem with a group of cells that will form the raphe nuclei91, between 
E9.5-E12 in mice (E10.5-E13 in rats) and from the fifth to the seventh week 
of gestation in humans91,92. This system is tightly controlled by a complex of 
signaling and gene regulatory networks, such as sonic hedgehog (Shh) 
signaling and the Nkx2-2/Lmx1b/Pet1 cascade93. However, brain synthesis of 
5-HT contributes to its PFC levels only around E14. Prior to this 
developmental time point the PFC receives 5-HT via the placenta or 
myenteric plexus94, from E10-E11 until E18, when the cerebral serotonergic 
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nucleus is developed, and it is able to supply the whole brain94. The raphe 
nuclei are grouped into nine clusters: the caudal division (B1-B4, including 
pale raphe, obscurus, magnus and pontis), the rostral division (B9), the dorsal 
division (B6, B7) and the median division (B5, B8), with the last two 
divisions projecting to the PFC88,95. The proportion of serotonergic neurons 
varies from 50% in the dorsal raphe (DRN) nuclei to 21% in the raphe median 
(MRN), 19% in rostral (RRN) and less than 10% in the raphe caudal 
(CRN)96,97 (Fig. 5A). 
Axons from the serotonergic neurons of the raphe nuclei send their 
projections to the frontal targets and reach the PFC, via the septum and 
internal capsule, around E14 in mice (E16 in rats), but only around E16 they 
reach the mPFC98 (Fig. 5B). In the mPFC, the serotonergic axons are initially 
divided into two major bundles98,99. The first bundle present in the MZ is in 
close proximity to CR cells, which may control the release of reelin and also 
guide neuronal migration and organization100,101,102. The second bundle is 
found below the CP, especially in the IZ and SP, where proliferating and 
migrating cells are located98,102. At the end of corticogenesis, the serotonergic 
axons gradually broadcast by sending numerous branches to the CP103,104. 
Serotonergic axons then progressively distribute uniformly in different 
cortical subdomains. However, only at PND28 serotonergic neurons show 
their mature pattern of innervation105. Factors regulating serotonergic axon 
growth and final innervation pattern may involve S-100, a protein secreted by 
astrocytes, which acts as a guidance molecule for the migration of raphe 
neurons103,104,105. 
 Cortical layers IV and V receive inputs from DRN which are 
anatomically thin and exhibiting numerous branches with varicosities102. In 
contrast, MRN projections are characterized by large spherical varicosities 
that can form true chemical synapses102,106. They preferentially forage into 
layer I and the lower white matter, and surround the neuronal cell bodies and 
proximal dendrites, and preferentially contact interneurons102,103,106. In the 
embryonic and mature mPFC, infralimbic and prelimbic cortex neurons also 
send their afferent projections to the raphe nuclei, and thereby control 
serotonergic release in a feedback mechanism, via serotonin 
autoreceptors107,108. 
  Acting on postsynaptic and presynaptic receptors, 5-HT is involved in 
cognition, mood, impulse control, and motor functions109. It modulates the 
activity of different types of neurons and influences the release of other 
neurotransmitters such as glutamate, GABA, acetylcholine, and dopamine103. 
In addition, 5-HT seems to play an important role in cortical development by 
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controlling cell proliferation, migration, organization through signaling via 
CR cells, apoptosis and neuronal maturation102,110, thus demonstrating the 
important neurotrophic role of 5-HT in cortical development in critical events 
that will last until adulthood. 
Fig. 5. Development of the serotonergic system and its mPFC projections. (A) 
Sagittal sections of developing brain demonstrating the proliferative onset of cells, 
in the hindbrain region, that will form the raphe nuclei at E10.5. Its serotonergic 
afferents will innervate the forebrain. (B) Cortical development in relation to 5-HT 
sources. Corticogenesis begins from embryonic day E10-11 through an intense 
proliferation of progenitor cells located in the VZ that will give rise to glutamatergic 
cells. Around E16.5, serotonergic afferences reach the sub-domains of mPFC in two 
bundles, one in MZ and one under SP, and make connections with CR, interneurons 
and proliferating cells. With layering and differentiation and cortical maturation, 
serotonergic innervation is distributed evenly across the layers. Layers V and VI 
preferably receive afferents from the dorsal raphe (B6, B7), while layer I receives 
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afferents, mainly from the median raphe (B5, B8). Midbrain (Mid), Hindbrain 
(Hind), Telencephalon (Tel), Cortex (Ctx), Striatum (Str),  Medial forebrain bundle 
(MFB), Raphe nucleus (RN), Prelate (PP), Subventricular zone (SVZ), Ventricular 
zone (VZ), Cortical plate (CP), Subplate (SP), Intermediate zone (IZ), White matter 
(WM). (1) Medial raphe (B5, B8), (2) Raphe rostral (B9), (3) Raphe caudal (B1-B3), 
(4) Dorsal raphe (B6, B7). Adapted from Vitalis and Parnavelas102, and Niederkofler 
et al.117.  
 
1.2.2 Dopaminergic system development and its relation to the mPFC 
 
  DA (or 3,4-dihydroxyphenethylamine) is a neurotransmitter and 
neurotrophic factor from the family of catecholamines that plays several 
important roles in the brain and body111,113. DA is synthesized from the 
essential amino acid phenylalanine and from the non-essential amino acid 
tyrosine111,112. DA itself also acts as a precursor in the synthesis of the 
neurotransmitters noradrenaline and epinephrine112. 
 During development, dopaminergic progenitors are generated in the 
mesencephalon around E10 in mice and E12 in rats116,117,118. Expression of 
TH is the first sign of acquisition of the dopaminergic neuronal phenotype 
and occurs shortly after the final mitosis of the dopaminergic neural 
progenitors, starting at E11.5, while they are actively migrating to their final 
positions119,120,121,122. In the adult brain, dopaminergic neurons are a 
heterogeneous group of cells located in the midbrain, diencephalon and 
olfactory bulb113. The dopaminergic neurons from midbrain send axonal 
projections to the PFC areas, and these cells are located in the retrorubral field 
(RRF, A8), compact substancia nigra (cSN, A9) and ventral tegmental area 
(VTA)114,115.  
 Starting at E11.5, dopaminergic neurons extend their axons frontally 
through the striatum, amygdala, septum and PFC, where the mesolimbic and 
mesocortical routes originate114,123, the axons reach the PFC, in E14 in mice, 
but only E16 in the mPFC114 (Fig. 6A). Distributed in two main bundles, one 
in MZ where CR cells are, and the second bundle in CP and SP124. Due to its 
proximity to CR cells, DA also participates in important stages during 
corticogenesis including neuronal migration, and also plays an important role 
during neuronal differentiation125,126 (Fig. 6B). 
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Fig. 6. Development of the dopaminergic system and its projections to the PFC. 
(A) Time point development of the origin of dopaminergic system in sagittal cuts. 
Cells located in midbrain send their projections to frontal targets around E10.5. 
These cells travel via the medial forebrain bundle and the striatum and arrive in the 
PCF around E14. (B) Development of mPFC in relation to dopaminergic innervation. 
Around E16.5, the axonal projections coming mainly from VTA and SN arrive at 
MZ and SP. It can thus stimulate and organize the neuronal migration via CR in the 
MZ and induce cell proliferation in proliferative zones. After maturation the 
dopaminergic system is distributed throughout all cortical layers thus making 
synapses with different cell types, both excitatory and inhibitory. Subventricular 
zone (SVZ), Ventricular zone (VZ), Midbrain (Mid), Hindbrain (Hind), 
Telencephalon (Tel), Cortex (Ctx), Striatum (Str), Medial forebrain bundle plate 
(MFB), Subplate (SP), Intermediate zone (IZ), White matter (WM). (1) Ventral 
tegmental area (VTA), (2) Substance nigra (SN). Adapted from Prestoz et al.114 and 
Niederkofler et al.117. 
 
 In the early postnatal days, the density and morphology of 
dopaminergic fibers increases117. The excitatory dopaminergic receptors D1 
and D5 or inhibitory D2, D3 and D4 are overproduced in early adolescence, 
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followed by pruning that is more evident in the subcortical than pre-frontal 
regions127,128. The net effect of increased dopaminergic projection to the PFC 
with less pruning is a change in the relative balance between subcortical and 
cortical dopaminergic systems with dominance of the mesocortical 
dopaminergic system, especially through pyramidal neurons in memory 
tasks127,129. In summary, DA is responsible for significant changes in cortical 
development and neural circuits involved in emotional and cognitive 
regulation, from the embryo to childhood, adolescence and the adult brain. 
 
1.2.3 Serotonin and dopamine interrelationship 
 
 During brain development, the serotonergic and dopaminergic 
systems reside close to each other, are influenced by a set of intercellular 
signaling factors, receive afferent input from the same brain regions, and send 
efferent projections to common targets, such as the mPFC, and in a similar 
time window. These data suggest an interrelationship between these two 
systems102,117,130,131. In addition, there are connections between serotonergic 
nuclei (DRN and MRN)132 and dopaminergic nuclei (VTA, SN), specially 
through GABAergic interneurons133 (Fig. 7). 
 The support for such an interaction is provided by experiments in 
which one of the systems is chemically or genetically damaged pre- or 
perinatally (Table 1)117. 5-HT seems to inhibit and oppose dopaminergic 
activity, particularly in relation to the role of DA in aggressive and impulsive 
behaviors117,137,138. When dopaminergic neurons are damaged in their supply 
of VTA and SN, they actually cause lesions in the serotonergic system, both 
at the molecular/cellular and behavioral levels134,135. Chemical ablation of the 
dopaminergic neurons causes disturbances in the serotonergic innervation of 
the mPFC126. In contrast, it appears that dopaminergic innervation of the 
mPFC is suppressed by serotonergic signaling, since neonatal chemical 
damage of serotonergic DRN neurons led to an increase in dopaminergic 
fibers in the mPFC136. The relative imbalance in serotonergic-dopaminergic 
activity during the final phase of cortical development may explain situations 
of increased sensitivity, resulting in a higher prevalence of risk behaviors139. 
The interaction between the monoaminergic and catecholaminergic neuronal 
systems, both during perinatal development and in the adult organism, 
generates a developmental window of vulnerability that extend to the field of 
psychiatric illness130. 
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Fig. 7. Interrelationship between DA and 5-HT system development. Drawings in 
a sagittal view of mouse brain show the anatomically proximity of the source of 5-
HT (orange) and DA (magenta) systems, as well as the parallel projection targets in 
embryonic and adult stage. Midbrain (Mid), Hindbrain (Hind), Telencephalon (Tel), 
Cortex (Ctx), Striatum (Str), Medial forebrain bundle (MFB), Prelate (PP), 
Subventricular zone (SVZ), Ventricular zone (VZ), Cortical plate (CP), Subplate 
(SP), Intermediate zone (IZ), White matter (WM). Ventral tegmental area (VTA), 
Substancia nigra (SN). Raphe pallidus (B1), Raphe obscurus (B2), Raphe magnus 
(B3), Dorsal raphe (B7, B6, B5), Median raphe (B8, B5) and Rostral raphe (B9). 
 
Table1  
Pharmacological interrelations between Serotonin (5-HT) and 
Dopamine (DA) in treatment strategies of mental disorders 
 
Drug 
 
Drug target 
Drug effect on 5-HT 
levels or 5-HT neurons 
                 
Ref 
 
           Dopamine 
 
Nonspecific DA 
receptor agonist 
 
Increased mPFC 5-HT levels 
Petty et al., 
1994
217 
 
 
 
Apomorphine 
Nonspecific DA 
receptor agonist, used 
systemic 
Increased DRN 5-HT 
release; increased 5-HT 
neutron firing rate. 
Aman et al., 
2007.
218
Lee 
EH, 
1987.
219
Mar
tin-Ruiz et 
al., 2001.
220 
 Nonspecific DA 
receptor agonist, used 
systemic, local mPFC 
Increased mPFC 5-HT levels Petty et al., 
1994.
 217 
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Drug 
 
Drug target 
Drug effect on 5-HT 
levels or 5-HT neurons 
                 
Ref 
 
Haloperidol 
D2-like receptor 
antagonist; used 
systematic 
Decreased in basal DRN 5-
HT levels  
Martín-Ruiz 
et al. 
2001.
220 
 D2-like receptor 
antagonist; local mPFC 
Increased mPFC 5-HT levels Petty et al., 
1994.
 217 
SSRI in 
combination with 
methylphenidate 
 
5-HT reuptake 
inhibitor 
 Increased in PFC DA release 
compared to methylphenidate 
alone; no such effect in the 
nigrostriatal pathway 
Weikop et 
al., 2007.
 221 
DRI Dopamine reuptake 
inhibitor  
Increased extracellular DA 
levels; increased 5-HT 
neuron firing rate 
Guiard et al., 
2009.
 222
 
TRI Triple reuptake 
inhibitor  
Increased extracellular levels 
of all monoamines; 
incomplete suppression of 5-
HT neuron activity, in 
contrast to SSRIs alone  
 
Guiard et al., 
2009. 
222 
mPFC, medial prefrontal cortex ; SNc, substantia nigra pars compacta; DRN, dorsal 
raphe nucleus. Adapted from Niederkofler et al117. 
 
1.3 Brain disorders 
 
1.3.1 Brief history of the role of the brain in mental illness 
 
Many cultures have seen brain disorders as a form of religious 
punishment or demonic possession. In ancient Egyptian, Persian, Greek, and 
Roman writings, mental illness was categorized as a religious problem140,142 
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(Fig. 8). In the fifth century BC, 
Hippocrates by using medication and 
change of environment, was the first to 
be able to treat mental illness without 
religious techniques 141,142. During the 
Middle Ages, it was believed that the 
mentally ill were possessed or in need 
of religion. Negative attitudes toward 
mental illness persisted until the 
eighteenth century, leading to the 
stigmatization of the disease and 
unhygienic (and often degrading) 
confinement of mentally ill 
individuals142. In the 1840s, activist 
Dorothea Dix lobbied for better living 
conditions for the mentally ill after 
witnessing the dangerous and 
unhealthy conditions in which many 
patients lived143. This model of 
institutional hospitalization, in which 
many patients lived in hospitals and 
were treated by professionals, was 
considered the most effective way of 
caring for the mentally ill until then141, 
also well-received by families and 
communities who struggled to care for 
mentally ill relatives143. Even 
providing access to mental health 
services, state hospitals were often 
underfunded and accused of poor 
living conditions and violation of 
human rights. This led to ambulatorial 
treatment, especially after the development of antipsychotic drugs, in the mid 
1950s144. Deinstitutionalization efforts reflected a broad international 
movement to reform mental health, based on the belief that psychiatric 
patients would have a better quality of life if treated in their communities 
rather than in large, undifferentiated and isolated mental hospitals145.     
Although large psychiatric hospitals are still common in some countries, 
particularly in Central and Eastern Europe, the deinstitutionalization 
Fig. 8. Mental disorders. Watercolor 
drawing of an anatomy book from 1488 
in Persia. Demonstrates beliefs about 
the correspondences between certain 
forms of mental illness and specific 
parts of the body. Source: Tashrih al-
Badan, 1488. The National Library of 
Medicine142. 
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movement has been widespread, drastically changing the nature of modern 
psychiatric care141,144. But what is a mental disorder? 
A mental disorder is a dysfunction in the developmental, 
psychological or biological processes underlying brain function145. Clinically 
this dysfunction culminates in a syndrome characterized by disordered 
emotional regulation, cognition or behavior of an individual147. There are 
many different categories of mental disorders involving behavior and 
personality. According to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) of the American Psychiatric Association, the list of major 
disorders includes anxiety disorder such as panic syndrome, generalized 
anxiety, stress, or phobia; bipolar disorder, which alternates periods of 
depression and periods of mania; depressive disorders, in which there are 
various types of depression; obsessive-compulsive disorder (OCD); psychotic 
disorders, such as schizophrenia or delusional disorder; eating disorders, such 
as anorexia or bulimia; post-traumatic stress disorder (PTSD); personality 
disorders, such as paranoid, antisocial, borderline, histrionic or narcissistic 
types; disorders related to the use of substances, such as illicit drugs, alcohol, 
drugs or cigarettes; neurocognitive disorders, such as delirium, Alzheimer's 
or other dementias, and finally neurodevelopmental disorders, such as 
intellectual disabilities, communication disorders, autism spectrum disorder 
(ASD) and attention deficit hyperactivity disorder (ADHD)145,146,147. 
 
1.3.2 The roles of 5-HT and DA in brain disorders 
 
 In addition to higher order cognitive functions and emotional 
regulation, the cerebral cortex integrates sensory and motor cortex through a 
complex neural network148. Precisely timed construction disturbances of the 
PFC, during development, affect the cortical structure and may confer risk for 
various neuropsychiatric disorders149,150. The involvement of 5-HT and DA 
in critical components of corticogenesis, including proliferation, migration of 
neurons and glia cells, with differentiation including adequate growth and 
orientation of axons towards their targets, are genetically determined and 
conserved phylogenetically, and their levels should be kept normal during 
such processes102,103,158. The dorsolateral cortex and anterior cingulate cortex 
are two PFC regions that are affected in autism, schizophrenia, depression, 
and anxiety151,152,153. For example, in autistic spectrum disorder (ASD), a low 
dopaminergic activity of the mPFC has been identified154,155,156. The PFC 
laminar organization of autistic children demonstrated an increase in neuronal 
density, suggesting that there are more neurons than expected in that 
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region162,163. However, at school age these differences disappear, and the 
cerebral volumes are normal or even slightly lower than normal164,165. It is 
believed that in schizophrenia there is a subcortical DA excess and a cortical 
DA deficit166. The serotonergic influence involves increased expression of 5-
HT2A and 5-HT1A receptors in the PFC, hippocampus and thalamus in 
schizophrenic patients compared to controls166,167. Morphologically, the 
anterior cingulate cortex is characterized by smaller and more widely spaced 
neurons in layer II, and reductions in synaptic and dendritic density168,169. 
 Biological, genetic and psychosocial factors interact with each other 
and may cause altered availability of biogenic brain amines, especially 5-HT, 
noradrenaline and DA, and thereby increase risk for depression and increased 
anxiety170. A polymorphism in the promoter region of the gene encoding the 
5-HT transporter (5-HTTLPR) has been associated with depression and high 
levels of anxiety171. Since the serotonin transporter (5-HTT) acts as a 
regulator of the 5-HT levels in the synaptic cleft, its absence causes an excess 
of this neurotransmitter172,173. 5-HTTLPR is a repeat polymorphism with long 
(1) and short (s) alleles. The allele (s) is associated with lower 5-HTT 
expression and function, and increases vulnerability for anxiety and 
depression in human171,172,173. In rats, 5-HTT knockout (5-HTT-/-) induces 
various behavioral phenotypes, which include anxiety, depression-like 
symptoms, and motor and cognitive delays174,175-178. The 5-HTT-/- genotype 
induces an increase of serotonergic innervation in the mPFC and damages the 
cortical layering during development179. In addition, an increase of 
extracellular 5-HT via a pharmacological block of 5-HTTs causes an 
interference with the development of many areas of the brain, such as the 
barrel cortex, amygdala, hippocampus and hypothalamus180,181,182,183. 
Selective serotonin reuptake inhibitors (SSRIs) are the most common 
medication prescribed during pregnancy for 20% of women to treat maternal 
depression, or during postpartum depression, where nearly 40% of women 
can develop this disturbance182. Prenatal SSRI exposure may increase risks 
for depressive, anxiety and abstinence behaviors184, delays in motor 
development185, abnormal psychomotor development such as hearing, vision 
and motor attention186, and autism spectrum disorders187. In another aspect, 
the non-selective serotonin reuptake blocker, such as Efavirenz (EFV), has 
also been associated with disturbances in the serotonergic system203,204,205. 
Efavirenz is the first line treatment for HIV-positive pregnant women, 
decreasing the chance of transmission of the HIV virus from mother to fetus 
to less than 5%206. However, EFV interacts with various receptors and 
transporters, including dopaminergic, serotonergic and noradrenergic204, and 
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has in adults been associated with side effects such as increased anxiety and 
depression205. In adult rats exposed to EFV, there was cell loss in various 
areas of the brain such as hippocampus, striatum, and cerebellum207-209. 
Prenatal exposure to EFV has been associated with deformities in nervous 
system formation, but with divergent results between studies in humans and 
animal models210-213. Studies demonstrating the perinatally toxicity of 
perinatal EFV exposure to rats and its what their consequences on cortical 
and ultimately behavioral development have not yet been performed. In 
contrast, adult EFV-exposed rats have been examined and showed behavioral 
changes such as an increase in anxiety, indicating a possible side effect of 
EFV on the serotonergic system through the increase of 5-HT levels and its 
risks for cortical development203,204,205. 
 In summary, different types of brain disorders have in common 
changes in the levels of 5-HT and morphology of the serotonergic system. 
During pre- or perinatal development these cause changes in cellular, 
structural and neural connections, in addition to altering other systems such 
as the dopaminergic system. These changes have an impact on adult life and 
are modulated by environmental factors. 
 
1.4.0 Aim and outline of the thesis 
 
 The aim of this thesis is to investigate how changes in 5-HT levels, 
via genetic or pharmacological manipulation, interfere with the intrinsic and 
structural mechanisms that control the development of the mPFC. In addition, 
we seek to identify possible interrelations of the serotonergic system with 
other systems, such as the catecholaminergic system, and how they together 
affect the stages of corticogenesis during neurodevelopment. Finally, we 
examine how these prenatal changes are reflected in postnatal and adult 
behavior. 
 In Chapter 2, we use mice to study the pattern of normal brain 
development in a dorsal-frontal wave at different embryonic and postnatal 
stages. We investigate the temporal and structural aspects of the prefrontal 
and somatosensory cortex, and various cortical developmental processes such 
as proliferation, migration, differentiation, and maturation. In addition, we 
show how the serotonergic and dopaminergic systems develop in different 
cortical areas at different developmental time points. The rationale here is to 
first understand how mPFC subareas normally develop before we enter into 
the use of different genetically or pharmacologically manipulated animal 
models in the next chapters. 
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 In Chapter 3, we use a rat mutant for 5-HTT (5-HTT-/-) displaying a 
disturbance in the serotonergic system. We investigate the intimate 
relationship between the developing serotonergic and dopaminergic systems, 
e.g. changes in the frontal projections of both systems. We also identify how 
disturbances in serotonergic and dopaminergic innervations of the mPFC are 
able to affect the cortical organization, especially through synaptic contacts 
with CR cells. 
 The aim of Chapter 4 is to investigate the changes in serotonergic 
projection and the identity of the mPFC layers when extracellular 5-HT levels 
are increased due to the absence of the 5-HTT in rats (5-HTT knockout (5-
HTT-/-) rat). We use transcription factors as layer markers and follow changes 
in columnar organization. In addition, we demonstrate changes in neuronal 
maturation and cell survival, via markers such as NeuN and Caspase-3, 
respectively. Furthermore, we employ the elevated plus maze test in 
adolescent and adult animals to study the emergence of anxiety in a given 
time window. As such, we show that in the absence of the 5-HTT structural 
changes in the mPFC are reflected at the behavioral level.  
 In Chapters 5 and 6, we examine the short- and long-term behavioral 
and neurodevelopmental consequences of perinatal exposure of pregnant rats 
to the HIV drug EFV or vehicle (from day 1 of gestation to P7). In Chapter 5, 
we focus on male offspring of the EFV- and vehicle-exposed rats and explore 
the development of the primary motor cortex, use behavioral tests during the 
first three postnatal weeks, adolescence and adulthood, and conduct brain 
immunohistochemical analyzes. Perinatal exposure to EFV causes structural 
alterations in the cytoarchitecture of the motor cortex through marked cellular 
loss which results in behavioral alterations and motor delay. The molecular 
findings in the motor cortex are similar to those in infralimbic, prelimbic and 
cingulate subareas of the mPFC. We demonstrate a developmental delay and 
persistent molecular and cellular changes in the cerebral cortex of rats 
exposed perinatally to EFV (Chapter 6). 
 Finally, in Chapter 7 we summarize the main findings and discuss the 
results of the studies described in Chapters 2-6. 
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Abstract 
 
 The cortex is a complex brain region organized into six layers and 
responsible for higher cognitive functions. Proper cortical development 
depends on consecutive processes, including proliferation, migration, 
differentiation and cell death, and follows an organizational dynamic process 
from early developing dorsal areas with basic functions to frontal regions with 
associative cognitive functions, such as the medial prefrontal cortex (mPFC). 
Furthermore, the cortex is sculpted by an invasion of migrating interneurons 
and afferents from other brain areas, each guided by intrinsic and extrinsic 
cues. Disturbances in cortical development have been associated with various 
neuropsychiatric disorders. Yet, the molecular and cellular programs 
controlling the development of the PFC are still poorly described. Here, we 
used BrdU and Ki67 assays to compare the proliferative events, such as cell-
cycle length and exit, occurring during the development of murine PFC with 
those of a more dorsal cortical region, the somatosensory cortex (S1). We 
furthermore examined the expression of several transcription factors (Ctip2, 
Tbr1, Satb2 and Cux1) in neurons of mPFC subareas (infralimbic, prelimbic 
and cingulate cortex) and compared these expression profiles with those in 
the S1. Lastly, we studied how the serotonergic and dopaminergic systems 
innervate these regions over time. Altogether, the frontal areas appeared to 
show a delay in neuronal maturation relative to that in the more dorsal S1 
area, suggesting that the PFC takes longer to mature than the S1. This is 
important regarding the timing of risk factors presented during 
neurodevelopment, which eventually may lead to disturbances in prefrontal 
functioning. 
 
Keywords: Medial Prefrontal Cortex; PFC Development; Somatosensory 
Development; Cortex Layering; Corticogenesis 
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Introduction 
 
 Proper brain development requires a complex and dynamic 
orchestration of events that is under genetic as well as environmental 
control1,2. Cortical development involves various processes beginning with 
neurogenesis of neuroepithelial cells of the telencephalon (from ~ embryonic 
day (E) 10 to E12 in mice) and progress to stages of neural migration, 
differentiation, synaptogenesis, pruning and myelin formation3,4,5. All areas 
contain five or six neuronal layers which develop in an inside-out 
organization1. Newborn neurons migrate using radial glial cells as scaffolds 
to reach the positions within the cortical plate (CP), with the deepest cortical 
layer emerging first, and the later-born migratory neurons forming 
successively more superficial layers6,7,8,9. 
 The control of complex cognitive functions, which basically involves 
all brain areas, is executed by the medial prefrontal cortex (mPFC)2,10,11. Our 
memory, planning, personality, emotion, decision making, inhibitory control, 
and attention functions are classified as executive functions, with a 
predominant activation of the mPFC12. Alterations in the maturation of the 
mPFC can eventually lead to higher impulsivity, aggressiveness and social 
deficits13. To unravel the complex cellular and molecular mechanisms of 
mPFC development, longitudinal studies are needed1,14. About 85% of the 
neuronal population within the mPFC is represented by excitatory projection 
neurons born in the ventricular zone (VZ) and subventricular zone (SVZ), and 
migrating radially to the correct position within the CP and the remaining 
15% are inhibitory GABAergic neurons that arise from different progenitor 
zones located in the lateral and medial ganglionic eminences15,16. The 
GABAergic interneurons migrate tangentially to the mPFC area, guided by 
intrinsic and extrinsic factors, and reelin released by the Cajal-Retzius (CR)  
cells17,18. Around postnatal day (P) 4, all layers of the cortex are positioned9. 
 When arrived at their final position, the neurons differentiate, and start 
to make connections with other brain areas through axon guidance molecules 
and their receptors19. Also, there is an increase in myelination and in the 
number and complexity of synapses1. Neurons that occupy the same radial 
positions are born in approximately the same time window and share common 
projection targets20. Deep cortical layers V and VI consist of corticofugal 
projection neurons and project to subcortical targets including the thalamus, 
internal capsule, spinal cord and tectum21. These neurons express, amongst 
others, the transcription factors COUP-TF-interacting protein 2 (Ctip2, also 
named Bcl11b) and T-box brain 1 (Tbr1)22,23,24 that are important for the 
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specification of deep-layer neurons and subplate25,26. In turn, upper-layer 
neurons, which include layer II/III projection neurons and layer IV 
thalamorecipient neurons, process intracortical connections and project their 
axons to the ipsilateral and contralateral cortex, and are marked by the 
expression of the transcription factors cut-like homeobox 1 (Cutl1 or Cux1) 
as well as special AT-rich sequence-binding protein 2 (Satb2)25,27,28. 
 As development proceeds, the mPFC furthermore receives 
innervations from various neural systems in the developing brain, such as the 
cholinergic, catecholaminergic and monoaminergic systems29,30. The 
integration of these neurotransmitter signals in the mPFC contributes to 
development, regulating various events during corticogenesis, including the 
formation of appropriate connections and resulting behavior31. Around E10, 
cholinergic projections originating from neurons located in the basal 
forebrain, distributed between the pedunculopontine and the laterodorsal 
tegmentar nuclei, innervate the cerebral cortex, and promote neuronal 
maturation and plasticity32. Around the same time dopaminergic and 
serotonergic neurons located in the ventral tegmental area (VTA)/substantial 
nigra (SN) and dorsal raphe nucleus (DRN), respectively, send their 
projections to the frontal cortical areas33-37. These projections innervate their 
cortical targets approximately around E14 during the peak of migration of 
GABAergic interneurons, but only at E16 they reach the mPFC 
subareas37,38,39. These axons initially are distributed in the marginal zone 
(MZ) and below the subplate (SP)40,41. Serotonin (5-HT) and dopamine (DA) 
are important neurotransmitters and neurotrophic factors that can control 
proliferation, migration, differentiation and cell death by directly binding to 
their receptors that are expressed on various cortical cell types or indirectly 
via CR cells, present in the MZ39,41,42,43. Around E12, axonal projections of 
subpopulations of norepinephrine (NA) neurons, located in the brainstem, 
begin to project towards the frontal areas44. NA plays a role in the 
organization and function of neuronal circuit formation and the synaptic 
plasticity of astrocytes and microglia44,45. Together, this indicates that there 
is ample evidence for the interaction of multiple neuronal systems during 
cortical development.  
 Cortical specification of visual, sensory, motor, associative and 
cognitive areas is regulated by a tightly controlled expression of transcription 
factors (intrinsic factors) as well as guidance cues (extrinsic factors), sculpted 
by environmental experiences46. Brain maturation and connections between 
different areas do not occur homogeneously or in the same time window, but 
follow a specific sequence with a characteristic directional path47,48. 
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However, regional maturation is more related to the function exerted by that 
specific area than to its location, such that areas with more complex functions 
ultimately develop following the development of the primitive 
functions46,47,48. The last regions of the brain to fully mature are the prefrontal, 
orbitofrontal and upper temporal cortical areas involved in complex executive 
functions and multimodal integration47,48,49,50. Because the mPFC is one of 
the last to develop and integrates inputs from various other brain areas into 
more complex functions, this relatively long developmental window makes 
the mPFC most vulnerable to all kinds of risk factors. This can eventually 
result in a psychiatric illness associated with the occurrence of various 
behavioral disturbances51,52. The dorsolateral PFC, and the infralimbic, 
prelimbic and cingulate cortex of the mPFC are regions that are often affected 
in autism spectrum disorder (ASD), schizophrenia, depression and anxiety 
disorders53,54. Therefore, it is important to perform detailed longitudinal 
studies on how the mPFC develops. 
  The purpose of this study was two-fold. As the mPFC consists of a 
conglomerate of subareas, we 1) compare the development of each of these 
subareas with one another and with the hallmark of corticogenesis, the well-
described primary somatosensory cortex (S1), and 2) examine whether the 
mPFC matures differently and/or in an extended manner compared to the 
more dorsal S1 region.  To these ends, we analysed the proliferation status 
and cell-cycle exit events, studied the expression of the transcription factors 
Satb2, Ctip2, Tbr1 and Cux1, and evaluated the serotonergic and 
dopaminergic innervation of the mPFC subareas in relation to S1.  
 
Methods 
 
Animals  
 
 All animal use and care were performed in accordance with the 
institutional and national guidelines and regulations of the Committee for 
Animal Experiments of the Radboud University Nijmegen, The Netherlands. 
Wild-type C57Bl/6 mice were obtained from Harlan Laboratories B.V. (The 
Netherlands) and housed with ad libitum food and water access, with a 12 hr 
light cycle at a controlled ambient temperature (21 ± 1°C) and a 60% relative 
humidity. Matings were set up late in the afternoon and vaginal plugs checked 
early in the morning to lower the variability between developmental time 
points. Pregnancy was confirmed after a vaginal plug was found and was 
considered E0.5. Pregnant mice were individually housed in standard 
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Macrolon® cages and sacrificed by means of cervical dislocation and the 
embryos collected at E14.5, E16.5 and E18.5 and pups were decapitated at 
P7.  
 
Tissue treatment and immunohistochemistry 
 
 Brains were rapidly dissected, collected in phosphate-buffered saline 
(PBS, pH 7.4) and fixed for 30-90 min by immersion in 4% paraformaldehyde 
(PFA, Electron Microscopy Sciences) in PBS. After fixation, brains were 
washed in PBS, cryoprotected in 30% sucrose (Sigma-Aldrich, St. Louis, 
Missouri, United States) in PBS, frozen in M-1 embedding matrix (Thermo 
Fisher Scientific, Waltham, MA, USA) on dry ice in a plastic cup and stored 
at -80°C. Cryostat coronal or sagittal sections were cut at 16 μm, mounted in 
series of 6–8 on Superfrost Plus slides (Thermo Fisher Scientific), air-dried, 
and stored desiccated at -20°C. Cryosections were stained 
immunohistochemically as described previously (Kolk et al., 2006). Primary 
antibodies used included mouse anti-Cux1 (1:300, Abcam, ab54583, 
Cambridge, United Kingdom), rat anti-Ctip2 (1:500, Abcam, ab10465, 
Cambridge, United Kingdom), mouse anti-Satb2 (1:500, Abcam, ab5102, 
Cambridge, United Kingdom), rabbit anti-Tbr1 (1:500, Abcam, ab31940, 
Cambridge, United Kingdom), mouse anti-NeuN (1:500, Merck Millipore, 
MAB377, Bedford, MA, USA), rabbit anti-5-hydroxytryptamine (5-HT) 
(1:500, Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands, S5545) and 
rabbit anti-tyrosine hydroxylase (TH) (1:500, Merck Millipore, AB152, 
Bedford, MA, USA). Antibodies were diluted in blocking buffer (BB) with 
1.7% normal donkey serum, 1.7% normal goat serum and 1.7% normal horse 
serum, 1% bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, Missouri, 
United States), 1% glycine (Sigma-Aldrich, St. Louis, Missouri, United 
States), 0.1% lysine (Sigma-Aldrich, St. Louis, Missouri, United States) and 
0.4% Triton X-100 in PBS and incubated overnight at 4°C. Secondary 
antibodies included Alexa 488 goat anti-mouse, Alexa 555 goat anti-rat, and 
Alexa 568 goat anti-rabbit (Molecular Probes, Life Technologies, Grand 
Island, NY at 1:500) and diluted in BB for 60 min at room temperature (RT). 
After washing in PBS, sections were counterstained with fluorescent Nissl 
stain (1:500, NeuroTrace; Invitrogen) or DAPI (1:1000, Molecular Probes) 
diluted in PBS for 15 min, thereafter, washed extensively in PBS and 
embedded in 90% glycerol in PBS. For visualization, a Leica DMRA 
Fluorescence microscope with DFC340FX camera and LASAF software or a 
Leica DMI6000B automated high-content microscope were used. Figure 
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images were reconstructed and digitized using Adobe Photoshop CS6 and 
Adobe Illustrator CS6. 
 
Analysis of cell-cycle entrance and exit 
 
 To label proliferating cells, pregnant mice received an intraperitoneal 
injection of 5-Bromo-2-deoxyUridine (BrdU, BD Pharmingen, San Diego, 10 
mg/mL in PBS) at E14.5, E16.5, and E18.5 in a dose of 50 μg/g body weight. 
The animals were either sacrificed after 2 hours (proliferation paradigm) or 
24 hours (migration paradigm) following treatment with BrdU by cervical 
dislocation, and brains were rapidly dissected and processed for fixation, 
freezing, and cryosectioning as described above. We incubated the sections 
for 12 seconds in 1:2 trypsin solution (0.1% trypsin, 0.1% CaCl2 in 0.1M Tris 
buffer). Trypsin was inactivated with fetal bovine serum (FBS) for 10 
minutes, followed by a wash in PBS and incubation in pre-warmed 2N HCl 
solution for 30 min at 37˚C. The solution was neutralized by incubating in 0.1 
M sodium borate buffer (pH 8.5) for 5 min at RT followed by wash in PBS 
for 30 minutes. Next, immunostaining was performed as described above 
using mouse anti-BrdU (1:500, Novus Biological, NB500-439) and rabbit 
anti-Ki67 (1:500, Abcam, Cambridge, United Kingdom, ab16667) overnight. 
The secondary antibodies included Alexa-conjugated 488 goat anti-mouse 
and goat anti-rabbit 555 (Molecular Probes, Life Technologies, Grand Island, 
NY at 1:500) and were diluted in BB for 30 min at RT. 
 
Data analysis 
 
 For assessing the number of Satb2-, Ctip2-, Cux1-, Tbr1- and NeuN-
positive cells, at least four to seven mouse embryo/pup brains were analysed 
for each marker, and three to six consecutive sections per brain were 
quantified. BrdU-positive cells were counted per animal (n = 3-4) and 
expressed as a percentage of proliferative activity in total Nissl+ cells. For cell 
cycle length and exit analysis, sections were double labeled with BrdU and 
the cell proliferation marker (Ki67). For the cell cycle length assessment, 
Ki67-positive (Ki67+) cells and Ki67- and BrdU-double positive 
(Ki67+/BrdU+) cells were counted and the proportion of Ki67+/BrdU+ cells to 
the total number of Ki67+ cells was calculated. For the cell cycle exit analysis, 
BrdU+/Ki67+ cells and BrdU+/Ki67− cells were counted and the proportion of 
BrdU+/Ki67− cells (cells withdrawn from the cell cycle) to the total number 
of BrdU+ cells was calculated. A 0.1-mm-wide rectangle spanning the 
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prefrontal wall was placed over the center of the subarea (either infralimbic, 
IL; prelimbic, PL; or cingulate cortex, CG) of the mPFC and S1. The overall 
cortical length of a subarea was divided into ten equal bins [bin 1 within the 
deep cortical layers and bin 10 within the presumptive layer I] within this 
rectangle, and 5-HT- or TH-positive axon length or number of marker-
positive neurons were counted within each bin using ImageJ software 
including the NeuronJ plugin (NIH, Bethesda, USA). Data were normalized 
to a total length per bin or to a percentage of the total number of Nissl+ or 
DAPI+ cells and averaged for each animal. 
 
Statistical analysis 
 
 Depending on whether data fulfilled the assumptions of homogeneity 
of variance and normality, data were analyzed either by a Student T-test, one-
way ANOVA (α = 5%) or Mann–Whitney U test followed by Tukey posthoc 
testing using GraphPad Prism 6 (San Diego, CA) or Excel data analysis 
toolkit (Microsoft Office) and expressed as means ± SEM.  
 
Results 
 
Radial cortical expansion differs between PFC and S1  
 
 The pre- and postnatal assessment of cortical thickness can be used to 
identify functionally distinct cortical areas55,56. The thickness and the overall 
cell density of subdomains of the mPFC and S1 were measured in coronal 
sections labelled with Nissl or DAPI at E14.5, E16.5, E18.5, and P7. At 
E14.5, a significant increase in cortical thickness was found in the S1 when 
compared with PL (p = 0.00004) and CG (p = 0.014) but not with IL (p = 
0.286) (Fig. 1C). However, no differences were found in the total number of 
cells per area when comparing S1 with IL (Fig. 2B; p = 0.327), PL (Fig. 2C; 
p = 0.900) and CG (Fig. 2D; p = 0.362). At E16.5, cortical thickness in S1 
was significantly higher compared to IL (p = 0.00002) and PL (p = 0.00005), 
but not to CG (p = 0.223) (Fig. 1D).  However, a higher number of cells was 
found in VZ/SVZ and IZ in the frontal areas when compared with S1 (Fig. 
2E; bin3, p = 0.047; bin4, p = 0.014; bin5, p = 0.034), PL (Fig. 2F; bin3, p = 
0.036; bin4, p = 0.006; bin5, p = 0.007; bin6, p = 0.0008), and CG (Fig. 2G; 
bin1, p = 0.032; bin3, p = 0.047; bin7, p = 0.015). At E18.5, a significant 
increase in the thickness of the CG was found when compared with S1 (Fig. 
1E; p = 0.000005), but in the other prefrontal subareas the thickness of the S1 
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was significantly larger (Fig. 1E; IL, p = 0.00001; PL, p = 0.00001) with a 
significantly higher number of cells in the CP of S1 when compared with IL 
(Fig. 2H; bin10 p = 0.054), PL (Fig. 2I; bin6, p = 0.0005; bin10, p = 0.001) 
and  CG (Fig. 2J; bin6, p = 0.021; bin10, p = 0.015). A similar pattern was 
found at P7, where only the thickness of the GC was significantly larger than 
that of the dorsal S1 (p = 0.004) (Fig. 1F), but the number of cells in the S1 
was significantly higher in upper-layers when compared with IL (Fig. 2K; 
bin8, p = 0.002; bin9, p = 0.001) and PL (Fig. 2L; bin9, p = 0.005) and in all 
layers of the CG (Fig. 2M; p = 0.003). Together, the results suggest an early 
temporal development in the S1 at the level of cortical thickness when 
compared with mPFC subareas, such as in cell density in the CP, where post-
migrational cells are located. 
 
Prefrontal subregions show a delay in proliferation rate compared to the 
S1 region 
 
 To investigate whether the mPFC subareas show differences in cell 
division compared to the S1, we performed at the same developmental age 
BrdU experiments in combination with immunohistochemical localization of 
Ki67. BrdU incorporates during the S-phase of the cell cycle and Ki67 is a 
marker for proliferating cells in all stages of the cell cycle, but is absent in 
resting cells (G0) and differentiated cells57,58,59. To assess relative changes in 
mPFC and S1 cell-cycle length, we calculated the percentage of BrdU+/Ki67+ 
cells relative to the total number of Ki67+ cells 2 hours after BrdU injection 
(Fig. 3A-G). First, we compared the number of proliferating cells between the 
cortices. Significant percentages of BrdU+ cells were found in the VZ/SVZ of 
the IL (Suppl. Fig. 1A; bin5, p = 0.00002, bin6, p = 0.0001, bin7, p = 0.023), 
the PL (Fig. 3B; Suppl. Fig. 1B; bin5, p = 0.001, bin6, p = 0.0001, bin7, p = 
0.006, bin8, p = 0.046) and CG (Suppl. Fig. 1C; bin5, p = 0.001, bin6, p = 
0.002, bin7, p = 0.009, bin8, p = 0.045) cortices when compared to the S1 at 
E14.5 (Fig. 3B). When we analysed the percentage of Ki67+ cells, no 
differences were found between the IL (p = 0.67) and PL (p = 0.47) subareas 
compared to the S1 (Fig. 3B), although we found a difference in the CG (p = 
0.02) compared to the S1 (Fig. 3B). A significant number of proliferative cells 
was found in BrdU+/Ki67+ cells in the frontal subareas IL (Fig. 3E; bin4, p = 
0.029, bin5, p = 0.0003, bin6, p = 0.0004), PL (Fig. 3F; bin5, p = 0.00001, 
bin6, p = 0.00002, bin7, p = 0.0008, bin8, p = 0.041) and CG (Figure 3G; 
bin2, p = 0.038, bin5, p = 0.0001, bin6, p = 0.0001, bin7, p = 0.011; bin8, p = 
0.003) when compared with the S1. At E16.5, we did not find significant 
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differences between the expression of the markers in all subareas examined, 
namely IL (BrdU, p = 0.287 (Fig. 3C; Suppl. Fig. 1D); Ki67, p = 0.488; 
double labelling, p = 0.678; Suppl. Fig. 2A), PL (BrdU, p = 0.585 Fig. 3C; 
Suppl. Fig. 1E); Ki67, p = 0.916; double labelling, p = 0.84; Suppl. figure 2B) 
and CG (BrdU, p = 0.187 (Figure 3C; Suppl. Fig. 1F); Ki67, p = 0.317; double 
labelling, p = 0.082, Suppl. Fig. 2C) compared to the S1. At E18.5, following 
2h of BrdU exposure, we did find significant difference in the number of 
proliferative cells only when comparing CG subareas with the S1 (Fig. 3D, p 
= 0.0017; Suppl. Fig. 1G-I; Suppl. Fig. 2D-F). Next, the balance between cell-
cycle re-entry and exit was determined using BrdU/Ki67 immunolabeling 24 
h following BrdU injection (Fig. 3H-O). Cells that re-entered the cell cycle at 
24 h were BrdU+/Ki67+, while those that exited were BrdU+/Ki67- 60. At 
E15.5, no significant differences were found in the percentage of cells that re-
entered the cell cycle between S1 and IL (Fig. 3N; p = 0.84), PL (Fig. 3N; p 
= 0.57) in superficial domains but not in CG (Fig. 3N; p = 0.24). Instead, in 
CG more cells were found to exit the cell cycle (BrdU+/Ki67-) when 
compared with S1 (Fig. 3L; p = 0.014). At E17.5, we did not find significant 
differences in the percentage of positive cells that exited the cell cycle 
between S1 and the frontal areas IL (p = 0.826), PL (p = 0.745) and CG (p = 
0.801) (Fig. 3M). Significant differences in the percentage of cells that re-
entered the cell cycle in S1 when compared with IL (p = 0.004), PL (p = 
0.00001) and CG (p = 0.002) were found (Fig. 3O). Together, the data suggest 
that early in development there are more cells that re-entered the cell cycle in 
frontal areas when compared to S1, but this difference is not maintained after 
24h exposure, when more cells were found to re-enter the cell cycle in the 
dorsal area when compared with mPFC areas, suggesting a delay in frontal 
development.  
 
Developmental differences in the deepest cortical layer between PFC 
subareas and the S1 
 
 Tbr1 seems to play distinct roles at different stages of cortical 
development. At early stages, Tbr1 promotes a frontal identity while 
suppressing caudal identity61. The Tbr1+ cells derived from the first 
progenitor cells are located in layer VI62 and contribute to the development of 
corticothalamic projection neurons62,63, but not sub-cerebral projection 
neurons64. To distinguish between these cells, we labeled sections of the 
cortical brain with anti-Tbr1 antibody and analysed the Tbr1+ cells per area 
expressed in subareas of the mPFC and S1. The expression of Tbr1 was 
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comparable between the frontal and sensory areas at E14.5 and decreased 
during further   development (Fig. 4A-E). Tbr1 expression was high at E14.5 
in CP but was not significantly different when comparing S1 with IL (Fig. 4F, 
p = 0,391), PL (Fig. 4G, p = 0,561) and CG (Fig. 4H, p = 0,684). At E16.5, 
the expression of Tbr1 in CP and SP was higher in the IL (Fig. 4I, bin10, p = 
0,005), PL (Fig. 4J, bin6; p = 0,003) and CG (bin6; p = 0.0002) cortices when 
compared to S1. In contrast, cells from the CG expressed less Tbr1 and the 
peak of expression was found at E18 (Fig. 4D and N). At E18.5, the number 
of Tbr1+ cells per area increased significantly in intermediate zone (IZ) and 
SP of S1 compared to IL (Fig. 4L, bin4, p = 0.041; bin5, p = 0.026), PL (Fig. 
4M, bin4,  p = 0.012; bin5, p = 0.000004, bin6, p = 0.001) and CG (Fig. 4N, 
bin4, p = 0.012; bin5, p = 0.0001), but significantly less in the CP in which 
more Tbr1+ cells were found in IL (bin8, p = 0,004; bin9, p = 0,001), PL (bin8, 
p = 0,053; bin9, p = 0,004) and CG (bin8, p = 0,001; bin9, p = 0,0007) (Fig. 
4L-N). At age P7, there was a decline in all cortical areas examined. A 
significantly higher number of Tbr1+ cells per area was found in deep layers 
in IL (Fig. 4O) and PL (Fig. 4P) compared to S1, but not in the upper-layers, 
and in CG and S1 (Fig. 4Q). These data suggest that deep-layer development 
was initiated approximately at the same time and place when the frontal and 
dorsal cortical areas were compared.  At the peak of expression at E18 frontal 
subareas showed more Tbr1+ cells in the more superficial aspects of the CP 
when compared to the S1, although almost comparable levels at P7. This is 
indicative for a developmental delay. 
 
Satb2 expression during cortical development 
 
 Following the corticogenesis steps, we analysed the next layer to arise, 
layer V. One potential regulatory determinant of this type of cells is Satb2, 
which is expressed during differentiation in a subgroup of neurons in layers 
II to V65. Consistent with previous reports66, we detected Satb2 
immunoreactive cells in the CP at E14.5 in all cortical areas, but this was not 
significantly different when comparing S1 with IL (p = 0.486), PL (p = 0.767) 
and CG (p = 0.964) (Fig. 5F-H). At E16.5, when late-born neurons are 
predominantly migrating, the number of Satb2+ cells increased significantly 
in CP in IL (Fig. 5I, bin7, p = 0.005) and PL (Fig. 5J, bin7, p = 0.004), and 
SP in CG (Fig. 5K, bin6, p = 0.04) when compared with S1. Also at E18.5, 
an increase of Satb2+ cells in all cortical areas was noted, which was 
significant in the CP and layer VI in S1 compared to IL (Fig. 5L, bin8, p = 
0.0004) and PL (Fig. 5M, bin5, p = 0.0009; bin6, p = 0.033) and in IZ and 
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layer VI in CG (Fig. 5N, bin4, p = 0.039; bin5, p = 0.008; bin8, p = 0.040). 
Instead, a significant number of Satb2+ cells were found in CP of the CG 
when compared with S1 (Figure 5N, bin9, p = 0.024; bin10, p= 0.042). The 
expression of Satb2 was strongly reduced at P7 in the superficial layers, as 
demonstrated by the reduction in the number of Satb2+ cells in the subareas 
of the mPFC and the S1 (Fig. 5O-Q), when the cortical neurons ended the 
migration and are refining their axonal projections. We found a significant 
increase of Satb2+ cells in upper-layers of S1 when compared with IL (Fig. 
5O, bin8, p = 0.008; bin9, p = 0.002), PL (Figure 5P, bin9, p = 0.020) and CG 
(Figure 5Q, bin7, p = 0.005; bin8, p = 0.003). Interestingly, at E14.5 and 
E16.5 no Satb2+ cells were found in active proliferation zones, including the 
SVZ and the underlying VZ, and only a limited number of Satb2+ cells in the 
IZ at E18.5 in both the frontal and dorsal areas (Fig. 5A, F-K). These data 
suggest that Satb2 is not expressed by cortical neurons prior to migration and 
that temporal expression seems to be higher at E16.5 in IL and PL when 
compared to S1, demonstrating more cells in the layer V. The peak of 
expression of this marker in all evaluated areas appears to be at age E18.5. 
We identified a significantly higher levels of Satb2 expression in S1 cortex 
when compared to the frontal areas, especially in the superficial layers. In 
addition, the expression of this marker seems more delayed in the cortex CG 
cortex when compared with other frontal areas and S1. Together, these 
findings suggest a delay in the frontal area development when compared with 
that of S1. 
 
Patterned expression of Ctip2 in neocortical layers II–V 
 
 In the cortical brain, Ctip2 is used as a marker for a subset of 
subcerebral projection neurons of deep layer V, as well as GABAergic 
interneurons, but is also expressed in other cell types in layers II, III and 
IV26,67. Immunohistochemistry revealed that during the peak production of 
the deep layer neurons between E12.5 and E14 the onset of Ctip2 expression 
in the CP is restricted to post-migratory neurons without expression in VZ or 
in migrant neurons of IZ (Fig. 6A, F-H), without significant differences in 
expression at E14.5 between cortical areas when comparing S1 with IL (p = 
0.836), PL (p = 0.901) and CG (p = 0.409). At E16.5, when surface layer 
neurons are generated, Ctip2 is strongly expressed in the CP (Fig. 6A, I-K). 
There was a significant increase of Ctip2+ cells in CP in IL (Fig. 6I, bin6, p = 
0.00003; bin7, p = 0.00001; bin8, p = 0.018), PL (Fig. 6J, bin7, p = 0.0003; 
bin8, p = 0.014) and CG (Fig. 6K, bin9, p = 0.002) when compared with S1. 
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At E18.5, all mPFC subareas showed a significantly higher level of Ctip2+ 
cells per area when comparing to S1 (IL (p = 0.0006), PL (p = 0.000008) and 
CG (p = 0.0001) (Fig. 6B-E, L-N)). On P7, significant down-regulation of 
Ctip2 starts in all cortical areas, with the IL having a significantly higher 
number of Ctip2+ cells in deep-layer (Fig. 6O, bin1, p = 0.018; bin2, p = 
0.020, bin5, p = 0.003) when compared with S1 but not in superficial layer 
cells, where we found more expression in S1 when compared with IL (Fig. 
6O, bin9, p = 0.0009; bin10, p = 0.002). The same pattern was observed in 
superficial layers of PL (Fig. 6P, bin9, p = 0.003; bin10, p = 0.008) and CG 
(Fig. 6Q, bin9, p = 0.007) when compared with S1. Together, these results 
suggest a common onset of Ctip2 expression at E14.5, and expression became 
more pronounced in frontal areas at E16.5 and E18.5 but was decreased by 
P7. 
 
Expression of Cux1 during superficial layer organisation  
 
 Homeobox transcription factor Cux1 is involved in embryonic 
patterning and cell-type specification68. Cux1 is a marker for upper-layer cells 
and expressed in precursor cells at the time the upper-layer neurons are 
generated (E13-E17), but a few scattered neurons in the deep layers (V–VI) 
and CR cells in the adult cortical brain also express Cux168,69. At E14.5, most 
cells in the CP represent neurons that are destined to form the deep cortical 
layers, and only a few of these cells also demonstrate Cux1 immunoreactivity 
in all sub-areas of mPFC and S1, but not significantly different when 
comparing S1 with IL (Fig. 7A and F; p = 0,208), PL (Fig. 7A and G; p = 
0,967), and CG (Fig. 7A and H; p = 0,796). At E16.5, when a large proportion 
of newborn upper-layer neurons are migrating away from proliferative areas, 
many Cutl1+ cells migrate through the IZ and the CP (Fig. 7A, I-K) being 
significantly higher in the IL (Fig. 7I; p = 0.001) and PL (Fig. 5J; p = 0.003) 
subareas when compared with S1, but not in CG when compared with S1 (Fig. 
7K; p = 0.760). Notably, Cux1-positive cells in the CP show much more 
intense immunoreactivity than the VZ and SVZ cells (Fig. 7A), as also 
observed at E18.5 where a significant number of Cux1+ cells are located in 
the CP of IL (Fig. 7L; p = 0.005), PL (Fig. 7M; p = 0.010) and CG (Fig. 7N; 
p = 0.0001) when compared to S1. At P7, Cux1+ cells were identified in deep 
and superficial layers, being significantly higher expressed in superficial 
layers of S1 when compared with IL (Fig. 7O; bin8, p = 0.010; bin9, p = 
0.00001), PL (Fig. 7P; bin9, p = 0.003) and CG (Fig. 7Q; bin7, p = 0.034; 
bin8, p = 0.005; bin9, p = 0.011). Therefore, at E14.5 the expression of Cux1 
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was not different between the frontal and dorsal areas, while at E16.5 and 
E18.5 there was a significant increase in expression in mPFC subdomains 
when compared with S1. At P7, a significantly higher number of Cux1+ cells 
were found in S1 when compared with mPFC subareas. Thus, Cux1 marks an 
initial step in the acquisition of neuronal identity of the upper layer, is 
expressed in both the precursor population and the neurons of the upper layer, 
and its expression in mPFC subdomains is always higher when compared 
with S1. 
 
Superficial domain vs deep domain : double labelling of Satb2 and Tbr1 
 
 Cortical neurons project to speciﬁc targets located nearby in the cortex 
or in distant subcortical regions26,28. Different populations of cortical neurons 
can be identified by their time of origin, laminar localization, projection 
pattern and molecular signatures, all of which are controlled by transcription 
factors69. Double marking identifies specific types of cells and give clues to 
which region that they will send their projections. For example, the co-
expression of Satb2 and Tbr1 is required for the specification of callosal 
neurons, as Satb2 promotes the expression of Tbr1 in the upper-layer 
neurons28,69. When expressed alone, Tbr1 is found only in corticothalamic 
neurons. In order to elucidate differences in identity, we compared the 
developmental time-line of these double-labeled cells of the mPFC 
subdomains with that of the S1. At E14.5, no significant differences were 
found in the total number of Satb2+/Tbr1+ cells per area in IL (Fig. 8C; p = 
0.705), PL (Fig. 8D; p = 0.520) and CG (Fig. 8E; p = 0.885) when compared 
with S1. At E16.5, the peak of late-born neurons, we found a significant 
increase in the number of double-labelled positive cells in IL (Fig. 8F; p = 
0.010) and PL (Fig. 8G; p = 0.019) when compared with S1, but not in CG 
(Fig. 8H; p = 0.612). At E18.5, a higher number of these double-labelled cells 
was identified in the VZ and IZ in S1 compared to IL (Fig. 8I; bin4, p = 
0.013), PL (Fig. 8J; bin4, p = 0.015, bin5, p = 0.00003) and CG (Fig. 8K; 
bin5, p = 0.002). In contrast, a significant increase of Satb2+/Tbr1+ cells in 
the CP in IL (bin9, p = 0.005) and CG (bin8, p = 0.017; bin9, p = 0.001) was 
found when compared with S1 (Fig. 8I and K). Seven days after birth, there 
was a significantly higher number of double-positive cells in upper-layer 
neurons in IL (Fig. 8L; p = 0.02) and PL (Fig. 8M; bin6, p = 0.02) when 
compared with S1, except in superficial layers where we found more positive 
cells in S1 when compared with IL (bin8, p = 0.03; bin9, p = 0.0008) and PL 
(bin9, p = 0.003) (Fig. 8L and M). No differences were found in CG when 
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compared with S1, except in the most superficial layer (Fig. 8N; bin10, p = 
0.039). Together, the data suggest that the callosal projection neurons appear 
at the same time point in frontal and dorsal areas in the cortex, however at 
E16.5 the CG showed a delayed expression when compared with the dorsal 
region. 
 
Differences between frontal and dorsal areas during cortical maturation  
 
 In order to elucidate the maturation state of the prefrontal subdomains 
compared to the S1, we stained for the neuronal nuclear protein (NeuN), 
localized in nuclei and perinuclear cytoplasm and considered to be a unique 
marker of postmitotic neurons70. In mice, NeuN expression starts around E16, 
and peaks at E18.5 and P79. At E18.5, we did not find significant differences 
in the number of NeuN+ neurons between S1 and IL (Fig. 9A and B; p = 
0.499), PL (Fig. 9C; p = 0.853) and CG (Fig. 9D; p = 0.822). However, at P7 
the neuronal density in all cortical layers of the S1 was significantly higher 
when compared to IL (Fig. 9E and I; p = 0,002; bin2, p = 0.008; bin3, p = 
0.003; bin8, p = 0.001; bin9, p = 0.00007; bin10, p = 0.0028), PL (Fig. 9F and 
I; p = 0,001; bin3, p = 0.01; bin7, p = 0.006; bin8, p = 0.006; bin9, p = 0.00002; 
bin10, p = 0.00008) and CG (Fig. 9G and I; p = 0,0004; bin2, p = 0.0006; 
bin3, p = 0.00002; bin4, p = 0.002; bin5, p = 0.007; bin6, p = 0.03; bin7, p = 
0.002; bin8, p = 0.0010). Together, the data suggest a delay in maturation of 
the mPFC when compared to somatosensory cortical maturation.  
 
Serotonergic and catecholaminergic innervation of the mPFC and S1 
 
 A proper cortical development requires extrinsic signals that include 
monoaminergic and catecholaminergic signals and growth factors. Together 
they regulate a series of timed events, which include proliferation, migration 
(via contact with the CR cells) and differentiation of neurons (i.e., proper 
growth and orientation of axons towards their targets), and occur mainly 
during embryonic and postnatal development3,71-75. In particular, 5-HT and 
DA are important regulators of cortical development30,36,37,39. In mice, 
serotonergic and dopaminergic neurons send their projections to frontal areas 
around E10-E11 and reach the PFC around E14.539. We analyzed the total 
length of 5-HT+ fibers in all subdomains of the mPFC and the S1 at E18.5 
when these fibers are more distributed throughout all cortical structures (Fig. 
10A-E). There was a significant increase in the lengths of these fibers in deep 
as well as superficial domains of the IL (Fig. 10C; bin1, p = 0.005; bin2, p = 
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0.026; bin3, p = 0.0004; bin4, p = 0.012; bin8, p = 0.00001), PL (Fig. 10D; 
bin2, p = 0.008; bin8, p = 0.0005) and CG (Fig. 10E; bin2, p = 0.0007; bin4, 
p = 0.012) when compared with the S1. The same pattern was found for 
dopaminergic innervation, where a significant increase in the mean lengths of 
TH+ fibers was found in the IL (Fig. 10F; bin3, p = 0.002; bin4, p = 0.007; 
bin7, p = 0.002), PL (Fig. 10G; bin7, p = 0.01) and CG (Fig. 10H; bin2, p = 
0.03; bin3, p = 0.019; bin6, p = 0.017; bin7, p = 0.017; bin10, p = 0.018) when 
compared with the S1. Together, the data showed a higher innervation of 5-
HT and DA in the frontal areas when compared with a dorsal area.  
 
Discussion     
 
Our objective was to investigate the similarities and differences in the 
development and maturation of the mPFC subdomains and the S1. When 
evaluating the cell cycle, a higher degree of proliferation in the frontal areas 
at the beginning of development was observed, when compared to S1. This 
difference does not persist after 24h, when more cells continued to proliferate 
in the dorsal area when the mPFC subareas were exiting the cycle. Through 
transcription factor expression analysis of the organization of the cortical 
layers, we identified a common starting point that was comparable between 
the subareas of the mPFC and S1.  Both the deep layers, marked with Tbr1, 
Satb2 and Ctip2, as well as the upper layers, labeled with Cux1, showed the 
highest expression in the subareas of mPFC when compared to S1. In 
addition, each marker presented a unique expression pattern in the cortical 
domains analysed. Using NeuN as a marker, we found a delay in the 
maturation of the mPFC subdomains when compared to the S1. Finally, when 
evaluating serotonergic and dopaminergic innervation, using 5-HT and TH as 
markers, respectively, we found that the mPFC subareas required a higher 
innervation of these systems when compared to the S1. Altogether, our 
findings suggest that the development of the mPFC areas was delayed and 
demanded a high expression of various transcription factors, which may be 
associated with their higher complexity when compared to the S1. 
 The neocortex occupies about 80% of the total human brain volume 
and is the most recent brain structure from an evolutionary point of view1,76,77. 
The PFC develops from neuroepithelial germ cells and proliferates, from E11 
to E12 in mice, to form a vast heterogeneous population of cells3. Using cross-
sectional magnetic resonance imaging studies on the brain, the development 
of the human cortex has been quantified by measuring the gray matter density 
in each lobe80. The first areas to mature are those with the most basic 
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functions, for example brain areas that process sensibility and movement81. 
Thus, the older cortical areas mature earlier than the new associative cortices 
that integrate information80-,84. The PFC has more advanced functions, 
including the integration of sensory, motor, reasoning and other executive 
functions, and is the last to mature  in early adulthood46,85,86. In mice, we 
found a similar pattern of development with faster maturation  of sensory and 
motor regions when compared to frontal areas, in line with results from other 
studies87,88. During development, proliferative cells are distributed 
throughout the brain and cell density progressively increases from the dorsal 
region of the brain to the frontal region78,79. We reconstructed this progenitor 
distribution in the embryonic brain using BrdU and Ki67 labeling, and 
identified a higher proliferative activity in the prefrontal subareas compared 
to the S1, but 24h after the BrdU injection the S1 contained more cells 
reentering the cell cycle. In general, regional cortical thickness is similar until 
early postnatal life compared to those observed in older children and 
adults75,77, with the cortex reaching the final thickness in late adolescence and 
early adulthood83,89. In addition to a larger number of cells and mature 
neurons, at the early postnatal age we found a thicker somatosensory cortex 
when compared to the mPFC subareas. During this period of brain 
development, the dorsolateral PFC and mPFC expand almost twice as much 
as some other regions, including the occipital and medial insular cortex47,100-
102. Throughout childhood and adolescence, the development of the brain is 
characterized by expansion followed by a decline of gray matter volume and 
increase in the volume of white matter102,103. Significant changes in cortical 
thickness with varying gray- or white-matter volumes are commonly found 
in developmental disorders such as bipolar disorder, attention deficit / 
hyperactivity disorder (ADHD), schizophrenia104 and Williams syndrome80. 
Studies focusing on cortical thickness are important for the diagnosis of brain 
disorders and accompanying cognitive problems, and to establish whether the 
disorder is stable or progressive80.   
 Correct cortical development depends on stimuli from external brain 
areas, via neurotrophic and neurotransmitter signaling. Some of these 
afferents responsible for the control of cell proliferation, migration and 
apoptosis arise from the serotoninergic system37,39,40. In addition to the initial 
events of corticogenesis, such as proliferation, migration, layer organization 
and apoptosis, the action of 5-HT as a developmental neuromodulator 
involves the adjustment of neuronal excitability via the various 5-HT 
receptors that are expressed in a spatial and temporal manner30,35,36. 
Serotonergic fibers emerge from the raphe nucleus while the dopaminergic 
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fibers emerge in the midbrain, both around E10.541,74. The ascending 5-HT 
and DA fiber passages are visible at E12, running on both sides of the midline, 
at which point the 5-HT axons leave the main tract of the medial forebrain 
bundle and begin to follow other fascicles until they arrive in the frontal 
areas41,36. At E14.5, these fibers innervate the somatosensory and frontal 
cortex, but only around E16.5 they are visible in the mPFC subareas39,74. 
These fibers target different cell types, for example, CR cells, astrocytes and 
neurons that express various receptors for 5-HT and DA36,105, thus actively 
participating in cortical development. A higher prefrontal than somatosensory 
cortex innervation by 5-HT and DA fibers was found in our study, which may 
be explained by the higher integrative complexity of the frontal than the 
somatosensory cortex. In rodents, changes in serotonergic signaling result in 
abnormal barrel formation, a reduction in cortical thickness and expression of 
activity-regulated genes essential for the formation of inhibitory cortical 
networks106 in the somatosensory cortex107,108. Animals lacking the 5-HT 
transporter showed an increase in serotonergic innervation of the mPFC and 
a decrease in the number of Satb2+ cells109, as well as a smaller number of 
CR-cells. These changes resulted in a cortical disorganization which 
interfered with cortical function and behaviour later on109,41, supporting an 
important role of 5-HT in mPFC developmental processes.  
 In the quest to understand which factors contribute to the normal 
course of brain development and to neurodevelopmental disorders, genetic 
and imaging methods are combined to answer questions about the influence 
of genes and the environment on brain structure21,22,110. However, little is 
known about the mechanisms that control the specification of neurons in 
different cortical layers, whereby transcription factors are responsible for the 
early brain developmental events22,26,111. Neurons of layer IV emerge around 
E14, and layers II and III neurons around E15 and E1626,112. Tbr1 and Ctip2 
are associated with the specification of neurons in the deep layers VI and V, 
respectively66, while Cux1 and Satb2 are expressed in the initial stages of the 
specification of the neurons of the upper layers15,66,68.  
In the neocortex, Tbr1 mRNA is expressed in postmitotic cells of the 
developing cortex from E10 to adulthood, with particularly high preplate 
expression and lower expression in the IZ, and no expression has been 
detected in the VZ15. Similar to our results in the mPFC and S1, the peak of 
Tbr1 expression appears to be from E16 to E18 and is more pronounced in 
the S1. The cortex of mutant Tbr1 mice shows developmental abnormalities 
in the laminar organization of neurons and orientation of afferent and efferent 
cortical axons, making these mice a suitable animal model for 
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autism61,62,113,114,115. Ctip2 is expressed at high levels in layers IV and V in a 
pattern that is comparable between cortical areas, the ventrolateral cortex as 
well in the ventromedial cortex. At E12, when the initial cortical progenitors 
are dividing, Ctip2 is expressed only in a small cluster of cells in the 
ventrolateral cortex66,116. At E14 and E16, during the peak of corticospinal 
motor neuron (CSMN) production, Ctip2 is highly expressed by post-mitotic 
cells in the CP, but not by cells in the VZ or SZ in the S1, suggesting that 
expression of this marker starts in the postmitotic CSMN116. Mice mutant for 
Ctip2 are born alive but soon die, showing the important function of this gene 
during early development22, 117. 
 Neurons of the upper cortical layers II-IV are generated between 
E13.5 and E16.568. During neocortical development, Cux1 is expressed in 
both VZ and SZ, and functions as a transcriptional repressor of several genes 
involved in cell proliferation and differentiation. In addition, Cux1 regulates 
the dendritic arborization of pyramidal neurons27,68,118. In deep layer IV, we 
found that Cux1 is expressed at E14.5 and other studies have shown that these 
Cux1-positive neurons do not contain GABA, indicating that they represent 
glutamatergic neurons in layer IV68,119. This is followed by a peak of Cux1 
expression in the mPFC at E16 and E18, where a large number of dendritic 
neurons are involved in the development of cortical circuits as well as in 
circuit refinement118. The expression of Satb2 is confined to the cerebral 
cortex with strict lateral and medial boundaries23,25,120,121. In the present study, 
Satb2 was initially detected at E14.5 in the neocortical SVZ and later in 
development in the upper layers of the PFC as well as in IZ122 and in S125,122, 
followed by increased IL and PL expression at E16.5 and E18.5 in the mPFC 
subareas. At E18.5, most cells expressing Satb2 were predominantly found to 
occupy the upper cortical plate, a pattern that has also been identified by 
others25. In mutant Satb2-/- mice, the neurons of cortical layers II/III 
assimilated the fate of the cells of layer V25,28,120, and upper- and lower-layer 
cells failed to form a correct corpus callosum and reach their sub-cerebral 
targets, respectively25,122,123. 
  Together, the data presented show the existence of a balance in the 
actions of extrinsic and intrinsic factors to determine the cellular phenotypes 
during mPFC and S1 development. We further report a difference between 
the development of the dorsal areas, represented by the S1, and the PFC 
subareas. Our data demonstrate a delay in the proliferation, migration and 
maturation of the PFC when compared to the S1, presumably related to a 
higher neuronal complexity and functioning of the prefrontal region of the 
brain. 
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Fig. 1. Cortical thickness of mPFC vs S1. (A-B) Nissl staining at E18.5 in mPFC 
and S1 coronal slices, respectively. (C) Total swatch area at E14.5 showing increased 
cortical thickness in S1 in comparison with PL and CG. (D) At E16.5, a significant 
increase in cortical thickness was found in S1 when compared with IL and PL areas. 
(E) At E18.5, a significant increase in CG area was found in comparison with IL, PL 
and S1, and in S1 in comparison with IL and PL. (F) At P7, the pattern of cortical 
thickness was similar to that at E18.5. Data show mean number of cells ± SEM, *p 
< 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (n = 5-7). 
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Fig. 2. Developmental timeline of radial expansion of cortex. (A) Cryosections 
showing total number of cells labeled by Nissl (E14.5, E16.5 and E18.5) and DAPI 
at P7. (B-D) Quantification of total number of cells per area at E14.5 between the 
cortical areas showing no significant differences, except by one deep domain in CG 
when compared with S1. (E-G) Significantly higher number of cells in deep and 
superficial layers in mPFC subareas when compared with S1. (H-J) Quantification 
of total number of cells at E18.5 showing differences between mPFC and S1. (K-M) 
Significantly higher number of cells in superficial layers in S1 when compared with 
IL and PL, and also in deep layers when compared with CG. Data show mean number 
of cells ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way 
ANOVA (n = 5-7). 
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Fig. 3. Proliferation and migration of cells in mPFC vs S1 during corticogenesis. 
(A) Immunostaining showing cells in proliferation (BrdU+ and Ki67+ cells) after 2h 
of BrdU exposure. (B-D) Quantification of BrdU+ and Ki67+ cells, after 2h BrdU 
exposure, at E14.5 (B), E16.6 (C), E18.5 (D) and the cell cycle length showing a 
significantly higher percentage of proliferative cells in mPFC subdomains into deep 
and superficial layers at E14.5 when compared with S1. (E-G). (H-I) 
Immunostaining showing BrdU+ and Ki67+ cells after 24h exposure to BrdU and in 
high magnification in J-K. (L, M) Quantification of BrdU+ and Ki67+ cells at E17.5 
and E19.5 after 24h exposure to BrdU. (N-O) Quantification of the percentage of re-
entry into the cell cycle after 24h exposure to BrdU (BrdU+/Ki67+). Data show mean 
number of cells ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-
way ANOVA (n = 3-5). 
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Fig. 4. Tbr1 is expressed by projection neurons in layer VI. (A) Immunostaining 
for Tbr1 at different time-points in PL cortices. (B-E) Quantification of total number 
of Tbr1+ cells per area in IL, PL, CG and S1 at different time-points. (F-Q) 
Quantification of Tbr1+ cells per area comparing mPFC subdomains and S1 in deep 
and superficial layers during development. Data show mean number of cells ± SEM, 
*p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (n = 5-7). 
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Fig. 5. Parallel developmental expression of Satb2 in mPFC and S1: (A) 
Immunostaining showing Satb2 labeling in PL slices at different time-points during 
development. (B-E) Quantification of Satb2+ cells between mPFC and S1 at E14, 
E16, E18 and P7. (F-Q) Comparison of Satb2+ cells per area in deep and superficial 
cortical layers of mPFC and S1. Data show mean number of cells ± SEM, *p < 0.05, 
**p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (n = 5-7). 
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Fig. 6. Patterned expression of Ctip2 in neocortical Layers II–V. (A) 
Immunostaining showing the pattern of Ctip2 expression in PL slices during cortical 
development. (B-E) Quantification of Ctip2+ cells per area in IL, PL, CG and S1 at 
different time points during development. (F-Q) Quantification of Ctip2+ cells in 
deep and superficial layers of mPFC and S1 during development. Data show mean 
number of cells ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-
way ANOVA (n = 5-7).  
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Fig. 7. Expression of Cux1 in late-born cortical neurons. (A) Immunostainig 
showing Cux1 expression during PL cortex development. (B-E) Quantification of 
Cux1+ cell per area at different time-points comparing frontal with dorsal areas. (F-
Q) Qualification of Cux1+ cells in deep and superficial layers of mPFC subdomains 
compared with S1. Data show mean number of cells ± SEM, *p < 0.05, **p < 0.01, 
***p < 0.001, analyzed using One-way ANOVA (n = 5-7). 
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Fig. 8. Superficial domain vs deep domain: double labelling of Tbr1 and Satb2. 
(A) Immunostaining in mPFC and S1 at P7 showing Tbr1+/Satb2+ cells, and in high 
magnification in (B). (C-N) Quantification of double-labeled cells in deep and 
superficial layers of mPFC and S1 at different time points during development. Data 
show mean number of cells ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed 
using One-way ANOVA (n = 5-7). 
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Fig. 9. Cortical maturation differences between frontal and dorsal areas. (A) 
Immunohistochemistry showing mature neurons (NeuN+) and dopaminergic 
innervation (TH+) in mPFC subdomains and S1 at E18.5. Quantification of NeuN+ 
cells per area in deep and superficial layers of mPFC and S1 at E18.5 (B-D) and at 
P7 (E-G). (H, I) Quantification of NeuN+ cells in total swatch area in mPFC and S1 
at E18.5 (H) and P7 (I). Data show mean number of cells ± SEM, *p < 0.05, **p < 
0.01, ***p < 0.001, analyzed using One-way ANOVA (n = 5-7). 
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Fig. 10. The development of serotonergic and catecholaminergic innervation in 
the mPFC and S1. (A, B) Coronal slices of mPFC and S1 immunoassayed for 5-HT. 
(C-E) Quantification of 5-HT+ fiber lengths per area at E18.5. (F-H) Quantification 
of dopaminergic innervation via TH+ fiber lengths per area at E18.5. Data show mean 
number of cells ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-
way ANOVA (n = 5). 5-HT: serotonin, 5-hydroxytryptamine; TH: Tyrosine 
hydroxylase. 
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Supplemental Fig. 1. Proliferative activity of cells in mPFC subareas and S1 after 
2-h exposure to BdrU. Quantification of the percentage of BdrU+ cells at E14.5 (A-
C), at E16.5 (D-F) and at E18.5 (G-I). Data show mean number of cells ± SEM, *p 
< 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (n = 5). 
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Supplemental Fig. 2. Cell-cycle re-entry of cells in mPFC subareas and S1. 
Quantification of cell re-entry into the cell cycle (BrdU+/Ki57+ cells) at E16.5 after 
2-h exposure to BrdU (A-C), at E18.5 after 2-h exposure to BrdU (D-F). Data show 
mean number of cells ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using 
One-way ANOVA (n = 5). 
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Abstract  
 
 Proper development of the medial prefrontal cortex (mPFC), crucial 
for correct cognitive functioning, requires projections from, among others, 
the serotonergic (5-HT) and catecholaminergic systems, but it is unclear how 
these systems influence each other during development. Here, we describe 
the parallel development of the 5-HT and catecholaminergic prefrontal 
projection systems in rat and demonstrate a close engagement of both systems 
in the proximity of Cajal-Retzius cells. We further show that in the absence 
of the 5-HT transporter (5-HTT), not only the developing 5-HT but also the 
catecholaminergic system, including their projections towards the mPFC, are 
affected. In addition, the layer identity of the mPFC neurons and reelin-
positive interneuron number and integration are altered in the absence of the 
5-HTT. Together, our data demonstrate a functional interplay between the 
developing mPFC 5-HT and catecholaminergic systems and call for a holistic 
approach in studying neurotransmitter systems-specific developmental 
consequences for adult behavior, to eventually allow the design of better 
treatment strategies for neuropsychiatric disorders.  
 
Keywords: Neurodevelopment;
 
Prefrontal Cortex (PFC); 5-HTT; TH;
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Introduction  
 
 Proper functioning of neural systems and correct targeting of their 
often-long projections to distant targets is crucial for cognitive performance. 
An important distant target of many neurotransmitters systems is the 
prefrontal cortex (PFC). The PFC is considered critical for executive and 
higher cognitive functioning1-3. Embryonic and early postnatal PFC 
development is directed by a sequence of intrinsic (e.g., proliferation, 
migration, and differentiation) and extrinsic (e.g., incoming 
projections/GABAergic interneurons) events which both can be affected in 
neurological and psychiatric disorders1,4,5. During development, the 
migration of newborn neurons establishes the characteristic inside-out 
layering of the PFC that furthermore receives numerous projections from 
various neurotransmitter systems, including the dopaminergic (DA), 
noradrenergic (NA), and serotonergic (5-hydroxytryptamine or 5-HT) 
systems6-10. It is unclear, however, how these systems interact during 
development and whether they influence each other. Cognitive and emotional 
disturbances are often attributed to the perturbed projection to the PFC of 
more than one neurotransmitter system11-14, including the catecholaminergic 
and 5-HT systems, in neurological psychiatric disorders15-22. The 5-HT 
system clearly interacts with the catecholaminergic system in adulthood but 
it remains to be elucidated how they interrelate during PFC development.  
 The 5-HT system is one of the earliest to emerge and sends out 
projections (around E10.5 in mice, E12 in rat) to cortical areas during 
embryonic development23,24. The rostral raphe comprises 5-HT cell clusters 
in the dorsal raphe (DR, B6, and B7) and the median raphe (MnR, B5, and 
B8) that project to the forebrain with predominantly the medial part of the DR 
projecting to the PFC where they arrive around E1625-27. It has become 
increasingly clear that 5-HT, but also other neurotransmitters, can act as a 
neurodevelopmental signal instructing the brain as time proceeds28-31. In fact, 
5- HT is able to modulate neurodevelopmental processes like proliferation, 
migration, and differentiation30,32. Within cortical areas, presumptive layer I 
Cajal-Retzius (CR) cells receive serotonergic and noradrenergic synaptic 
input during embryonic development and might therefore control their 
functioning6,33,34. Initially, CR cells secrete reelin which has been proven to 
be important for the specific inside-out patterning of cortical layers35-37. Later, 
CR cells develop into a heterogeneous population of GABAergic 
interneurons38-40. It remains to be determined however how exactly 
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disturbance of the developing 5-HT system influences the intrinsic 
neurodevelopmental events of the PFC.  
 The catecholaminergic system sends out projections to the forebrain 
approximately at the same time as the 5-HT system (E11.5 in mice, E13 in 
rat)9,41-43. Tyrosine hydroxylase- or TH-positive axons from the rostral part of 
the ventral tegmental area (VTA) arrive in the PFC around E15, somewhat 
earlier than the 5-HT system, in two streams within the subplate (SP) and the 
marginal zone (MZ) where the CR cells reside9,44. Although it remains 
speculative to what extent the catecholaminergic projections within the MZ 
are in synaptic contact with the CR cells, it is known that DA plays a 
developmental as well as a maturational role in prefrontal areas45-49. DAergic 
projections to the PFC are able to modulate proliferation, migration, and 
differentiation processes, and any interference during development could 
contribute to the cortical dysfunction in neuropsychiatric disorders50. Until 
recently, research was focused on understanding the ontogeny and 
functioning of separate neurotransmitter systems. However, comprehending 
the development and functioning of the brain in all its facets requires detailed 
knowledge of how various neural systems interact. In the adult brain, there is 
a clear interaction between the 5-HT and catecholaminergic projections 
towards the PFC, especially in the light of their engaged involvement in 
higher-order cognitive functioning12,15,51. Anatomically, the two systems 
considerably overlap in adulthood and seem to receive inputs from one 
another52-54. Less is known, however, about the extent to which the 5-HT and 
catecholaminergic systems influence each other during neurodevelopment51-
55.  
 Here, we describe the parallel development of the 5-HT and 
catecholaminergic systems in the rat between E16 and P6 with special 
emphasis on their common projection target, the medial PFC (mPFC). We 
show that in the absence of the 5-HT transporter (5-HTT), not only the 5-HT 
but also the catecholaminergic system, including TH-positive projections 
towards the mPFC, are affected. Within the mPFC, the reelin-containing CR 
cells are in close proximity to 5-HT and TH-positive fibers, and in the absence 
of the 5-HTT, they differ in number. We furthermore demonstrate that the 
identity of especially deep-layer neurons is altered in the 5-HTT-/- rats. 
Altogether, these data suggest that there is a functional interplay between the 
5-HT and catecholaminergic systems during development leading to a 
distortion of the cytoarchitecture of the PFC. Thus, the possible interplay of 
multiple neural neurotransmitter systems during development has to be taken 
into account when studying the etiology of neuropsychiatric disorders.  
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Materials and Methods  
 
Animals  
 
 The control neuroanatomical descriptions were performed on 
wildtype rats of the Wistar background purchased from a commercial breeder 
(Janvier, Labs, RjHan: WI; Hannover, Germany). The generation of the 
Slc6a4 wildtype (5-HTT+/+) and mutant rats (5-HTT-/-) has been described 
previously56. They were bred onto a Wistar genetic background. The day of 
the plug was considered to be embryonic day (E)0 and the day of birth to be 
postnatal day (P)0. All experiments were performed in compliance with the 
standard ethics guidelines of the European Community and in accordance 
with the recommendations of the local animal welfare committee (DEC) of 
the Radboud University. The protocol was approved by the DEC. Male and 
female embryos and pups were used indiscriminately in all experiments and 
sacrificed by decapitation.  
 
Section preparation and immunohistochemistry  
 
 Brains were rapidly dissected from E16.5, E18.5, and E20.5 embryos, 
P6 pups, and P25 adolescents, and fixed by immersion for 0.5–1.5 h in 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS), pH 7.4. After 
fixation, brains were washed in PBS, cryoprotected in 30% sucrose overnight, 
frozen in M-1 embedding matrix (Shandon, Thermo Fisher Scientific Inc., 
Waltham, MA, USA) on dry ice in a plastic cup, and stored at − 80°C. 
Cryostat coronal or sagittal sections were cut at 16 μm, mounted as series of 
6–8 on Superfrost Plus slides (Thermo Fisher Scientific), air-dried, and stored 
desiccated at −20°C. Cryosections were stained immunohistochemically and 
imaged as described previously10,57 with the following exceptions; incubation 
of P6 and P25 sections with primary antibodies was done for either 3 h at 
room temperature (RT) or overnight (ON) at 4°C. Immunofluorescence was 
visualized using either an Invitrogen/Thermo Fisher Scientific EVOSTM FL 
Auto Imaging System with a high-sensitivity CMOS camera or EVOS FL 
Auto Software or using a Leica DMRA fluorescence microscope coupled 
with a DFC340FX digital camera and LASAF software. The primary 
antibodies, dilutions used, and antibody suppliers can be found in Table 1. 
The nomenclature to describe neurons and axons within different brain areas 
is as described previously by Schambra et al.58 and Jacobowitz and Abott59 
and extended as outlined in9,10 and in Supplemental Figure 1.  
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Data analysis  
 
 All data analyses were performed in a blinded fashion without 
knowledge of the animal’s genotype. For assessing 5-HT- or TH-positive 
axon length and number of layer marker-positive neurons within the various 
subareas of the medial PFC (mPFC) of 5-HTT+/+ and of 5-HTT-/- rats, three 
to five P6 pups were analyzed and two to four well-spaced (120 μm) sections 
at the same neuroanatomical level were imaged. A 0.1-mm-wide rectangle 
spanning the prefrontal wall was placed over the center of the subarea (either 
infralimbic, IL; prelimbic, PL; or cingulate cortex, Cg) of the mPFC. The 
overall cortical length of a subarea was divided into ten equal bins [bin 1 
within the deep cortical layers and bin 10 within the presumptive layer I] 
within this rectangle, and 5-HT- or TH-positive axon length or number of 
layer marker-positive neurons were measured within each bin using ImageJ 
software including the NeuronJ plugin (NIH, Bethesda, USA). Data were 
normalized to a total length per bin, or to a percentage of the total number of 
cells and averaged for each pup. To better visualize and compare 5-HT and/or 
catecholaminergic innervation of wildtype and mutant mPFC, reconstructions 
of the individual fibers from two to three consecutive sections were obtained 
bilaterally using the NeuronJ plugin. Data were statistically analyzed by one-
way ANOVA (α = 5%) using Graphpad Prism 6/Excel data analysis toolkit 
and expressed as means ± SEM. Surface area of TH+ (tyrosine hydroxylase, 
rate-limiting enzyme responsible for DA synthesis) area within the ventral 
midbrain was measured by dividing the area along the midline. 
 The surface area was then measured in μm2 with Image J and averaged 
between left and right of two to three well-spaced sections. For each n, the 
same neuroanatomical level was chosen in terms of rostral-to-caudal extent. 
The measurements of 5-HT+ surface area of the B7 and B8 nuclei in the 
hindbrain was performed in a similar fashion with the exception that the entire 
nucleus was measured and not divided along the midline. 5-HT+ cell numbers 
of the B7 and B8 nuclei were counted in Adobe Photoshop in the same area 
used to measure the surface area in two to four well-spaced sections. Again, 
for each n, the same neuroanatomical level was chosen in terms of rostral-to-
caudal extent. Data were statistically analyzed by one-way ANOVA (α = 5%) 
using Graphpad Prism 6/Excel data analysis toolkit and expressed as means 
± SEM.  
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Results  
 
Developing 5-HT and catecholaminergic systems targeting the mPFC  
  
In rats, 5-HT neurons start extending axons by E12 and TH+
 
axons by 
E139,23. Both neurotransmitter systems send out ascending axonal projections 
to distant forebrain targets including the mPFC9,23,43. The ontogeny of both 
systems has been described in detail for each system individually, however 
little is known of the concurrent development of both systems. In order to 
examine the relationship between the developing 5-HT and 
catecholaminergic system, we immunostained cryosections of developing rat 
brains (E16, E18, E20, and P6) for TH and 5-HT. Sagittal sections suggest a 
close interrelationship of especially ascending TH+ and 5-HT+ axons (Fig. 1a–
d). When we took a closer look at the origin of both ascending neural systems, 
the DA midbrain and the 5-HT DR and MnR at the coronal level, we were 
able to observe a close contiguity between the TH+ and 5-HT+ axons (Fig. 1e–
t). Within the developing DR and MnR, besides the 5-HT neuron clusters, a 
combination of both TH+ axons as well as TH+ cell bodies could be observed 
(Fig. 1e–h). At E16, we observed overlapping positioning of the majority of 
the TH- and 5-HT- positive neurons (Fig. 1e). At E18, most of the TH+ 
neurons and fibers could be observed dorsally within or near the B7 of the 
DR (Fig. 1e–h). Within the developing DA midbrain at E16, 5-HT axonal 
projections were closely intermingled with the developing and still migrating 
TH+ neurons in both the substantia nigra (SN) and the VTA. The latter seemed 
to be more innervated by 5-HT projections throughout the course of 
development (Fig. 1i–l). TH+ and 5-HT axons travel together towards 
forebrain targets and they run in parallel within the median forebrain bundle 
(MFB). We observed that TH+ axons bundle in larger fascicles and reside 
more dorsal within the extent of the MFB when compared to the 5-HT axons 
(Fig. 1m–p). The 5-HT axons are located more ventral within the MFB and 
seemed to get more varicose as development proceeds (Fig. 1m–p). However, 
a large proportion of the TH+ and 5-HT+ axons coincide, suggesting a close 
contiguity within the MFB during development (Fig. 1m–p). Eventually, both 
neural systems reached numerous forebrain targets including the mPFC (Fig. 
1q–t). Especially within the region of the lateral septum (ls), the 
catecholaminergic system concurred with the 5-HT system although there 
was only partial overlap. Within the mPFC, there are two main fascicle paths 
of TH+ and 5-HT+ axon bundles. At E18, the first path was observed as a 
robust bundle of fascicles and individual 5-HT-positive fibers were detected 
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above the subplate (SP) of all three mPFC subdomains (infralimbic, IL; 
prelimbic, PL; and Cingulate, Cg), although the fibers were less prominent 
within SP of the Cg (Fig. 1q–t). TH-positive fibers could also be observed at 
E18 but were less conspicuous and fasciculated (Fig. 1q–t). The other path of 
concurring TH+ and 5-HT+ fibers was found within the marginal zone (MZ) 
or the presumptive layer 1 where again the presence of 5-HT fibers exceeded 
that of the TH+ ones (Fig. 1q–t). At E20, the innervation within the mPFC 
subdomains had increased in both paths and both systems innervated the 
cortical plate (CP) (Fig. 1s, t). In summary, there is a close intercalation and 
proximity of the catecholaminergic system and 5-HT system during 
development. They both innervate the mPFC in a similar pattern and time 
frame. Although the catecholaminergic system arrives earlier, the 5-HT 
system remains more prominent throughout development.  
 
Close proximity of DA and 5-HT projections within the developing 
mPFC  
 
 There is a vast amount of information on the innervation of the mPFC 
by each of the catecholaminergic and 5-HT systems. However, less is known 
about the coinciding innervation of the mPFC during development. To 
address the coinciding localization and possible interaction of the 
catecholaminergic and the 5-HT system within the developing mPFC, we 
focused on the immunoreactive TH and 5-HT fibers within the different 
aspects of the mPFC subdomains. To show the proximity and intercalation of 
both neural systems, camera lucida drawings were obtained. At E16, no TH+ 
or 5-HT+ fibers could be observed within all cortical aspects of the individual 
subdomains (data not shown). At E18, the two above-mentioned paths could 
be observed especially in the IL and PL (shown) with TH+ and 5-HT+ varicose 
fibers running above the SP and within presumptive layer 1 (Fig. 2b, e, and 
h). Hardly, any innervation of the CP was present at this time point. At E20, 
both streams were still prominent with 5-HT+ exceeding TH+ fibers in the 
presumptive layer 1 and to a lesser extent above the SP (Fig. 2c, f, i, and k). 
Substantial innervation of the CP of mostly 5-HT+ fibers could also be 
observed. At P6, extensive innervation by both neurotransmitter systems of 
all cortical aspects could be observed (Fig. 2d, g, j, and k). Yet, there was a 
clear 5-HT- and TH-positive band within layer I, which is most likely in close 
proximity of CR cells (Fig. 2b–j). TH+ and 5-HT+ axons seemed to run in 
close proximity especially early within development but, as was also clear 
from the camera lucida drawings, they appear to have their own distinct target 
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cells across layers. Thus, within the developing mPFC, both the 
catecholaminergic and the 5-HT systems are present and innervate cortical 
areas via the SP and MZ. Later, a large variety of neurons within the mPFC 
cortical layers get innervated by both the catecholaminergic as well as the 5-
HT system.  
  
The developing catecholaminergic system is affected in the absence of 
the 5-HTT  
 
 It is well accepted that 5-HT has an important neurodevelopmental 
role30,60-62. In previous work, we demonstrated that in the absence of 5-HTT, 
the amount of 5-HT-positive fibers increased dramatically within certain 
cortical layers of the IL and PL and to a lesser extent of the Cg ([10] and Fig. 
3, Supplemental Figure 1). This raises the question of how elevated levels of 
extracellular 5-HT during development might influence other neural systems. 
To address whether the catecholaminergic system would be affected, we 
studied P6 brains of the 5-HTT mutant rat model. First, we tried to 
recapitulate our previous results: the 5-HT innervation of the subdomains of 
the mPFC was higher in 5-HTT-/- animals (n = 5) compared to wildtype (n = 
5). Indeed, we again observed a significant increase of total 5-HT innervation 
in both the IL (p = 0.000016) and PL (p = 0.000059) and to a lesser extent in 
the Cg (p = 0.11049; Fig. 3c, f, i). Strikingly, we discovered that the 
catecholaminergic innervation of the mPFC subdomains is also affected in 5-
HTT-/- animals. Within the IL and PL, we found a significant increase of TH+ 
innervation in especially the deeper layers and in bins 10 and 8 (more 
superficial layers) for the IL and PL of 5-HTT-/- animals, respectively (Fig. 
3a, b, d, and e). Interestingly, the TH+ innervation of the CG tended to be 
higher in the deeper cortical layers whereas it was significantly lower in the 
more superficial layers, mimicking the results we obtained before for the 5-
HT innervation10 (Fig. 3g–h).  
 As the TH+ and 5-HT+ innervation of the mPFC was affected in 5-
HTT-/- animals, the question remained whether also the source of the TH+ 
rostral VTA or rVTA) and 5-HT+ (DR and MnR) prefrontal fibers were 
affected by changes in 5-HT levels during development. To this end, we 
measured the surface area of the DA midbrain including the rVTA and the 
SN of both 5-HTT-/- P6 animals (n = 3) and their control counterparts (n = 3). 
The total amount of surface area comprising TH+ neurons was significantly 
lower in 5-HTT-/- animals as compared to controls (p = 0.013; Fig. 4g). In 
addition, there seemed to be more axons leaving the VTA area and TH-
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positive neurons looked sparser and more disorganized, especially within the 
SN (Fig. 4d, e). We furthermore measured the total surface area of the raphe 
B7 and the B8 cluster in P6 5-HTT-/- animals and wildtypes, counted the 5-
HT-positive cells in both clusters, and calculated the cell density. The total 
surface area comprising 5-HT neurons was significantly larger in both the B7 
and the B8 cell cluster in 5-HTT-/- animals compared to controls (p = 0.01 and 
p = 0.006, respectively) Fig. 4n, q). This was reflected by an increase in length 
of the B7 cluster and an increase in width of the B8 cluster (p = 0.031) and (p 
= 0.037) respectively; Fig. 4o, r). Additionally, the total amount of 5-HT-
positive cells within each cluster was significantly lower, resulting in a lower 
cell density for both cell clusters (p = 0.002 and p = 0.0002, respectively; Fig. 
4m, p).  
 Together, we can conclude that when 5-HTT is absent during 
development, the mesoprefrontal catecholaminergic system and rhomben 
prefrontal 5-HT system are affected.  
 
Reelin in relation to 5-HT and catecholaminergic signaling  
 
 The 5-HT fibers within the MZ have been shown to contact CR cells, 
and thereby control reelin release6. By combining immunostaining for 5-HT 
and for TH, we observed that there are numerous TH+ and 5-HT+ projections 
running through the MZ where the CR reside. The question remains, however, 
to what extent the absence of 5-HTT interferes with reelin release, either 
directly or indirectly, through altered 5-HT or other projections. To visualize 
the proximity of TH+ and 5-HT+ fibers with CR cells, we immunostained 
cryosections of E18 and E20 with either 5-HT or TH in combination with 
reelin. Throughout cortical regions, including all subdomains of the mPFC, 
5-HT- and TH-positive fibers running through the MZ are in close proximity 
with CR cells (Fig. 5a–h). Confocal images showed that some varicosities 
were indeed contacting the CR cells (Fig. 5j and Supplemental Figure 2). 
Triple-labeling the cryosections with TH, 5-HT, and reelin revealed that the 
5-HT and TH fibers both contact the CR cells, albeit at different sites (Fig. 
5i), suggesting that besides the known 5-HT, also the TH fibers are in the 
vicinity to be able to influence CR cell output and possible reelin release.  
 
Prefrontal cytoarchitecture is affected in the absence of the 5-HTT 
  
 The fact throughout development, 5-HT and TH fibers reside in close 
proximity with CR cells and that they are affected in the absence of 5-HTT, 
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made us speculate whether these innervation alterations could have impacted 
cortical build-up. To address the question to what extent layer-specific 
markers were affected, we immunostained mutant and wildtype P6 
cryosections for a deep-layer marker, Tbr1 (Fig. 6a–c) and an upper-layer 
marker, Cux1 (Fig. 6d–f). Indeed, both markers were severely affected in 
their expression pattern (Fig. 6). The percentage of cells affected was 
significant in all ten bins but was most striking for the bins in deeper layers, 
specifically for Tbr1 (Fig. 6a–c). The total number of Cux1- and Tbr1-
positive cells was significantly affected as well (Supplemental Figure 3). This 
is in coherence with our previous findings demonstrating that Satb2, a layer 
2–5 marker was severely affected10. The total number of cells (DAPI-
positive) was not significantly different in IL (p = 0.2), PL (p = 0.9), and CG 
(p = 0.9); (Supplemental Figure 3), suggesting that the altered layer marker 
expression is due to an altered identity. To investigate marker expression at a 
later developmental age, we immunostained mutant and wildtype P25 
cryosections for two different deep-layer markers; Tbr1 and Satb2 (Fig. 6k– 
o). Expression levels of both markers were more restricted to the deeper layers 
in the wildtype brains and most affected when 5-HTT was absent (Fig. 6m–
o). This suggests that, even though the percentage of cells expressing deep-
layer markers catch up a bit at P25 reflecting some sort of developmental 
delay, a large portion will not be able to express these markers. Reelin-
positive interneurons will dispense throughout the cerebral wall in early 
postnatal ages36,37,63. Even though the ontogeny of reelin-positive CR cells 
and the reelin-positive GABAergic interneurons differ in their ontogeny64, we 
pursued to find out whether the number and integration of reelin-positive cells 
was affected by the lack of 5-HTT during the course of development. We 
counted the reelin-positive cells in the P6 mutant and the control animals. We 
discovered that in all subdomains of the mPFC, the number and distribution 
of reelin-positive neurons was affected in the 5-HTT-/- animals as compared 
to wildtypes (Fig. 7). In the IL, only bins 2, 5, and 6 showed lower number of 
reelin-positive cells (Fig. 7a, b), while in the PL, all bins except for 4, 5, and 
8 showed significant lower numbers of reelin-positive cells (Fig. 7d, e). 
Within the CG, bins 4, 6, 9, and 10 showed significant lower numbers of 
reelin-positive cells (Fig. 7g, h). Together, we found a decrease in the total 
number of reelin- positive cells in all subdomains although the number did 
not reach significance within the IL (Fig. 7c, f, and i). This suggests that the 
integration and/or number of reelin-positive interneurons within the 
subdomains of the mPFC is affected as well.  
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 In all, we observed a strong interdependence between the developing 
5-HT and catecholaminergic system. In the absence of 5-HTT, we found 
significant differences in the shape (rVTA) and in the shape and content 
(DR/MnR) of the origins of both neural systems, a striking increase of both 
5-HT and catecholaminergic innervations of the mPFC, altered deep-layer 
identity of mPFC neurons, and a decrease in reelin-positive cells, and which 
is summarized in Fig. 8.  
 
Discussion  
 
 In this study, we show the coinciding development of the 5-HT and 
the catecholaminergic systems between E16 and P25 within their origin, their 
outgrowing projections through the MFB and their common projection target, 
the mPFC. In addition, our results demonstrate that in the absence of the 5-
HTT and next to the 5-HT, also the catecholaminergic system and their 
projections towards the mPFC are altered. We further demonstrate that within 
the mPFC, the TH and 5-HT fibers are in close proximity to reelin-containing 
CR cells and are different in number when 5-HTT is lacking. We also observe 
that, with differences in 5-HT/TH innervation of the mPFC, prefrontal cell 
identity is altered. Altogether, these data suggest that there is a functional 
interplay between the 5-HT and catecholaminergic systems during 
development with an effect on the proper cytoarchitecture of the PFC.  
 
Catecholaminergic and 5-HT control of prefrontal development  
 
 It is now well accepted that 5-HT plays an important role during 
neurodevelopment and that any disturbance of the system could add to the 
risk of developing neuropsychiatric conditions30,65-67. There is considerable 
genetic diversity among 5-HT neurons resulting in a vast and meticulously 
constructed network projecting to a large variety of targets8,24,68,69. The 
development of this heterogeneous pool of 5-HT neurons is under the control 
of intrinsic factors (e.g., transcription factors) and in interplay with extrinsic 
factors (e.g., guidance cues or cell adhesion molecules) that can steer the 
targeting projections70-75. Prefrontal 5-HT neurons arise in the rostral raphe 
cluster and the ascending axonal projections bundle up within the MFB and 
the fascicles traverse through the septal area towards the mPFC6,23,76. Here, 
they are bundled in two paths; one within the superficial MZ and one on top 
of the SP underneath the CP which they innervate after a short waiting 
period6,23,77. Essentially, the same developmental trajectory holds true for the 
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mesoprefrontal catecholaminergic projections, although the 
catecholaminergic system reaches the mPFC earlier42,43,49. Within the MZ and 
presumptive layer I of the mPFC, we observed 5-HT- and TH-positive 
varicosities in very close proximity of the reelin-positive CR cells. Synaptic 
structures, stained with either pre- or postsynaptic markers, could shed light 
on to what degree the CR cells receive TH- and/or 5-HT- synaptic inputs 
during development. In addition, varicosities do not necessarily have to imply 
synapses but can be a reflection of the complex that uses diffuse/volume 
transmission to communicate78-80. Nonetheless, there is certainly a spatial 
closeness of 5-HT+ as well as TH+ fibers that could imply the ability to 
influence CR output and maybe even reelin release. Reelin is known for its 
ability to direct cortical layer formation81,82. However, the developmental role 
of the effect of 5-HT, DA, or other neurotransmitters on reelin release needs 
to be further characterized.  
 
Direct or indirect effects of 5-HTT on cortical integrity  
 
 One critical way by which extracellular 5-HT levels can be controlled 
is through expression of 5-HTT. The transporter can clear 5-HT from the 
synaptic cleft to maintain homeostasis83. Remarkably, the expression of 5-
HTT is already quite robust in early development, even before serotonergic 
axons have reached their targets60,84. What does this imply? It is known that 
there is an extra-embryonic source of 5-HT from the placenta that could 
regulate certain aspects of central nervous system development30,85,86. Yet, 
many questions remain. Narboux-Nème and colleagues60 elegantly showed a 
transient 5-HTT expression within layers II, V, and VI of the mPFC at E15.5, 
thus even before 5-HT fibers reach the mPFC. Could it be that these deep-
layer cortical neurons are most affected by the absence of 5-HTT and the 
resulting elevation of extracellular 5-HT? We indeed observed that in both 
layers V and VI as well as more superficial aspects of the prefrontal subareas, 
5-HT- and TH-innervation were altered in the absence of 5-HTT. In addition, 
in our experiments, the number of predominantly deep-layer but also of the 
superficial-layer neurons was affected in the absence of 5-HTT at P6. At P25, 
however, we still see this effect for two different deep-layer markers (Tbr1 
and Satb2); however, there is some percentage expression that does express 
these markers in the mutant suggesting a developmental delay. There are no 
indications that proliferation or migration (data not shown) was affected. 
Altamura and colleagues showed that in 5-HTT-deficient mice there are 
differences in cell density and layer thickness87. Does this mean that there is 
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a different window of expression of layer-specific markers Cux1 and Tbr1 
when 5-HTT is absent? At this point, it is hard to conclude whether this 
change in expression of layer markers is due to cell-autonomous effects 
(absence of 5-HTT) or cell non-autonomous effects (differences in 
innervation patterns/reelin effect), or a combination of both. Experiments 
using conditional mutants88 that have a cell-type-specific deletion of 5-HTT 
could shed more light on this.  
 
Interaction of the developing catecholaminergic and 5-HT systems  
 
 Numerous studies have proven that there is an interdependence 
between 5-HT and DA11,15,16,18,89, although less is known about this 
phenomenon during development. Both systems are able to influence 
neurodevelopmental events such as proliferation, migration, and 
differentiation30,51,62,90. But can one system be facilitated by the other during 
development? We showed that the TH+ projections within subdomains of the 
mPFC are altered in absence of the 5- HTT. Expression of 5-HTT has been 
found within virtually all DR neurons60,84,91. Are 5-HTT-deficient DR 
neurons able to alter the course of TH+ projections? And if yes, what are the 
exact neurodevelopmental events of the developing DA neurons that can be 
influenced by the 5-HT system and at what developmental time points? 
Alongside the changes in 5-HT receptor expression92,99, the expression of DA 
receptors and transporters might be altered as a consequence of a disrupted 5-
HT system and DA system. This can result in changes in system sensitivity 
and excitability which would have extreme consequences for the maturation 
of cortical cells. For example, reelin-positive interneurons express the 5-HT3A 
receptor64,100. Could changes in the 5-HT projection system have led to the 
changes we observed in the number and distribution of the reelin-positive 
cells? We need to have a complete picture of the spatial and temporal aspects 
of these developing systems in order to be able to design preventive measures 
or curative treatment without any side effects.  
 
Guidance of interconnected systems  
 
 The 5-HT projections to target-selective forebrain regions are under 
the control of classical guidance molecules2,70,75. The 5-HT system is 
furthermore capable of modulating the responsiveness of axons to guidance 
cues such as netrins62. However, the catecholaminergic system reaches the 
mutual forebrain targets earlier than the 5-HT system does. Can it be that the 
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altered catecholaminergic system development due to the absence of 5-HTT 
influences the developing mPFC earlier than the 5-HT and in a different 
manner? Or is it the absence of 5-HTT in target areas and within guidepost 
positions along the way that has changed guidance cue expression or the 
responsiveness of the TH+ fibers? Even though the DR and MnR project to 
different targets, their development involves a common guidance family101. 
The differential expression of EphA5 and ephrina5, and consequential 
difference in Eph ephrin signaling, steers the region-specific 5-HT 
innervation. Whether developing catecholaminergic projections within the 
same temporal and spatial window are also responsive to the same guidance 
cues as the 5-HT axons headed towards the mPFC remains to be established. 
Neurodevelopmental processes may diverge in different brain regions and at 
various developmental time points. For example, the ontogeny of 
neurotransmitter systems can be affected by risk factors and aberrant 
projections may result1,9,10,22,50. Depending on the type of risk factor involved 
and their sensitive windows, which control the timing of when a disorder 
becomes overt, it is either the mPFC itself or its connected brain areas that 
may maldevelop. Yet, the net effect of faulty projections on other developing 
systems remains to be determined. Longitudinal studies at the systems level, 
including a complete inventory of the expression of a variety of 
neurotransmitter receptors and transporters in relation to the developing 
projections traveling together and their actions within the mPFC are needed. 
This would generate an important wealth of knowledge in order to understand 
the complexity of these interacting systems during development.  
 
Conclusions  
 
 Our study shows a functional interplay between the 5-HT and 
catecholaminergic systems during development. As expect- ed, due to the 
absence of the 5-HTT the 5-HT system was disturbed but we found that the 
catecholaminergic system was perturbed as well, together resulting in an 
altered maturation of the mPFC. Overall, the striking observation of both 5-
HT and catecholaminergic hyperinnervation of prefrontal subregions 
highlights the need for precise system-oriented dissection of neural systems 
that concomitantly develop. The removal of only one building block may 
destabilize a plethora of interacting neurodevelopmental systems leading to 
impairment of cognitive functioning. This calls for more studies on the 
dissection of neurotransmitter systems-specific consequences on adult 
 
 
121 
 
behavior to eventually allow the design of better treatment strategies for 
neuropsychiatric disorders.  
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Table 1 The primary antibodies, dilutions used, and antibody 
suppliers  
 
Antibody  Dilution Company 
Rabbit anti-5-Hydroxytryptamine (5-HT) 1:1000 Sigma-Aldrich  
Mouse anti-Satb2  1:500 Abcam 
Mouse anti-Reelin 1:500 Chemicon 
Mouse anti-Cux1 1:300 Abcam 
Rabbit anti-Tyrosine Hydroxylase (TH) 1:1000 Millipore 
Chicken anti-Tyrosine Hydroxylase (TH) 1:500 Abcam 
Rabbit anti-Tbr1 1:500 Abcam 
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Fig. 1. Developing 5-HT and catecholaminergic systems target the mPFC. Sagittal 
cryosections of E16 (a), E18 (b), E20 (c), and P6 (d) rat brains immunostained for 
5-HT (red) and TH (green) and stained with DAPI (blue) to visualize cell nuclei 
showing the 5-HT and the catecholaminergic developing systems. Dotted lines 
indicate the coronal section levels. Enlargements of coronal cryosections of E16 (e), 
E18 (f), E20 (g), and P6 (h) rat brains immunostained for 5-HT (red) and TH (green) 
and stained with DAPI (blue) showing the DR with the B7, B8, and/or B9 5-HT-
positive cell clusters closely intermingled with TH-positive neurons and fibers. 
Enlargements of coronal cryosections of E16 (i), E18 (j), E20 (k), and P6 (l) rat 
brains immunostained for 5-HT (red) and TH (green) and stained with DAPI (blue) 
showing the rostral ventral tegmental area (rVTA) and the substantia nigra (SN) with 
the TH- positive cell clusters/fibers closely intermingled with 5-HT-positive neurons 
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and fibers. Dotted lines indicate the midline. Enlargements of coronal cryosections 
of E16 (m), E18 (n), E20 (o), and P6 (p) rat brain immunostained for 5-HT (red) and 
TH (green) and stained with DAPI (blue) showing the medial forebrain bundle 
(MFB) with TH residing mainly in dorsal fascicles while 5-HT is present mostly 
within more caudal ones. Coronal (half shown) cryosections of E18 (q) and E20 (r) 
rat brains immunostained for 5-HT (red) and TH (green) and stained with DAPI 
(blue) showing the forebrain targets of both systems including the caudate putamen 
(CPu), the lateral septum (ls), the nucleus accumbens (Acb), and the medial 
prefrontal cortex (mPFC). Enlargements of the mPFC region of E18 (s) and E20 (t) 
rat brains showing a TH/5-HT- positive stream above the subplate (SP) and one in 
the marginal zone (MZ) in all three prefrontal subdomains (infralimbic, IL; 
prelimbic, PL; and cingulate, Cg). ls, lateral septum. Bar in a–d, 500 μm; e, 200 μm; 
f, 300 μm; g, 250 μm; h, 200 μm; i–l,300 μm; m–p, 200 μm; qandr, 300 μm; sandt, 
250 μm.  
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Fig. 2. Caecholaminergic and 5-HT interaction within the developing mPFC. (a) 
Schematic representation of a sagittal view of a developing embryonic rodent brain 
showing the catecholaminergic mesoprefrontal topographic projection (green arrow) 
and the 5-HTergic rhomben prefrontal topographic projection (red arrow) 
highlighting the forebrain target; the mPFC (within the gray circle). Enlargement of 
coronal cryosections of E18 (b), E20 (c), and P6 (d) rat brains immunostained for 5-
HT (red) and TH (green) and stained with DAPI (blue) showing a cortical swatch of 
the mPFC IL subarea. Enlargements of the boxed areas in B-D showing TH- and 5-
HT-positive fibers within the marginal zone (MZ, upper box) and subplate (SP, 
lower box) region of the E18 (e), E20 (f), and P6 (g) mPFC flanked by the gray-
valued separated channels (TH upper and 5-HT lower box). (h–j) Camera lucida 
drawings of the boxed areas in b–d showing the proximity of the TH- (green) with 
the 5-HT- positive (red) fibers. (k) Quantification of the total length of TH (green) 
and 5-HT-positive (red) fibers within the three subareas (IL, PL, and Cg) of the 
mPFC. IZ intermediate zone, PZ proliferative zone. Bar in a, 100 μm; b, 80 μm; c, 
70 μm.  
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Fig. 3. Catecholaminergic innervation of the mPFC affected in 5-HTT-deficient 
rat model. Enlargements of cryosections of P6 5-HTT+/+ and 5- HTT-/- rat brains 
showing prefrontal swatches of the IL (a), PL (d), and the Cg (g) immunostained for 
TH (white). Quantification of the TH+ fiber length (in μm) within the bins indicated 
in a, d, and g in the IL (b), PL (e), and Cg (h) of 5-HTT-/- compared to 5-HTT+/+ pups 
confirming the qualitative observations. The gray boxes represent the non-significant 
(NS) bins. Graphs in b, e, and h show average total length of TH-positive fibers per 
bin ± SEM. One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. Quantification 
of the total TH-positive (left) as compared to the total 5-HT-positive fiber length (in 
μm) over the complete length of the prefrontal swatch in the IL (c), PL (f), and Cg 
(i) of 5-HTT-/- compared to 5-HTT+/+ pups. Graphs in c, f, and i show average total 
length of TH- and 5-HT-positive fibers ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, 
analyzed using One-way ANOVA. Bar in all, 50 μm. 
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Fig 4. Catecholaminergic system is affected when 5-HT levels are perturbed 
during development. (a) Schematic representation of a sagittal view of a developing 
postnatal rodent brain showing the catecholaminergic mesoprefrontal topographic 
projection (red arrow) and the 5-HTergic rhomben prefrontal topographic projection 
(green arrow) towards the mPFC highlighting the DA origin rVTA, the 5-HT origin 
DR, and the MFB (within the gray circles). Enlargements of coronal cryosections of 
P6 rat brain immunostained for 5-HT (red) and TH (green) and stained with DAPI 
(blue) showing the MFB of 5-HTT-/- (c) compared to 5-HTT+/+ animals (b) showing 
a higher level of defasciculation of TH+ fibers and a lower level of 5-HT fibers in the 
5-HTT-/- pups. Boxed area shows the individual fascicles of the catecholaminergic 
(middle box) and 5-HT (lower box) system. Enlargements of coronal cryosections 
of P6 rat brain immunostained for TH (white) showing the rVTA of 5-HTT-/- (e) 
compared to 5-HTT+/+ (d) animals showing more catecholaminergic fibers exiting 
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the VTA area (arrowhead) and fewer and less organized TH+ neurons in the SN 
(asterisk) of 5-HTT-/- pups. (f) Schematic representation of a coronal view of a 
developing DA midbrain including the VTA and SN showing the measured surface 
area (surrounded by red dotted lines). Aq aqueduct. (g) Graph showing the surface 
area occupied by TH+ fibers/neurons ± SEM which is significantly smaller for 5-
HTT-/- pups. One-way ANOVA, *p < 0.05. Enlargements of coronal cryosections of 
P6 rat brain immunostained for 5-HT (white) showing the DR B7 (h, i) and B8 (j, k) 
cell cluster of 5-HTT-/- (i, k) compared to 5-HTT+/+ (h, j) animals showing 
irregularities in both cell clusters (asterisks) of 5- HTT-/- pups. (l) Schematic 
representation of a coronal view of the developing 5-HT raphe area including the B7 
and B8 cell clusters showing the measured surface area (surrounded by red dotted 
lines) and the maximal width (max W) and the maximal lengths (max L) of both 
clusters (red lines). Aq aqueduct. Quantification of the number of the 5- HT-positive 
neurons in the B7 (m) and B8 (p) cluster, the measured surface area of the B7 (n) 
and the B8 (q) area, the maximal length of the B7 cluster (o), and the maximal width 
of the B8 cluster (r). Bar in b and c, 200 μm; d and e, 300 μm; h–k, 100 μm.  
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Fig. 5. The 5-HT and catecholaminergic systems are in close proximity of the CR 
cells. Coronal cryosections of E18 (a–c, e, and f) and E20 (d, i) rat brains 
immunostained for TH (red, a–d) or 5-HT (red, e–h) and reelin (green), 
counterstained with DAPI (blue). b, c Enlargements of the boxed area in a showing 
the TH fibers in close proximity to the reelin-positive CR cells. d Overview of the 
relation of TH innervation within the mPFC at E20. Coronal cryosections of an E18 
rat brain immunostained for 5-HT (red, e–h, i) and reelin (green), counterstained 
with DAPI (blue). f Enlargement of the boxed area in e showing the 5-HT fibers in 
close proximity to the reelin-positive Cajal-Retzius (CR) cells. g Enlargement of the 
boxed area in f showing the 5-HT fibers in close proximity to the reelin-positive CR 
cells. h Enlargement of the septal region in e showing the 5-HT fibers in close 
proximity to the reelin-positive CR cells. i E20 cryosection stained for TH (green), 
5-HT (light blue) and reelin (red) and counterstained with DAPI (blue). Inset shows 
the close proximity of the TH and 5-HT fibers with the CR cells. j Confocal image 
of the marginal zone showing TH (green) and 5-HT fibers (purple) in close proximity 
to reelin-positive CR cells (red). Bar in a and e, 300 μm; i, 30 μm; j, 20 μm.  
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Fig. 6. Prefrontal cytoarchitecture is affected in the absence of 5-HTT. 
Enlargements of cryosections of P6 5-HTT+/+ and 5-HTT-/- rat brains showing 
prefrontal swatches of the PL immunostained for Tbr1 (red, a, b) or Cux1 (red, d, e) 
and counterstained with DAPI (blue). b, e Quantification of the percentage of Tbr1-
positive (c) or Cux1-positive (f) neurons within the bins indicated in a, b, d, and e. 
g, h Enlargements of cryosections of P6 5-HTT+/+ and 5-HTT-/- rat brains showing 
prefrontal swatches of the PL double-immunostained for Tbr1 (red) and Satb2 
(green) and counterstained with DAPI (blue). i Quantification of the percentage of 
Satb2-positive neurons within the bins indicated in h. j Quantification of the 
percentage of Satb2/Tbr1 double-positive neurons within the bins indicated in h. k, 
l Enlargements of cryosections of P25 5-HTT+/+ and 5-HTT-/- rat brains showing 
prefrontal swatches of the PL double-immunostained for Tbr1 (red) and Satb2 
(green). m Quantification of the percentage of Satb2-positive neurons within the bins 
indicated in l. n Quantification of the percentage of Satb2-positive neurons within 
the bins indicated in l. o Quantification of the percentage of Satb2/Tbr1 double-
positive neurons within the bins indicated in l. Graphs in c–o show average 
percentage ± SEM. One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. Bar in 
a–l, 100 μm. 
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Fig. 7. The number of reelin-positive cells is diminished in the absence of 5-HTT. 
Enlargements of cryosections of P6 5-HTT+/+ and 5-HTT-/- rat brains showing 
prefrontal swatches of the IL (a), PL (d), and the Cg (g) immunostained for reelin 
(red) and counterstained with DAPI (blue). Quantification of the percentage of 
reelin-positive neurons within the bins indicated in a, d, and g in the IL (b), PL (e), 
and Cg (h) of 5-HTT-/- compared to 5-HTT+/+ pups confirming the qualitative 
observations. Graphs in b, e, and h show average percentage of reelin-positive 
neurons normalized to total number of cells per bin ± SEM. One-way ANOVA, *p 
< 0.05, **p < 0.01, ***p < 0.001. Quantification of the total number of reelin-
positive cells over the complete length of the prefrontal swatch in the IL (c), PL (f), 
and Cg (i) of 5-HTT-/- (black bar) compared to 5-HTT+/+ pups (white bar). Graphs in 
c, f, and i show average number ± SEM. One-way ANOVA, *p < 0.05, **p < 0.01, 
***p < 0.001. Bar in a–g, 100 μm.  
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Fig. 8. Schematic overview of the results observed in the 5-HTT rat model. DA 
dopaminergic, Cg cingulate, DR dorsal raphe, 5-HT serotonergic, IL infralimbic, 
MnR medial raphe; mPFC medial prefrontal cortex, PL prelimbic, rVTA rostral 
ventral tegmental area. 
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Supplemental Fig. 1. 5-HT and DA systems affected in 5-HTT mutant rat model. 
(A, B, C) Quantification of the 5-HT fibers length (in µm) per bin in mPFC subareas: 
IL (A), PL (B) and Cg (C) of 5-HTT-/- compared to 5-HTT+/+ pups showing a 
significant increase of 5-HT fibers in all mPFC subdomains of 5-HTT-/- animals. (D) 
Enlargements of cryosections of P6 5-HTT+/+ and 5-HTT-/- rat brain showing dorsal 
VTA immunostained for TH (white) with more aberrant fibers leaving the VTA in 
5-HTT-/- animals. Graphs in A, B and C show average total length of 5-HT-positive 
fibers per bin ± SEM. One-way ANOVA (α = 0.05), *p < 0.05, **p < 0.01, ***p < 
0.001. 
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Supplemental Fig. 2. Prefrontal cytoarchitecture is affected in the absence of the 
5-HTT. (A, B, C) Quantification of  total number of Cux1-positive (A), Tb1-positive 
(B)  and DAPI-positive (C) neurons over the complete length  of the prefrontal 
swatch in IL, PL and CG, showing the total number of Cux1-positive and Tbr1-
positive cells decrease in the 5-HTT-/- animals (A, B) the total number of DAPI-
positive cells remain unchanged when we compare 5-HTT+/+ with 5-HTT-/- animals 
(D), confirming our significant results in A and B are not due to the smaller number 
of cells in the mutant animal 5-HTT-/-. Graphs in A, B and C show average number 
± SEM. One-way ANOVA (α = 0.05), *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
147 
 
.  
 
 
 
 
 
 
 
 
148 
 
 
 
 
149 
 
4 
Developmental switch in 
anxiety-like behavior and 
coinciding prefrontal 
aberrations in serotonin 
transporter knockout rats 
 
 
L.P. Garcia, A. Middelman, A.M. Hoppenreijs, J.A. van 
Hulten, G.J.M. Martens, J.R. Homberg, S.M. Kolk 
 
 
 
 
 
In preparation for submittance 
 
 
150 
 
Abstract 
 
 Besides the known functions of serotonin (5-HT) in key cognitive 
abilities and emotional regulation, a more complex role for this 
neurotransmitter during development has now been acknowledged. 
Serotonergic neurons send their projections to the medial prefrontal cortex 
(mPFC) and disturbances in the serotonergic system can cause mPFC 
developmental changes that have lifelong consequences, including increased 
anxiety. Therefore, more insight into the relationship between serotonergic 
system development in the mPFC and the appearance of anxiety would be 
informative. Here, we investigated anxiety-like behavior and mPFC 
anatomical correlates at adolescent and early-adult ages in 5-HT transporter 
knockout (5-HTT-/-) rats. We find that the 5-HTT-/--induced increase in 
anxiety is not observed at postnatal day (PND)17 and PND25 and emerges 
only at PND35 and then persists into adulthood. At PND35, but not at PND17, 
we found a number of molecular and cellular alterations in the mPFC of 5-
HTT-/- animals, including neuronal loss through activation of Caspase-3 as 
well as an increased serotonergic innervation in the prelimbic and cingulate 
cortices. In conclusion, 5-HTT-deficient rats show an altered cytoarchitecture 
in the developing mPFC and increased anxiety-like behaviour that only 
emerges during adolescence. 
 
Keywords: Prefrontal Cortex Development; Serotonergic System; 5-HTT-/- 
Knockout Rats; Anxiety; Disturbed Behaviour 
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Introduction 
 
 Anxiety is a feeling associated with excessive worry about the future 
and fears that something can get out of control and end up wrong1. It is a 
natural, protective and instinctive biological reaction that is important for 
human beings, because it allows the individual to prepare and plan actions to 
deal with situations that are interpreted by the brain as uncomfortable or 
threatening2,3. A combination of genetic, hormonal and environmental factors 
within a subjective context may increase anxiety4.  
 When an anxiety response starts, a surge of hormones and 
neurotransmitters is triggered, which prepares the body for a reaction2,5. One 
of the major neurotransmitters involved in this response is the monoamine 
serotonin (5-HT)9,10,11 that is released by serotonergic neurons located in the 
raphe nuclei in the brainstem42,43. These neurons send projections to all brain 
areas involved in the regulation of mood and behavior, including the limbic 
system and the prefrontal cortex (PFC)21,22. Interestingly, 5-HT is one of the 
first neurotransmitters to appear during embryonic development of the central 
nervous system (CNS)72. During cortical development 5-HT acts as a 
neurotrophic factor controlling developmental events such as proliferation, 
migration, differentiation, cell death, formation of synapses and a correct 
organization of the cerebral cortex93. Thus, the regulation of 5-HT 
homeostasis during brain development and later in life is critical for normal 
CNS development and maturation, and its dysregulation has been associated 
with anatomical, functional and behavioral abnormalities71,9, including 
anxiety 73,74. 
 One key gene variant mediating individual differences in anxiety is 
the serotonin transporter (5-HTT)-linked polymorphic region (5-
HTTLPR)9,10,11, which regulates the expression of the 5-HTT gene 
(SLC6A4)75,76. Compared to the long (l) allelic variant, the short (s) variant 
is associated with reduced transcription of the 5-HTT gene and confers 
increased anxiety62. Genetic vulnerability may manifest itself in subjective 
markers of pathological anxiety only when triggered by environmental factors 
such as stress77,78. 
 To understand anxiety-like behavior and its molecular and cellular 
underpinnings, animal studies are essential. These studies allow 
measurements of behavioral responses caused by exposure to potentially 
anxiogenic situations under controlled laboratory conditions79. For instance, 
5-HTT knockout (5-HTT-/-) rodents are known to display anxiety-related 
responses when exploring a novel environment48. Furthermore, animals allow 
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more detailed understanding of genotype effects on brain neurocircuitry that 
may explain 5-HT-dependent anxiety responses. The anxiety response is 
strongly dependent on the medial PFC (mPFC)21,22, most likely through its 
reciprocal connections with the amygdala and other structures of the limbic 
system37,38,39 as well as by regulating the monoaminergic nuclei in the 
brainstem such as the dorsal raphe nucleus (DRN)42,43. In turn, serotonergic 
projections from the DRN regulate the mPFC, thus creating a feedback 
loop49,50,51. In humans, functional magnetic resonance imaging studies have 
found increased amygdala and cingulate cortex, limbic regions critical for 
processing of negative emotion, reactivity to fearful stimuli in healthy 
subjects carrying the s-allele80,81,85,83, as well as reduced gray matter volume 
in 81,86,83. Furthermore, the genetically induced absence of 5-HTT in rodents 
causes increased serotonergic and catecholaminergic innervation, and 
alterations in the cytoarchitecture of the subareas of the mPFC, such as the 
infralimbic, prelimbic and cingulate cortices58,59. However, the mechanisms 
underlying the effects of reduced or lack of 5-HTT, and consequently 
increased mPFC 5-HT (and dopamine) levels, on cortical cytoarchitecture and 
anxiety are still unclear. Since inherited 5-HTT down-regulation in animals, 
and likely also in humans, is associated with a lifelong increase in CNS 5-HT 
levels, and the function of 5-HT changes over time from exerting 
neurotrophic actions to being a neurotransmitter, anxiety may have an origin 
in 5-HT-mediated neurodevelopmental effects on PFC cytoarchitecture. 
 Here, we aimed to investigate the effect of the absence of the 5-HTT 
on anxiety and on mPFC cytoarchitecture during a specific developmental 
time window. To this end, we used 5-HTT knockout rats and wild-type 
controls to dissect how anxiety develops across juvenile, adolescent and adult 
stages. To investigate the underlying structural changes in the mPFC, we 
assessed across these stages the cytoarchitecture and furthermore focused on 
the serotonergic innervation of this brain area. 
 
Material and methods 
 
Animals 
 
 All animal use and care were in accordance with institutional and 
European guidelines and approved by the Committee for Animal Experiments 
of Radboud University (Nijmegen, The Netherlands). Wild-type 
Slc6a41Hubr (5-HTT+/+), heterozygous Slc6a41Hubr (5-HTT+/-) and 
knockout Slc6a41Hubr (5-HTT-/-) rats were generated by ENU-induced 
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mutagenesis with Wistar genetic background, as described by Smits et al.70. 
All animals were bred at the Central Animal Laboratory of Radboud 
Nijmegen University (Nijmegen, The Netherlands). Breeding animals were 
derived from heterozygous knockout rats (5-HTT+/-) after 15 generations. 
Experimental animals were derived from homozygous reproduction. 
Behavioural and molecular experiments were performed on male animals on 
postnatal days (PND) 17, 25, 35 and 70. Animals were group-housed (2-4 
animals per cage) in standard Macrolon® type 3 cages in temperature-
controlled rooms (21°C ± 1°C) and fed with food and water ad libitum and 
were kept in a light/dark cycle of 12:12 h (lights on at 06:00 h). After the 
behavioural tests, the animals were decapitated and processed as described 
below. 
 
Elevated Plus Maze (EPM)  
 
 To measure anxiety-like behaviour, the animals were housed (2 
animals per cage) and handled in their cages for 5 minutes for at least 5 days 
prior to the test to avoid stress reactions that could interfere with the results. 
The behaviour testing room was soundproof and the illumination level was 
maintained at 100 lux. The EPM is an apparatus with two open arms (50 × 10 
cm, light intensity 12.1 lux) and two enclosed arms (50 × 10 × 40 cm, light 
intensity 4.5 lux) both made of polyvinyl chloride and elevated to a height of 
50 cm. Rats of PND17, PND25, PND35 and PND70 were placed in the center 
of the EPM facing the north open arm and allowed to explore the maze for 5 
min. Exploratory behaviour on the EPM was recorded using a video camera 
attached to a computer, which is controlled by a remote device, and 
EthoVision XT9 Tracking System Noldus software (Wageningen, The 
Netherlands). After each trial, all arms and the center area were cleaned with 
super hypochlorous water. The number of entries (an entry is defined as the 
center of mass of the rat entering the arm) into each arm and the time spent in 
the open arms were recorded and these measurements serve as an index of 
anxiety-like behaviour.  
 
Immunohistochemical analyses 
 
 After the behavioural test, the animals were sacrificed by decapitation 
and the brains were rapidly dissected and fixed by overnight immersion in 4% 
paraformaldehyde (PFA) in phosphate buffered saline (PBS), pH 7.4 at 4˚C. 
After fixation, the brains were cryoprotected in 30% sucrose in PBS until 
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saturated, and then embedded in an M-1 embedding matrix (Shandon, 
Thermo Fisher Scientific Inc., Waltham, MA, USA) and frozen on dry ice in 
a plastic cup and stored at -80°C. The cryostat coronal sections were cut at 16 
μm, assembled as a series of 10 on Superfrost Plus slides (Thermo Fisher 
Scientific), air dried and stored desiccated at -20°C. The cryosections were 
stained immunohistochemically overnight at 4˚C with primary antibodies 
using  mouse anti-NeuN (1:500, Merck Millipore, Bedford, MA, USA; 
MAB377), rabbit anti-cleaved-Caspase-3 (cl-Casp3, 1:500, Cell Signaling 
Technologies, Danvers, MA, USA), rabbit anti-5-HT (1:500, Sigma-Aldrich 
Chemie, Zwijndrecht, The Netherlands, S5545) and mouse anti-Satb2 (1:500, 
Abcam, Cambridge, United Kingdom, ab150502) all diluted in blocking 
buffer (BB, 5% NGS/NDS/NHS, 0.1% D-lysine, 1% BSA, 1% glycine and 
0.4% Triton X-100). After overnight incubation, the sections were washed in 
PBS and incubated with corresponding species-specific Alexa-conjugated 
secondary antibody (1:500, Thermo Fisher Scientific) in BB for 30 minutes 
at room temperature. After washing in PBS, the sections were co-stained with 
fluorescent 4′,6-diamidino-2-phenylindole (DAPI, 1:1000, Thermo Fisher 
Scientific, 62248) diluted in PBS for 15 minutes, washed extensively in PBS 
and embedded in 90% glycerol in PBS. For visualization, a Leica DMI6000B 
automated high-content fluorescence microscope with the DFC340FX 
camera and LASAF software was used. 
 All analyses were performed blindly in at least 4 sequential coronal 
sections of each mPFC subarea of at least 3 animals of each genotype, which 
were photographed for cell and fiber quantification. The area which we 
analyzed in the subdomains of the mPFC was obtained using a 0.1 mm wide 
square extending from the white matter to the marginal zone, thus including 
all cortical layers of 5-HTT+/+, 5-HTT+/- and 5-HTT-/- rats. This rectangle was 
subdivided into 10 equal bins, in which bin 1 represents the deepest layer and 
bin 10 the most superficial layer. For counting the cells, we used Photoshop 
CS6 (Adobe) tools and marker-positive cells were normalized (percentage of 
total number of DAPI-positive cells or total area of each bin) obtaining a mean 
for each animal. To better visualize and compare serotonergic innervation in 
wild-type and mutant mPFC subareas, individual fiber reconstructions of two 
to four consecutive sections of each animal were obtained bilaterally using 
NeuronJ, the ImageJ software plugin (National Institutes of Health, Bethesda, 
USA).  
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Statistical analysis 
  
 Molecular and behavioral data were statistically analyzed by one-way 
ANOVA (α = 5%) with Bonferroni multiple comparison testing to analyze 
significant differences between multiple groups using GraphPad Prism 6 (San 
Diego, California). Data are expressed as means ± SEM. 
 
Results 
 
Absence of 5-HTT results in anxiety-like behavior in an age-dependent 
manner 
 
 In order to examine anxiety-like behavior longitudinally in the 
absence of 5-HTT, 5-HTT+/+ and 5-HTT-/- rats were subjected to the EPM. In 
the EPM test, the time spent in the open arm was measured for the rats at the 
ages of PND17, PND25, PND35 and PND70 (Fig. 1). The mean time spent, 
in seconds, by animals in the 5-HTT-/- group was 24.75s ± 9.3 versus 14.47s 
± 5.2 in the 5-HTT+/+ group at PND17 (Fig. 1E). In PND25 animals, the mean 
open arm time in the 5-HTT+/+ group was 7.71s ± 2.5 seconds versus 12.62s 
± 3.9 seconds in the 5-HTT-/- group (Fig. 1F). Thus, no significant differences 
in the time spent in the open arm were found between the two genotypes at 
the ages of PND17 (F(3.164,9.9) = 0.1013; p = 0.35) and PND25 (F(2.440,9.9) = 
0.2001; p = 0.31; Fig. 1E-F). Yet, 5-HTT-/- rats did show a significantly higher 
distance moved (F(1.623,9.9) = 0.0011; p = 0.019) in the EPM test when 
compared to the control group at PND25 (Fig. 1I). Anxiety-like behaviour 
was therefore significantly different between 5-HTT-/- and 5-HTT+/+ animals 
at the ages of PND35 (F(19.25,9.9) = 0.0002; p = 0.0056) and PND70 (F(20.99,9.9) 
= 0.0001; p = 0.0078)(Fig. 1G-H). No significant differences were found 
between 5-HTT+/- and 5-HTT+/+ animals at the ages of PND25, PND35 and 
PND70 in EPM test parameters evaluated (Supplemental Fig.1). Together, 
the data suggest increased anxiety-like behaviour in 5-HTT knockout animals 
at the ages of PND35 and PND70, but not at PND17 and PND25 when anxiety 
tended to be lower than in the control situation.  
 
Absence of 5-HTT affects the cytoarchitecture of developing mPFC 
subareas 
 
 To identify any cellular changes in the mPFC underlying the age-
dependent differences in anxiety-like behavior in 5-HTT-/- versus 5-HTT+/+ 
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rats, we first immunostained cryosections from mPFC subareas with DAPI in 
rats of PND17 and PND35 (Fig. 2), two ages at which the EPM data are most 
distinct from one another. At the age of PND17, we found no significant 
differences in the number of DAPI-positive cells across layers of infralimbic 
(p = 0.68, Fig. 2E and Supplemental Fig. 2D), prelimbic (p = 0.91, Fig. 2F 
and Supplemental Fig. 2E) and cingulate (p = 0.52; Fig. 2G and Supplemental 
Fig. 2F) subareas of the mPFC in 5-HTT-/- versus wild-type rats. However, at 
PND35 we observed a significant decrease in DAPI-positive cells in the deep 
layers of the prelimbic cortex (bin1, p = 0.0034; bin2, p = 0.0031; bin6, p = 
0.023; Fig. 2I) and cingulate (bin3, p = 0.012; bin5, p = 0.024; bin6, p = 0.026; 
Fig. 2J) of the 5-HTT-/- rats compared to controls. When we evaluated the 
cortical thickness of the mPFC subdomains, we found a significant increase 
in the cingulate cortex of the PND35 5-HTT-/- group when compared to 5-
HTT+/+ rats (p = 0.0036; Fig. 2D), but not between the genotypes in 
infralimbic (Fig. 2B) and prelimbic (Fig. 2C) areas at the ages analysed. 
Neuronal number assessments using NeuN as a marker revealed only at 
PND35 a significant decrease in the number of mature neurons in the deep 
cortical layers of the infralimbic (bin5, p = 0.033; Fig. 3F) and cingulate 
(bin3, p = 0.041; Fig. 3H) cortices and deep and superficial layers of the 
prelimbic cortex (bin1, p = 0.0019; bin2, p = 0.0019; bin5, p = 0.034; bin10, 
p = 0.0020; Fig.  3G) of the 5-HTT-/- animals when compared to controls. No 
significant differences were found in the number of mature neurons per area 
among the groups analyzed at PND17 (Fig. 3C-E, I-K). To investigate the 
levels of programmed cell death, a significant increase of the cleaved-
Caspase-3 (cl-Casp3) cell death marker was observed in all cortical layers of 
the infralimbic (p = 0.00039; Fig. 4C and I), prelimbic (p = 0.000028, Fig. 
4D and J) and cingulate (p = 0.000011; Fig. 4E and K) cortices in animals of 
the PND17 5-HTT-/- group. At PND35, a significant increase in cl-Casp3-
positive cells was found in the superficial layers of the infralimbic cortex 
(bin9, p = 0.024, Fig. 4F and I), prelimbic (bin6, p = 0.0095, bin9, p = 0.047, 
Fig. 4G and J) and in all layers of the cingulate cortex (p = 0.00038; Fig. 4H 
and K) of 5-HTT-/- animals. Furthermore, PND35 5-HTT-/- rats showed a 
significant increase in the number of apoptotic neurons in all subareas of the 
mPFC (Supplementary Fig. 2A-C) at PND35. Interestingly, not all cl-Casp3-
positive cells colocalized with NeuN-positive cells (Fig. 4A-B), suggesting 
apoptosis of an additional cell type other than neuronal. Together, the data 
suggest that loss of the 5-HTT results in cellular differences across layers in 
all subareas of the mPFC and that these disturbances are more pronounced in 
PND35 than PND17 animals. 
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 The fact that we found changes in the total number of mature neurons 
in all mPFC subareas tested brought us to the question of how these changes 
could impact the structure of the cortical layers and which specific layer 
would be more affected. To address this question, we used the layers II-V 
marker Satb2. Immunostaining of PND17 5-HTT-/- and 5-HTT+/+ 
cryosections showed no significant differences between the two groups in 
infralimbic (p = 0.34), prelimbic (p = 0.85) and cingulate (p = 0.14) cortices 
(Fig. 5A-K), while in PND35 5-HTT-/- animals a significant increase in the 
superficial layer of the prelimbic cortex (bin 8, p = 0.011; Fig. 5G) was 
observed. 
 
Absence of 5-HTT causes disturbances in serotonergic innervation of 
mPFC subareas 
 
 Previous studies have demonstrated an important role of the 
serotonergic system in the development of the mPFC58,59. Furthermore, 
proper PFC functioning is required for the afferent control of the DRN, thus 
regulating the 5-HT supply during a stress response42,43. When we measured 
the number of positive serotonergic fibers in mPFC cryosections, we found a 
significant increase in the lengths of these fibers in the infralimbic (p = 0.025, 
Fig. 6C and I), prelimbic (p = 0.000065, Fig.  6D and J) and cingulate (p = 
0.000024, Fig. 6E and K) cortex of PND17 5-HTT-/- animals. However, at 
PND35 this significant increase was identified only in the prelimbic (p = 
0.000012; Fig. 6G and J) and cingulate (p = 0.015, Fig. 6H and K) cortices of 
the 5-HTT-/- animals. Together, the data suggest that in the absence of the 5-
HTT, serotonergic innervation of the mPFC subareas is increased at PND17 
and PND35. 
 
Discussion 
 
 In this study, we demonstrate that in 5-HTT-/- rats increased anxiety 
emerges in a defined age window, namely between PND25 and PND35. We 
also demonstrate that changes in cortical cytoarchitecture and cell death in 
mPFC subdomains of adolescent and adult 5-HTT-/- rats. The structural 
changes were observed in the infralimbic, prelimbic and cingulate cortices; a 
decrease in the total number of cells was found, mainly in layers II-V. 
Furthermore, the absence of the transporter interfered with the degree of 
neuron maturation and led to an increase of cleaved-Caspase-3-positive cells 
suggesting increased programmed cell death. Finally, we found an increase 
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in serotonergic innervation of all subareas of the mPFC in 5-HTT-/- animals, 
indicating a strong genotype effect on cortical development and organization 
via modulation of 5-HT levels. 
 We used the EPM test to measure anxiety in 5-HTT-/- and wild-type 
controls across ages. We observed increased anxiety in adolescent and adult, 
but not juvenile 5-HTT-/- rats. Heterozygous 5-HTT+/- rats behaved like 5-
HTT+/+ rats.  The absence of anxiety in juvenile 5-HTT-/- rats may be due to 
a delay in brain development caused by increased brain 5-HT levels. Excess 
of cortical 5-HT affects the migration speed and positioning of pyramidal 
glutamatergic neurons116 and GABAergic interneurons94 in the superficial 
embryonic cortical layers of 5-HTT-/- knockout mice. Owing to its high 
functional complexity and the large number of connections with various 
subcortical areas100, PFC maturation is relatively late. Therefore, a delay in 
cortical development due to a slower speed of excitatory and inhibitory 
neuron migration may particularly affect the PFC cytoarchitecture and PFC-
dependent behaviours. 
 Morphogenic responses to the change in 5-HT levels may vary 
enormously, depending on the genetic polymorphism as well as the 5-HT 
receptor subtypes expressed by different target cells104,105. Serotonergic 
receptors located on neural progenitor cells induce proliferation, and 
maturation of postmitotic neurons, cell survival as well as the release of 
astroglial neurotrophic factors that also influence neuronal 
maturation106,112,113. For example, 5-HT1A and 5-HT2A receptors are expressed 
on astrocytes and neurons and regulate, among other functions, c-AMP levels 
and calcium availability, which alters the internal cytoskeleton and results in 
cell proliferation, synaptogenesis and apoptosis104.  In 5-HTT-/- animals, the 
expression of these receptors is deregulated105. The alteration in 5-HT levels 
during embryonic rat development affects the maturation of pyramidal 
neurons and causes a reduction of dendritic arborization in the somatosensory 
cortex95, and alters neurite outgrowth in the neocortex of 5-HTT-/- mice117. 
Furthermore, apoptotic pathways are activated, as demonstrated by an 
increased number of cleaved-Caspase-3-positive cells in all mPFC subareas, 
presumably explaining the significant reduction in mature neurons. 
Interestingly, the death of neurons was more pronounced at PND35 than at 
PND17, which may contribute to the emergence of increased anxiety at 
PND35 in the 5-HTT-/- rats.  
Reduced levels or the absence of the 5-HTT in humans and rodents 
alter cortical characteristics in the adult115. Although, in contrast to the S179,90-
92 of 5-HTT-/- rats, the cortical thickness of the mPFC subdomains appears 
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normal, various cortical layers showed significant changes in expression of 
certain markers such as Satb2 and Cux1119,58,59. Some of these alterations may 
be due to changes in the positioning of interneurons and pyramidal neurons 
within the superficial cortical layers94,116.  
  The structural abnormalities and functional consequences found in 
the absence of the 5-HTT probably result from the elevated extracellular 5-
HT levels during critical developmental time periods109. Extracellular 5-HT 
concentrations are markedly increased in the striatum and cortex of 5-HTT+/- 
and 5-HTT-/- mice96,114. Measurements of serotonergic axon length and 
number of axonal varicosities by quantitative immunocytochemistry have 
shown an increase in the density of serotonergic innervation in various brain 
regions of 5-HTT-/- animals58,59,115, in line with our results in the mPFC. 
Serotonergic hyperinnervation of not only subdomains of the mPFC, but also 
the amygdala-hippocampal nucleus and ventral hippocampus may be 
responsible for the observed anxious behavior115,120.  Neuroimaging studies 
in children and adolescents exposed to stressful situations have demonstrated 
alterations in amygdala-mPFC connectivity, increased depression, attention 
problems, and aggressive and anxiety-like behavior121, and these poor 
connections persist until adulthood125,126. Early-life stress events in rodents 
also alter mPFC-amygdala activity in adult life123,124. 
 A limitation of this work is that the molecular changes associated with 
behavior have been identified only in a specific developmental time window 
and not at all ages. Yet, our previous studies on 5-HTT-/- rats at early-postnatal 
ages have demonstrated delayed cortical development, and altered identity of 
deep and superficial cortical layers in the mPFC58,59. We now find that these 
alterations last throughout adulthood, despite the appearance of possible 
compensation mechanisms with an increase in Satb2 expression between the 
ages of PND658,59, PND17 and PND35.  
In conclusion, absence of the 5-HTT gene in rats causes anxiety-like 
behavior between PND25 and PND35. The associated neuroanatomical 
changes in the mPFC involve serotonergic hyperinnervation and a significant 
loss of neurons. The latter is possibly due to activation of cellular apoptosis 
pathways in the prelimbic and cingulate cortices of 5-HTT-/- animals. Since 
the death of neurons coincides with increased serotonergic innervation in the 
cingulate cortex and the emergence of an anxiety-like phenotype in 5-HTT-/- 
rats, a neuronal excess earlier in life may protect against this phenotype. 
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Fig. 1. The absence of the serotonin transporter (5-HTT) affects anxiety-like 
behavior in the elevated plus-maze (EPM) test in an age-dependent manner. (A-
D) Movement traces by EthoVision XT9 Tracking) of 5-HTT-/- and wild-type (WT) 
rats at PND25 and PND35. (E-H) Anxiety-like behavior identified by the total time 
spent in the open arms at PND35 (G) and PND70 (H) and not at PND17 (E) and 
PND25 (F). (I) Total distance traveled data showed an increase of mobility in 5-
HTT-/- rats compared to controls at PND25. (J) No differences were found between 
the genotypes in the total time spent in the center. Data show mean (± SEM), *p < 
0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA. (5-HTT-/-, n = 
10; WT, n = 10). 
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Fig. 2. The absence of 5-HTT changes the cortical thickness of the mPFC 
resulting in a significant decrease in the total number of DAPI+ cells in the deep 
cortical layers in an age- and subdomain-dependent manner. (A) Staining of 
cryosections of cingulate cortex at PND35 in 5-HTT-/- and wild-type (WT) rats, 
showing DAPI-positive cells (white). (B-D) Measurement of cortical thickness 
showing a significant increase in cingulate cortex thickness in 5-HTT-/- animals at 
PND35 when compared to WT rats. (E-G) No significant differences in the total 
number of cells at PND17 between 5-HTT-/- and WT in all mPFC subareas. (H-J) A 
significant decrease in the total number of cells in deep layers of prelimbic and 
cingulate cortices, but not infralimbic, in 5-HTT-/- animals at PND35, when 
compared to the WT group. Data show mean (± SEM) number of cells, *p < 0.05, 
**p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (5-HTT-/-, n = 3; WT, 
n = 3). 
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Fig. 3. The absence of 5-HTT decreases the number of mature neurons in all 
subareas of the mPFC. (A, B) Immunostaining showing NeuN-positive cells (red) 
in prelimbic cryosections of 5-HTT-/- and WT brains at PND35 counterstained with 
DAPI (blue). (C-E) Quantification of mature neurons (NeuN+) showing no 
significant differences between 5-HTT-/- and wild-type (WT) rats at PND17. (F-H) 
A significant decrease in NeuN-positive neurons in deep and superficial layers of 5-
HTT-/- rats when compared to WT at PND35. (I-K) No significant differences were 
found in the total number of NeuN-positive neurons in total mPFC subarea of 5-
HTT-/- animals when compared to WT. Data show mean (± SEM) number of 
neurons, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (5-
HTT-/-, n = 3; WT, n = 3). 
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Fig. 4. The absence of 5-HTT increases number of apoptosic cells in mPFC 
subareas. (A, B) Immunostaining showing cl-Casp-3- and NeuN-positive cells and 
their co-expression in the cingulate cortex at PND17. (C-E) Quantitative results 
showing a significant increase in cl-Casp3-positive cells in deep and superficial 
layers of the infralimbic, prelimbic and cingulate cortices of 5-HTT-/- animals when 
compared to wild-type (WT) at PND17 and PND35 (F-H). (I, K) Significant 
increase of cl-Casp3-positive cells in all mPFC subareas of 5-HTT-/- rats when 
compared with WT at PND17 and PND35. Data show mean (± SEM) number of 
cells, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (5-
HTT-/-, n = 3; WT, n = 3). 
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Fig. 5. The absence of 5-HTT affects prefrontal cytoarchitecture. (A, B) 
Qualitative data showing immunostaining for Satb2 in cryosections of the prelimbic 
cortex at PND17 and PND35 in 5-HTT-/- and wild-type (WT rats. (C-H) No 
significant differences were found in the total number of Satb2-positive cells of 5-
HTT-/- compared to WT animals except for bin8 (superficial) of the prelimbic at 
PND35. (I, K) No significant differences were found in the total number of Satb2-
positive cells per subareas at PND17 and PND35. Data show mean (± SEM) number 
of cells, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (5-
HTT-/-, n = 3; WT, n = 3). 
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Fig. 6. The absence of 5-HTT affects mPFC serotonergic innervation. (A, B) 
Immunostaining for 5-hydroxytryptamine (5-HT, white) of cryosections of the 
prelimbic cortex of 5-HTT-/- and wild-type (WT) animals at PND17 and cingulate 
cortex at PND35. (C-E). A significant increase of serotonergic innervation in deep 
and superficial layers in the prelimbic cortex of 5-HTT-/- rats when compared to WT 
at PND17. (F-H) A significant increase in serotonergic innervation in deep and 
superficial layers of the cingulate cortex of 5-HTT-/- rats when compared to WT at 
PND35, but not in infra- and prelimbic cortices. (I-K) A significant increase of fiber 
length per total area of the infralimbic, prelimbic and cingulate cortices at PND17 in 
absence of 5-HTT. However, this was significant only in the prelimbic and cingulate 
cortices at PND35. Data show mean (± SEM) fiber length, *p < 0.05, **p < 0.01, 
***p < 0.001, analyzed using One-way ANOVA (5-HTT-/-, n = 3; WT, n = 3). 
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Supplemental Fig. 1. Elevated plus-maze (EPM) test parameters on anxiety-like 
behavior in 5-HTT+/- and WT rats. No significant differences were found between 
5-HTT+/- and wild-type (WT) rats in the total time spent in the open arm (A), total 
distance traveled (B), total time spent at center (C), and number of entries into open 
arms (D) at PND25, PND35, and PND70. Data show mean (± SEM), *p < 0.05, **p 
< 0.01, ***p < 0.001, analyzed using One-way ANOVA (5-HTT+/-, n = 10; WT, n = 
10). 
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Supplemental Fig. 2. The absence of 5-HTT increases apoptosis in neurons of the 
mPFC. (A-C) Quantification of the percentage of Casp3+/NeuN+ cells showing a 
significant increase in mature neuron death in infralimbic, prelimbic and cingulate 
at PND35. (D-F) The total number of cells per total mPFC subarea, showing a 
significant decrease in the number of DAPI positive cells in 5-HT-/- animals at 
PND35 when compared to wild-type (WT) rats.  Data show mean (± SEM), *p < 
0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (5-HTT-/-, n = 3; 
WT, n = 3). 
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Abstract 
 
 Efavirenz is recommended as a preferred first-line drug for women of 
childbearing potential living with human immunodeficiency virus. Efavirenz 
is known for its central nervous system side effects, which are partly mediated 
by serotonergic actions. The neurotransmitter serotonin exerts neurotrophic 
effects during neurodevelopment and antenatal exposure to serotonergic 
agents has been linked to developmental delay. Although the teratogenic risks 
of efavirenz appear to be minimal, data on long-term developmental effects 
remain scarce. Here, we aimed to investigate the short- and long-term 
behavioral and neurodevelopmental effects of perinatal efavirenz exposure. 
We treated pregnant rats from gestation day 1 until postnatal day 7 with 
efavirenz (100 mg/kg) or vehicle. We measured behavioral outcomes in male 
offspring during the first three postnatal weeks, adolescence and adulthood, 
and conducted brain immunohistochemistry analyses after sacrifice. Perinatal 
efavirenz exposure resulted in reduced body weight and delayed reflex and 
motor development. During adulthood we observed a decrease in the total 
number of cells and mature neurons in the motor cortex, as well as an increase 
in the number of cleaved-Caspase-3-positive cells and serotonergic fibers. 
Together, our data show a developmental delay and persistent changes in the 
brain motor cortex of rats exposed to efavirenz perinatally. Because over one 
million children born annually are exposed to antiretroviral therapy, our 
findings underline the need for clinical studies on long-term 
neurodevelopmental outcomes of perinatal exposure to efavirenz. 
 
Keywords: Neurodevelopment, Perinatal, Corticogenesis, Side Effect, 
Antiretroviral Therapy, Efavirenz, Serotonin
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Introduction 
 
 Every year, an estimated 1.4 million women living with human 
immunodeficiency virus (HIV) become pregnant. The use of antiretroviral 
therapy (ART) during pregnancy, delivery and breastfeeding, successfully 
reduces the risk of mother-to-child transmission of HIV to less than 5%1. The 
latest interim guidelines of the World Health Organization (WHO) 
recommend dolutegravir as the general drug of choice for people living with 
HIV2. However, due to concerns about neural tube defects among first-
trimester dolutegravir exposures, efavirenz (EFV) remains the preferred 
option in women of childbearing potential3. Research on the safety of EFV 
during pregnancy has focused largely on infant health shortly after birth4. 
Although risks for gross teratogenicity seem to be minimal, research on long-
term neurodevelopmental effects of perinatal exposure to EFV remains 
scarce5, 6. 
 EFV passes through the placenta and is present in breast milk, 
resulting in detectable concentrations in the blood of fetuses and breast-fed 
infants7, 8. After entry into the blood stream, both EFV and its primary 
metabolite 8-hydroxy-efavirenz (8-OH-EFV) readily penetrate the 
cerebrospinal fluid and target various cellular pathways within the central 
nervous system (CNS), predominantly the serotonergic system9-12. For 
example, EFV acts as a serotonin(5-HT)6 receptor inverse agonist, 5-HT2A, 
5-HT2C and 5-HT3A receptor antagonist, and a blocker of the 5-HT transporter 
(5-HTT)13. In rats, EFV preferentially binds to the 5-HT2A receptor
14. 
 Importantly, 5-HT exerts neurotrophic functions during early 
development15, 16. Increases in brain 5-HT levels, induced by genetic 5-HTT 
inactivation, have been shown to alter the serotonergic innervation of the 
prefrontal cortex17, migration of inhibitory neurons to the neocortex18, and 
maturation of the sensory cortex19. The latter has also been observed after 
pharmacological 5-HTT inhibition by prenatal selective serotonin reuptake 
inhibitor (SSRI) exposure18, 20. Both genetic and pharmacological 5-HTT 
modulation during early development have been associated with a delay in 
reflex and motor development, disturbed sensorimotor gating, decreased 
social behavior, and anxiety and depression-like phenotypes21-25. Moreover, 
children perinatally exposed to SSRIs show reduced language and motor 
development, and a two-fold increased risk of autism spectrum phenotypes26-
28. Given that EFV particularly targets the serotonergic system, we 
hypothesized that perinatal EFV exposure might also lead to long-lasting 
neurodevelopmental consequences.  
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 Here, we aimed to investigate the short- and long-term behavioral and 
neurodevelopmental effects of perinatal EFV exposure in a rodent model. We 
conducted a behavioral test battery including tests for reflex development, 
motor performance, sensorimotor gating and anxiety- and depressive-like 
behavior, during early life, adolescence, and adulthood. Throughout the 
treatment period, we monitored maternal care. Because we observed changes 
in motor behavior, we investigated the cytoarchitecture of the motor cortex to 
study the underlying cellular mechanisms. Our results indicate that perinatal 
EFV exposure is associated with neurodevelopmental delay, accompanied by 
long-lasting changes in motor cortex morphology. 
 
Materials and methods 
 
Animals 
  
 Rats used in this experiment were bred in-house from Wistar male 
breeders and nulliparous Wistar females weighing 185-215 g, purchased from 
Charles River, Cologne, Germany. After a two-week acclimatization period, 
female rats were subjected to a timed mating procedure (using Impedance 
Checker MK-10B, Muromachi Kikai, Tokyo, Japan) as described 
previously25. Pregnancy was determined by observation of a vaginal plug the 
day after breeding gestational day (GD) 1. Pregnant rats were alternally 
assigned to daily treatment with EFV or vehicle from GD1 to postnatal day 
(PND) 7 by order of birth. PND7 resembles the human functional brain 
maturity around birth29. Litters were culled to 10 pups and pups were weaned 
on PND21. Male offspring from four EFV-exposed (n = 24) and four vehicle-
exposed nests (n = 20) were used for experiments. Developmental milestones 
and behavior were assessed during the first three weeks of life (PND2-21), 
adolescence (PND34-35), and adulthood (PND69-70). After completion of 
the last experiments, rats (PND73-75) were sacrificed and their brains were 
removed for immunohistochemistry analyses. Fig. 1 shows a schematic 
representation of the experimental timeline. Sample sizes were based on 
power calculations from previous studies using comparable animal models 
and similar behavioral analyses 24, 25. Animals were tested randomly, and both 
investigators and caregivers were blinded to the groups during experiments 
and outcome assessment. Blinding was ensured using coded treatment 
containers of identical appearance. Videos of the reflex and motor 
performance tests were re-analyzed by a second blinded researcher resulting 
in similar results. Animals were housed in pairs in standard Macrolon® type 
 
 
191 
 
3 cages in temperature-controlled rooms (21°C ± 1°C) under a standard 12-h 
light/dark cycle (lights on at 07:00 h) with food and water available ad libitum 
(Sniff, long cut pellet, Bio Services, Uden, The Netherlands). Experiments 
were carried out in accordance with the European Communities Council 
Directive (2010/63/EU) and approved by the Committee for Animal 
Experiments of the Radboud university medical center Nijmegen, The 
Netherlands (ref no. 2012-236). 
 
Drug treatment 
 
 EFV or vehicle was administered blindly by oral gavage in a volume 
of 5 mL/kg. We used a dose of 100 mg/kg, based on previous work 
demonstrating plasma levels within the human therapeutic range (1.0-4.0 
mg/L)30 and unpublished pilot work. Drug solution was prepared by diluting 
EFV oral suspension (Stocrin suspension 30 mg/mL, Merck Sharp & Dohme, 
Haarlem, The Netherlands) with distilled water. As vehicle, we used a 1% 
cellulose suspension (Genfarma B.V., Maarssen, The Netherlands), enriched 
with the EFV solution additives, consisting of medium chain triglyceride oil 
(Newpharma, Liège, Belgium) and strawberry and peppermint essence 
(Lecocq N.V./S.A., Zonhoven, Belgium). 
 
Measurement of EFV in blood plasma 
 
 Ninety minutes (min) after drug administration at GD4, we collected 
blood, obtained by tail cut, of all pregnant rats (n = 8). Blood was collected 
in Microvette CB 300 tubes (containing EDTA; Sarstedt, Germany) and 
centrifuged for 15 min at 4°C with a speed of 4000 rpm. The supernatant 
(plasma) was stored at -20°C until analysis. Supernatants from the 
experimental group were used for determination of plasma peak EFV levels 
using a validated reversed phase ultra-performance liquid chromatography 
with ultraviolet detection bioanalytical assay, validated for human plasma. 
Fur the current analysis, quality control samples prepared with blank rat 
plasma were included to assure validity of the assay. During the bioanalysis, 
the quality control samples in rat plasma did not deviate more than 15% from 
the theoretical value. 
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Maternal care 
 
 Maternal care was scored from PND2 to PND9 using a procedure 
adapted from Ivy et al31. Litters were observed during three sessions per day 
of 75 min each: at 7:30 am, 1:30 pm (light phase) and 7:30 pm (dark phase). 
Throughout each session, behavior was scored every third min (25 
observations per session). The behaviors scored include: (1) nursing more 
than half of the nest, (2) licking or grooming any pup, (3) spending time out 
of the nest, (4) self-licking or grooming, and (5) eating or drinking. 
 
General development 
 
 Body weight was measured daily during early life (PND2-21), 
adolescence (PND34) and adulthood (PND70). In addition, we recorded eye-
opening every morning from PND13 until both eyes were open. Scores were 
defined as: (0) both eyes closed, (1) one eye open, (2) both eyes open. An eye 
was considered “open” if the palpebral fissure was ≥2 mm32. 
 
Behavioral development 
 
 The experimental test battery was adapted from Kroeze et al. and 
included the following functional domains25: reflex development (righting 
reflex, negative geotaxis and acoustic startle reflex), motor development 
(swimming performance and bar holding), sensorimotor gating (prepulse 
inhibition [PPI]), and anxiety- and depressive-like behavior (elevated plus 
maze and forced swim test).  
 
Reflex development – righting reflex, negative geotaxis, acoustic startle reflex 
 
 During the righting reflex test, rats (PND2-10) were placed on their 
back, while recording the time until they returned to prostate position, with a 
maximum of 60 seconds (sec)33. Negative geotaxis was examined using a 40° 
inclined wooden plank with a wire mesh. Rats (PND4-14) were placed facing 
down the slope and allowed to turn 180° within 90 sec21. All test sessions 
were recorded for later rescoring by a second researcher. See below for 
methods of the acoustic startle reflex. 
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Motor development – swimming performance, bar holding 
 
 During the swimming performance test, rats (PND8, 10, 12, 14, 22) 
were dropped from ± 20 cm into a basin filled with 27°C water and observed 
for 5-10 sec. Scoring was based on the position of the nose in the water: 1) 
entire head underwater, (2) nose underwater, ears partially underwater with 
the back of head above water level, (3) nose above water level but ears 
partially underwater, (4) entire head above water level34. Bar holding was 
tested by positioning rats (PND10-21) with their forepaws on a wooden bar 
(3 mm x 40 cm), suspended 45 cm above the bench surface. The latency to 
fall from the bar was recorded, with a maximum of 50 sec. If the rat fell 
immediately, the procedure was repeated up to three times25, 35. 
 
Acoustic startle reflex and sensorimotor gating - prepulse inhibition 
 
 At PND 21, 35 and 70, acoustic startle and prepulse inhibition (PPI) 
experiments were performed in four acoustic startle chambers (San Diego 
Instruments, San Diego, USA), according to the methods of Sontag et al.36. 
Acoustic startle response was defined as the mean startle amplitude from the 
ten test blocks of the startle trials. The percentage of prepulse inhibition was 
calculated using the formula: 100 – (average of startle amplitude on prepulse 
trial/average of startle amplitude on startle trial) x 100%36. 
 
Anxiety-like behavior - Elevated Plus Maze 
 
 The elevated plus maze is a polyvinylchloride apparatus with two 
open (50 x 10 cm, light intensity 12.1 lux) and two enclosed (50 x 10 x 40 
cm, light intensity 4.5 lux) arms, elevated at a height of 50 cm37. Rats 
(PND69) were placed in the center of the elevated plus maze facing one of 
the open arms and allowed to freely explore the maze for 5 min. Movements 
were measured using the EthoVision XT9 Tracking System, Noldus, 
Wageningen, The Netherlands. 
 
Depressive-like behavior - Forced Swim Test 
 
 During the induction phase, rats (PND69) were placed in cylindrical 
glass tanks (24 cm diameter x 65 cm height filled to 35 cm with 22°C water) 
for 15 min. After 24 hours, rats (PND70) were placed in the same tank for 5 
min (test phase). Immobility was defined as no movements or minimal 
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movements necessary to keep the nose above water level for ≥ 2 sec. While 
slight movements of forepaws or paw placement on cylinder walls were still 
considered immobility, active climbing, diving, and swimming were scored 
as mobility24. The duration of immobility (sec) was recorded with Observer 
XT 12.5 (Noldus Information Technology, Wageningen, The Netherlands). 
Both phases of the forced swim test (induction and test phase) were performed 
at the end of the testing days (after completion of the other behavioral tests). 
 
Immunohistochemistry 
 
 After a minimum of two days after completion of the last behavior 
experiments, rats (PND73-75) were deeply anesthetized by an intraperitoneal 
injection of sodium pentobarbital (200mg/kg) and perfused transcardially 
with cold phosphate-buffered saline (PBS), followed by 4% 
paraformaldehyde (PFA). Brains were quickly removed and immersed in 4% 
PFA for 48 hours. Next, brains were washed in PBS, placed in a 30% sucrose 
solution, frozen on dry-ice, and stored at -80˚C. A minimum of five brains 
per treatment group were selected for immunohistochemistry analyses. 16 μm 
sections were cut on a Microm Cryostat, mounted on Superfrost® Plus slides 
(Thermo Fisher Scientific, Waltham, MA, USA), air-dried and stored 
desiccated at -20°C. Cryosections were obtained and stained 
immunohistochemically as previously described17, using the following 
antibodies: mouse anti-NeuN (1:500, Merck Millipore, Bedford, MA, USA; 
MAB377), rabbit anti-cleaved-Caspase-3 (cl-Casp3, 1:500, Cell Signaling 
Technologies, Danvers, MA, USA; ASP175), rabbit anti-5-HT (1:500, 
Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands; S5545), and rabbit 
anti-TH (1:500, Merck Millipore, Bedford, MA, USA; AB152), species-
specific Alexa-conjugated secondary antibody (1:500, Thermo Fisher 
Scientific; A32732, A32723). After washing in PBS, sections were 
counterstained with fluorescent DAPI (1:1000, Thermo Fisher Scientific; 
62248) diluted in PBS for 15 minutes, washed extensively in PBS and 
embedded in 90% glycerol in PBS. For visualization, a Leica DMRA 
fluorescence microscope equipped with a DFC340FX camera and LASAF 
software was used.  
 
Quantification 
 
 For quantification of cells and fibers in coronal sections, pictures of at 
least eight brains per group were acquired similar to Witteveen et al.38. 
 
 
195 
 
Stained cells were counted in radial units of 0.1-mm wide in the presumptive 
primary motor cortex (M1) of anatomically matched brain sections using 
Photoshop CS6 (Adobe). The overall cortical length, above white matter, of 
M1 was divided into 10 equal bins (bin 1 within the deep cortical layers and 
bin 10 within the presumptive layer 1) within this rectangle, ImageJ, 
including the NeuronJ plugin, was used for counts and measurements 
(National Institutes of Health, Bethesda, USA). 
 
Statistical analysis 
 
 Data are expressed as mean ± standard error of the mean (SEM) unless 
indicated otherwise. Continuous behavioral data were analyzed using 
repeated measures analysis of variance (ANOVA). In case of significant 
violations of sphericity or error variances, the Greenhouse-Geisser 
adjustment was applied and df were adjusted. Significant ANOVA results 
were followed by post hoc independent T-tests, in order to identify the 
specific time points with the largest effect of EFV. Differences in non-
continuous data were analyzed by Pearson’s Chi-square (or Fisher’s exact). 
Immunohostochemical data were analyzed using one-way ANOVA. We 
observed extreme outliers in the acoustic startle/PPI test and removed these 
according to Tukey’s principles. Cumulative behavioral development was 
defined using area-under-the-curves (AUC) for continuous data (righting 
reflex, negative geotaxis, bar holding) and sum scores for non-continuous 
data (swimming performance). Spearman’s correlations were used to 
correlate behavioral development with immunohistochemistry results. 
Statistical analyses were performed using SPSS version 22.0 (SPSS Inc., 
Chicago, IL, USA) and GraphPad Prism3 software (California corporation). 
All tests were performed using a two-tailed hypothesis, with significance set 
at 0.05. The Benjamini-Hochberg correction for multiple comparisons was 
applied to behavioral post hoc analyses - reported p-values represent raw p-
values that are significant using FDR = 0.1.  
 
Results 
 
Pregnancy outcomes and maternal care 
 
 On GD 4, 1.5 hours following the administration of EFV, mean (± 
SEM) EFV plasma levels in EFV-treated dams (n = 4) were 0.28 ± 0.13 mg/l. 
Gestational length did not differ between EFV (22.0 ± 0.0 days) and controls 
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(22.3 ± 0.2 days, p = 0.69). No apparent anatomical abnormalities were seen 
in the EFV-exposed offspring. Furthermore, there were no significant 
differences in the number of pups per litter (EFV 10.8 ± 0.7 vs. controls 8.8 
± 1.3, p = 0.34), nor differences in the survival rates for pups at weaning. 
Finally, the mean (± SEM) percentage of female pups per litter did not differ 
between groups (EFV 42 ± 3% vs. controls 41 ± 6%, p = 0.89; Supplemental 
Table S1). To examine effects of EFV on dam-pup interactions, maternal 
behavior was scored from PND2 until PND9 and did not differ between 
groups (p > 0.10 for main effects of EFV and interaction between time and 
EFV; Fig. 2a). 
 
General development  
 
 Fig. 2b shows the body weights of EFV- (n = 24) and vehicle-exposed 
(n = 19) rats during early life (PND2-PND21), adolescence (PND34) and 
adulthood (PND70). Body weight increased with age (F(1.2,49.3) = 6209.51, p 
< 0.0001). Perinatal EFV exposure was associated with reduced weight gain 
(main effect EFV: F(1,41) = 29.09, p < 0.0001, time x EFV interaction effect: 
F(1.2,49.3) = 7.99, p = 0.0045). Body weight was significantly reduced in EFV-
exposed rats for all testing days (post-hoc T-tests, p < 0.010). Eye opening 
was scored daily from PND13-PND18. On PND 17, EFV-exposed rats 
showed a delay in eye-opening (p = 0.0027, Fisher’s exact; Fig. 2c).  
 
Reflex and motor development  
 
 The time until the rats were able to roll from back to the front (righting 
reflex) reduced with age (F(3.8,158.4) = 20.09, p < 0.0001; Fig. 2d). There were 
no main or interaction effects of EFV on righting time. In the negative 
geotaxis test, the time until turning decreased with age (F(5.0,207.6) = 127.04, p 
< 0.0001; Fig. 2e). Rats perinatally exposed to EFV showed a developmental 
delay for negative geotaxis (main effect F(1,41) = 13.59, p = 0.00066; time x 
EFV interaction F(5.1,207.6) = 0.1.17, p = 0.32). Post-hoc analyses showed a 
trend for longer turning times in EFV-exposed animals on PND11 and 
PND12 (post-hoc T-tests, p = 0.075). We observed an improvement of 
performance in the bar holding test over time (F(7.5,306.6) = 35.02, p < 0.0001; 
Fig. 2f). We did not see any main effect of EFV on bar holding (F(1,41) = 1.17, 
p = 0.285), but we observed a trend in time x EFV interaction (F(7.5,306.6) = 
1.81, p = 0.079), with significant differences between groups on PND20 
(post-hoc T-test, p = 0.0048). In the swimming test, EFV-exposed rats scored 
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significantly lower than their controls on PND14 (p = 0.00046, Fisher’s exact; 
Fig. 2g). Finally, startle reflexes were assessed. The amplitudes of the startle 
response increased over time (F(1.5,57.1) = 33.32, p < 0.001; Fig. 3a), with a 
main effect of EFV (F(1,37) = 5.65, p = 0.023), and a trend for time x EFV 
interaction (F(1.5,57.1) = 2.72, p = 0.087). Post-hoc analyses showed trends for 
lower startle responses in the EFV group in early life (PND21, post-hoc T-
test, p = 0.066) and adolescence (PND35, post-hoc T-test, p = 0.051), but not 
in adulthood (PND70, post-hoc T-test, p = 0.95). Taken together, these data 
demonstrate that EFV-exposure affected early reflex and motor development, 
which normalized in later life. 
 
Development of sensorimotor gating and anxiety- and depressive-like 
behavior 
 
 For all prepulses, the effects of PPI increased over time (F(2,64) = 58.44, 
p < 0.001 for 3 dB, F(2,70) = 33.21, p < 0.001 for 5 dB, and F(1.18,42.4) = 8.57, p 
= 0.004 for 10 dB)  We did not observe any main or interaction effects of 
EFV on PPI, regardless of the prepulse strength (Fig. 3b,c,d). We found no 
group differences in elevated plus maze open arm time (F(1,41) = 0.01, p = 0.92; 
Fig. 3e). The number of open arm entries (F(1,41) = 0.11, p = 0.74) and closed 
arm entries (F(1,41) = 0.01, p = 0.92) also did not differ between control- and 
EFV-exposed rats (Fig. 3f,g), suggesting that EFV did not affect anxiety. 
Finally, no differences were found in the total distance moved (F(1,41) = 0.86, 
p = 0.361; Fig. 3h), indicating that EFV had also no effect on exploratory 
locomotion. While there were no differences between the groups in the total 
duration of immobility (F(1,39) = 0.64, p = 0.48), or the total number of 
immobility counts (F(1,39) = 0.598, p = 0.44), there was a significant difference 
in latency to the first episode of immobility (F(1,39) = 9.88, p = 0.003), with 
EFV-exposed rats exhibiting reduced latencies (Fig. 3i-k).  
 
Motor cortex cytoarchitecture 
 
 To investigate whether perinatal EFV exposure affected the 
architecture of the primary motor cortex (M1), we assessed the M1 cell 
composition in randomly selected brains from adult animals (PND73-75; Fig. 
4a). We observed a reduction in the total number of DAPI+ cells in the M1 of 
the EFV-exposed compared to the control group (p = 0.045; Fig. 4a, b, c and 
Supplemental Figure S1b). This decrease was present in the superficial layers 
(bin8, p = 0.014; bin9, p = 0.00030) and to a lesser extent in deep layers (bin6, 
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p = 0.0096). Groups did not differ, however, in M1 cortical thickness (p= 
0.37; Supplemental Figure S1g). To assess whether the observed reduction in 
cells was neuron-specific, we immunostained the M1 for the neuronal nuclei 
marker NeuN (Fig. 4a, d, e). We found a significant reduction of NeuN+ 
neurons in the M1 of the EFV-exposed group (p < 0.0001; Fig. 4d and 
Supplemental Figure S1c), which was present in all layers (bin1-bin9, p < 
0.05; Fig. 4e). Next, we focused on cell apoptotic features of perinatal EFV 
exposure in the M1 (Fig. 4a, f, g). We observed a significant increase of 
Casp3+ cells in the M1 of EFV-exposed animals (p = 0.023; Fig. 4f and 
Supplemental Figure S1d), that was apparent in deep (bin1, p = 0.0087; bin3, 
p = 0.0059; bin5, p = 0.049 and bin6, p = 0.0071) and superficial layers of the 
M1 (bin7, p = 0.023 and bin9, p = 0.041; Fig. 4g) of the M1. The number of 
NeuN+ neurons positive for Casp3 was higher in the EFV-exposed group 
compared to the control group (p = 0.037; Fig. 4h, I and Supplemental Figure 
S1e, f). In addition, we noticed a small population of Casp3+ cells that were 
astrocytes (positive for GFAP) (Supplemental Figure S1a). When comparing 
nuclear size (using NeuN), we observed significantly reduced nuclear sizes in 
superficial layers of the EFV-exposed group (bin8, p = 0.0054; bin9, p = 
0.0080; Fig. 4j, k), suggesting a possible difference in apoptotic state. 
Together, these data suggest (neuronal) cell loss in M1 cortical areas which 
persists into adulthood in perinatally EFV-exposed animals. 
 Given the serotonergic pharmacological profile of EFV, we 
hypothesized that early EFV exposure could have long-term effects on the 
serotonergic system and potentially indirectly on other neurotransmitter 
systems such as the catecholaminergic system39. To test this hypothesis, we 
immunostained M1 cortical slices for 5-HT and TH (Fig. 5a, b) and found 
that perinatal EFV exposure was associated with increased 5-HT+ fiber length 
(p = 0.028; Fig. 5c, e) in deep and superficial layers of the M1 (bin2, p = 
0.034; bin6, p = 0.040; Fig. 5c). We found no differences in TH+ fiber length 
(p = 0.19; Fig. 5d, e), suggesting that perinatal exposure to EFV influences 
the development and maintenance of the serotonergic, but not the 
catecholaminergic, system. 
 
Correlations between reflex and motor development and M1 
cytoarchitecture 
 
 Swimming performance correlated positively with the number of cells 
(DAPI+; rs = 0.631, p = 0.009, Supplemental Figure S2) and post-mitotic 
neurons (NeuN+; rs = 0.642, p = 0.007) in the M1. In addition, we found a 
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significant positive correlation between negative geotaxis and 5-HT+ fiber 
length (rs = 0.700, p = 0.036) and a trend between negative geotaxis and the 
number of DAPI+ cells in M1 (rs = -0.492, p = 0.053). These results suggest 
that the M1 of animals that performed better on the motor-related tests 
contained more DAPI+ cells, more neurons and shorter 5-HT fibers. 
 
Discussion 
 
 In this study we demonstrate that perinatal exposure to EFV in rats 
results in a transient delay in reflex and motor development and in persistent 
changes in M1 cytoarchitecture. Since maternal care was not affected by EFV 
treatment, the behavioral changes most likely arise from direct EFV brain 
toxicity. Correspondingly, EFV-exposure caused persistent structural 
changes in motor cortical layers, reflected by a reduction in the number of 
mature neurons. The increased number of Casp3+ neurons points to neuronal 
cell death as the underlying cause. Finally, we found increased serotonergic, 
but not catecholaminergic, innervation of the M1 in EFV-exposed rats 
compared to controls, indicating that EFV, either directly or indirectly, affects 
the serotonergic system.  
 At the outset of our study, no studies had been published on long-term 
neurodevelopmental effects of EFV. Given EFV’ ability to interfere with the 
brain serotonergic system,12-14 we focused on behavioral domains known to 
be affected by genetic or pharmacological inactivation of the 5-HTT: reflex 
development22, 40, motor performance21, 25, and emotion24, 41. We found that 
perinatal EFV exposure resulted in delayed reflex development, reflected by 
increased latencies in the negative geotaxis test, and reduced startle responses. 
The reduced startle responses may indicate decreased capability of these rats 
to react to new auditory stimuli, but also point to a reduced ability to initiate 
motor responses. Correspondingly, EFV-exposed rats performed poorer in 
the swimming and bar holding tests. Adequate swimming requires the smooth 
integrative organization of multiple reflexes, including vestibular reflexes and 
extensor-flexor reflexes, which progressively develop during the postnatal 
phase of CNS maturation34. The delayed development of swimming ability in 
EFV-exposed rats suggests that early EFV exposure might modify these 
integrated neuromuscular mechanisms. The fact that bar holding performance 
was reduced as well indicates that muscle strength may have contributed to 
reduced swimming performance. We observed no group differences in PPI, 
the elevated plus maze test, or behavioral despair in the forced swim test. We 
did, however, observe shorter latencies to immobility in the forced swim test, 
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possibly reflecting motor-related problems. Taken together, these results 
suggest that perinatal exposure to EFV affects reflex and motor development, 
but not emotional behavior. The results are in line with recent findings 
showing that, compared to HIV-unexposed infants, HIV-uninfected infants 
perinatally exposed to EFV (aged 12-14 months) are at an increased risk for 
motor delay (particularly those born prematurely)6. 
 Alterations in care provided by the mother can potentially mediate 
effects of EFV on motor development. As one-third of EFV-treated adults 
report CNS symptoms10, 42, and EFV-treated adult rats show anxiety and 
depressive-like behavior14, 43, dams treated with EFV may have provided 
lower-quality care of pups than mothers treated with vehicle. For this reason, 
we measured maternal care and did not find significant differences between 
EFV- and vehicle-treated dams. Hence, the observed behavioral and 
morphological neurodevelopmental changes in EFV-exposed rats likely 
reflect (in)direct drug toxicity, rather than indirect effects mediated by altered 
maternal care. 
 To elucidate to what extent perinatal drug toxicity effects could 
explain the observed delay in reflex- and motor development, we investigated 
the cytoarchitecture of the motor cortex (region M1) in adult rats. In the M1 
of perinatally EFV-exposed rats, we observed a marked decrease in total cell 
numbers, including mature neurons, and an increase in the number of neurons 
that expressed the apoptotic marker Casp3. These findings indicate that 
perinatal EFV causes cell death later in life, leading to a partial loss of 
neurons. The positive correlation between motor development and number of 
cells suggests that the delayed motor function is related to reduced cell 
number in the M1. The EFV-induced loss of cells may be attributed to EFV’ 
(in)direct ability to interfere with cellular metabolism. For example, EFV has 
been shown to decrease neuronal ATP storage, leading to increased levels of 
reactive oxygen species and cell death44, 45.  
Alternatively, perinatal EFV exposure could indirectly lead to 
neurodevelopmental changes and cell death, by targeting the serotonergic 
system. We therefore determined whether the observed neuronal loss and cell 
death were related to changes in the serotonergic system. We measured the 
length of 5-HT+ and TH+ fibers in the M1 and observed an increased length 
of 5-HT+, but not TH+, fibers, which correlated with reduced performance in 
the negative geotaxis test. This result resembles the case of perinatal SSRI 
exposure, which also results in increased cortical serotonergic innervation in 
later life19, 46. 5-HT is one of the earliest neurotransmitter in the brain and 
performs neurotrophic functions during early development47. Hence, any 
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interference with the serotonergic system by perinatal drug exposure can have 
profound long-lasting indirect effects on neurodevelopmental events. The 5-
HT2, 5-HT3, and 5-HT6 receptors are involved in cell division
48, 
differentiation49, survival50, and neuronal migration pathways47. EFV, as a 5-
HT receptor (ant)agonist13, could directly interfere with these processes, 
consequently leading to neuronal cell death45. Elucidation of the exact 
molecular and cellular consequences at various developmental time points 
after perinatal EFV exposure in cortical and other brain areas requires further 
research. 
 We observed no signs of EFV-related pregnancy complications or 
teratogenicity, which is in line with findings in a recent meta-analyses 
including 2026 first-trimester EFV-exposures5. Still, EFV-exposed rats 
showed delayed maturation (delayed eyelid opening) and reduced body 
weights throughout life. Reduced birth weights have been reported in EFV-
exposed infants, although most studies in humans report comparable birth 
weights with infants exposed to other ART4, 51, 52. Interpretation of these data 
is difficult as drug-related effects cannot easily be isolated from other HIV-
related factors. Interestingly, the reduced body weight finding is in line with 
animal and human data derived from other early-life 5-HT stimulation 
models24, 25, 53. There are several ways in which EFV exposure might reduce 
body weight: via 5-HT, which through hypothalamic 5-HT receptors can 
interfere with the central regulation of eating behavior54, or via 5-HT-
independent mechanisms such as increased metabolism and altered adipocyte 
differentiation55. 
 In contrast to other behavioral EFV studies14, 43, we measured plasma 
levels of EFV. Using a 100 mg/kg daily dose, we produced EFV plasma levels 
that were detectable, yet below the therapeutic range in humans (1.0-4.0 
mg/L)56. One may argue that our experiment was, therefore, not 
representative for the human situation. However, it is known that the main 
neurotoxic metabolite of efavirenz approximates human exposure, despite 
apparent relatively low efavirenz plasma levels55. In addition, even at 
relatively low concentrations, EFV has been shown to extensively accumulate 
in brain tissue in rats57. Lastly, at similar doses in rats, efavirenz has been 
shown to induce neurotoxic changes12.  We, therefore, postulate that our 
experimental set-up was sufficiently valid to induce the desired effects.   
 The major strength of using a rat model is that potential HIV-related 
and socioeconomic confounders of adverse neurodevelopmental effects of 
EFV in humans (e.g. parental loss; co-medication) can be eliminated. As EFV 
did not affect maternal care, developmental effects through care provided by 
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the mother can be excluded. Our study has also limitations. We performed 
multiple behavioral tests with the same animals, which could have influenced 
test outcomes. We expect this carry-over effect to be limited, as tests were 
generally not stressful. Furthermore, molecular and cellular experiments 
involved adult rats, while behavior was measured mostly during early life. 
Thus, while we observed correlations between motor performance and 
neuronal loss in M1, we cannot draw conclusions on the timeline of events 
exerted by perinatal EFV exposure eventually leading to cell loss. Finally, to 
provide a causal relationship between behavioral and molecular changes 
observed, an intervention (e.g. co-administration of 5-HT2A receptor 
antagonist during efavirenz exposure) would be required. 
 There is a clear indication of HIV treatment during pregnancy as it not 
only protects the (unborn) child, but also benefits the mother’s health. The 
vast majority of children exposed to EFV during pregnancy will be HIV-
uninfected with normal life expectancies. However, this outcome may come 
at a cost. As we demonstrate, perinatal exposure to EFV in rats leads to a 
delay in reflex and motor development and a long-lasting loss of neurons in 
the motor cortex. Thus, EFV could affect the development of children who 
may already be experiencing multiple adverse conditions (such as having a 
mother living with HIV). Our findings underline the need for long-term 
clinical studies in children that are perinatally exposed to EFV, as well as 
more detailed studies on the underlying neurodevelopmental mechanisms. 
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Fig. 1. Experimental timeline. Pregnant dams were treated with efavirenz (n = 4) or 
vehicle (n = 4) from GD1 until PND7. At GD4, plasma levels of efavirenz were 
determined 1.5 hours post administration. Developmental milestones and behavior 
were assessed during the first three weeks of life (PND2-21), adolescence (PND34-
35) and adulthood (PND69-70). Maternal care was monitored from PND2 until 
PND9. After completion of the last experiments, rats (PND73-75) were sacrificed 
and their brains were removed for immunohistochemistry analyses. 
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Fig. 2. Perinatal exposure to EFV significantly affects bodyweight, eye opening, 
reflex and motor development, without effects on maternal care. EFV: efavirenz; 
Ctrl: vehicle; PND: postnatal day. (a) No effect of EFV on maternal behaviors N: 
nursing; LG: licking/grooming; C: contact; X: out of nest; SG: self-grooming; ED: 
eating/drinking (n = 4 litters per group, PND2-9). (b, c) Effects of perinatal EFV on 
general development (b) Main effect of EFV on bodyweight, with EFV-exposed rats 
showing reduced body weight (c) EFV affects eye opening (PND17) scored as (0) 
both eyes closed; (1) one eye open; (2) two eyes open (d, e). Effect of perinatal EFV 
on reflex development (d) No effect of EFV on righting time (s) in the righting reflex 
test (e) Main effect of EFV on negative geotaxis test, with EFV-exposed rats 
exhibiting longer latencies (s) until turning 180˚ (f, g) Effects of perinatal EFV on 
motor development (f) No main effect of EFV on the latency (s) to fall off the bar in 
the bar holding test, with a trend in EFV x time interaction (g) EFV affects swimming 
performance (PND14), scored as (1) entire head underwater, (2) nose underwater, 
ears partially underwater with the back of head above water level, (3) nose above 
water, ears partially underwater, (4) entire head above water (PND8, 10, 12, 14, 22). 
EFV n = 24, Ctrl n = 19. Data represent mean (± SEM), #p < 0.10, *p < 0.05, **p < 
0.01, ***p < 0.001, analyzed using repeated measures ANOVA (a, b, d, e, f) or 
Fisher’s exact (c, g). 
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Fig. 3. Perinatal EFV exposure affects the startle reflex and latency to immobility 
in the forced swim test, but has no effects on prepulse inhibition, or anxiety- and 
depressive-like behavior. EFV: efavirenz; Ctrl: vehicle; PND: postnatal day; PP: 
prepulse. (a-d) Effect of perinatal EFV on acoustic startle reflexes and prepulse 
inhibition (PPI). (a) Main effect of EFV on average startle amplitude development, 
with EFV-exposed rats exhibiting shorter startle amplitudes. No effect of EFV on 
PPI on (b) PND21, (c) PND35, and (d) PND70. PPI was calculated as: 100-(Average 
of all startle amplitudes on prepulse trial/startle amplitude on startle trial) x 100%. 
Three different prepulses were tested: 3 dB (PP3), 5 dB (PP5) or 10 dB (PP10) above 
background noise. (e-h) No effect of perinatal EFV on anxiety-like behavior in the 
elevated plus maze. (e) Number of open arm entries, (f) Number of closed arm 
entries, (g) Time (s) spent in open arms, and (h) Total distance (cm) moved. (i-k) 
Effects of perinatal EFV on depressive-like behavior in the forced swim test (i) No 
effect of EFV on the time (s) spent immobile, or (j) the number of immobility times. 
(k) Main effect of EFV on the latency (s) to immobility, with EFV-exposed rats 
exhibiting shorter latencies. EFV n = 22-24 and Ctrl n = 17-19. Data represent mean 
(± SEM), #p < 0.10, **p < 0.01, analyzed using repeated measures ANOVA (a-d) or 
One-way ANOVA (e-k).  
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Fig. 4. Perinatal exposure of EFV increases apoptosis in neurons of the motor 
cortex (M1) (a-k). EFV: efavirenz; Ctrl: vehicle (a) Immunostaining for DAPI, 
mature neurons (NeuN) and apoptosis (Caspase-3; Casp3) in the primary motor 
cortex (M1) of EFV- (n = 8) and Ctrl-exposed (n = 8) animals. The boxed areas are 
enlarged in (j). (b, c) Significant decrease of the total number of DAPI+ cells in the 
superficial cortical layer of the EFV–exposed group. (d, e) Quantification of mature 
neurons (NeuN+) showing a significant decrease in NeuN+ cells in deep and 
superficial layers in the EFV-exposed group. (f, g) Quantitative results showing a 
significant increase in Casp3+ cells in deep and superficial layers of the M1 of EFV-
exposed animals. (h-i) A significant increase in Casp3+/Neun+ cells in the EFV group 
compared to controls. (k) Significant differences in the area occupied by NeuN+ 
nuclei in 2 bins of superficial layers between EFV-treated and control animals. Data 
show mean (± SEM) number of cells, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed 
using One-way ANOVA. 
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Fig. 5. Perinatal exposure to EFV affects serotonergic (but not catecholaminergic) 
innervation of the M1. EFV: efavirenz; Ctrl: vehicle; 5-HT: serotonin; TH: tyrosine 
hydroxylase. (a, b) Camera lucida drawings of immunostaining for (a) 5-HT+ and 
(b) TH+ fibers in deep and superficial layers of the M1 in EFV-exposed (n = 5-7) 
and Ctrl-exposed brains (n = 5-7). (c) Significant increase in 5-HT+ fiber length in 
bin 2 and 6 in the EFV group (d, e) Significant increase in 5-HT+ fiber length, but 
no difference in TH+ fiber length in the total M1 area of the EFV-exposed group. 
Data show mean (± SEM) number of fibers, *p < 0.05 analyzed using One-way 
ANOVA. 
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Supplementary Table 1. General characteristics litters 
 
Data are depicted as mean (± SEM) 
  
 
Control 
(n = 4) 
EFV 
(n = 4) 
P-value 
Gestational length, days 22 (0.0) 22 (0.2) 0.686 
No. of pups per litter 8.8 (1.3) 10.8 (0.7) 0.343 
No. of still births 0 (0.0) 0 (0.0) - 
No. of neonatal deaths 0.0 (0.0) 0.5 (0.3) 0.343 
Gender pups, % female 41 (12) 42 (7) 0.886 
EFV plasma level (mg/L) - 0.28 (0.13) - 
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Supplementary Fig. 1. Perinatal exposure of EFV increases apoptosis in several 
types of motor cortex cells including astrocytes (a-f) but has no effect on motor 
cortical thickness. EFV: efavirenz; Ctrl: vehicle (a) Swatch of immunostaining 
showing colocalization with cleaved-Caspase-3 (Casp3) and GFAP, an astrocyte 
marker, in the motor cortex of EFV- (n = 8) and Ctrl-exposed (n = 8) animals. (b, c, 
d) Significant decrease in the total number of cells (b), total number of mature 
neurons (c) and total number of cells that are Casp3+ (d) in the EFV-exposed group 
compared with the Ctrl-exposed group. (e) Significant increase in the total number 
of Casp3+ neurons. (f) Increased percentage of neurons that are Casp3+ in the EFV-
exposure group. (g) No differences in the total length of a cortical swatch (h, i) No 
differences in the percentage of area occupied by NeuN+ cells and average size of 
NeuN+ cells in EFV group compared to the control group. Data show average ± 
SEM. One-Way ANOVA, *p < 0.05, **p < 0.01.
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Supplementary Fig. 2. Spearman correlations between behavioral development 
and immunohistochemistry data of control (n = 8) and efavirenz-exposed (n = 8) 
animals. Cumulative behavioral development was defined using area-under-the-
curve for righting reflex (PND2-10), negative geotaxis (PND4-14) and bar holding 
(PND10-21) and total sum score for swimming performance (PND 8, 10, 12, 14, 22). 
Immunohistochemistry data reflect the total number of DAPI+ cells, mature neurons 
(NeuN+), apoptotic cells (cleaved-Caspase-3 (Casp3)), total serotonin (5-HT+) fiber 
length, and total TH+ fiber length in the primary motor cortex (M1).  
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Abstract 
 
 Efavirenz (EFV) is used for antiretroviral treatment of HIV infection, 
and successfully inhibits viral replication and mother-to-child transmission of 
HIV during pregnancy and childbirth. Unfortunately, the drug induces side 
effects regarding cognitive functioning, including neuropsychiatric 
symptoms such as anxiety and depressed mood. EFV acts on, among others, 
the receptors and transporter of serotonin that are expressed throughout the 
developing brain. Yet, how perinatal EFV exposure affects brain 
cytoarchitecture is still unclear. Here, we exposed pregnant and lactating rats 
to EFV, and examined in the prefrontal cortex (PFC) of their offspring the 
effects of the maternal EFV exposure on cortical architecture. We observed a 
significant decrease in the number of cells, mainly mature neurons, in the 
infra/prelimbic and cingulate cortices of adult offspring. Futhermore, an 
altered cortical cytoarchitecture characterized by a significant reduction in 
deep-layer Tbr1+ and superficial-layer Cux1+ cells was found. We also 
observed a sharp increase in programmed cell death as we identified a 
significantly higher number of cleaved-Caspase-3+ cells. In addition, the 
serotonergic and dopaminergic innervations of the PFC subdomains were 
increased. Thus, the perinatal exposure to EFV provoked in the mPFC of adult 
offspring cell death, significantly altered cytoarchitecture, and disturbances 
in serotonergic and dopaminergic innervations. Our results are important in 
light of EFV treatment of HIV-positive pregnant women, and its effect on 
brain development and cognitive behavior. 
 
Keywords: Prefrontal Cortex Development, PFC, Corticogenesis, 
Neurodevelopment, Efavirenz, Antiretroviral Therapy, Serotonin, Side 
Effect. 
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Introduction 
 
 For the treatment of HIV infection, antiretroviral therapy is used, 
reducing morbidity and mortality significantly by decreasing retroviral 
replication1. International guidelines for HIV treatment recommend the use 
of two first-line nucleoside reverse transcriptase inhibitors and a third drug, 
which should be either an enhanced protease inhibitor, an integrase strand 
transfer inhibitor, or a non-nucleoside reverse transcriptase inhibitor. 
Efavirenz (EFV) is a drug that falls within the last category2,3. EFV effectively 
reduces viral replication, displays a low degree of interaction with the other 
antiretroviral drugs, is low in costs, requires single daily dosing and has 
moderate side effects which facilitates adherence to the treatment. Because of 
these characteristics, EFV is advised to be used by pregnant women to prevent 
the transfer of HIV from mother to child, decreasing the chance of infection 
to 5%1,4,5,6.  
 During the prenatal period, EFV crosses the placenta freely7, reaching 
the fetal blood and is able to cross the blood-brain barrier8 with potential 
effects on the developing brain. In the postnatal period, EFV is found in breast 
milk9,10, indirectly reaching the fetal blood and brain, to possibly affect brain 
development as well. The potential teratogenic effects of EFV are still not 
well described2,11. Prematurity, low birth weight and anomalies in the 
development of the neural tube have been demonstrated when EFV was used 
by the mother12,13,14. Preliminary data from a pioneer study conducted in 
children with fetal EFV exposure showed that these children exhibit poorer 
neurodevelopmental and social-emotional outcomes than children with fetal 
exposure to non-EFV-based antiretroviral regimens15. In addition, exposure 
of pregnant cynomolgus monkeys to EFV at the onset of gestation caused 
anencephaly and palatine cleft in 15% of the animals exposed at therapeutic 
EFV doses1,16. In rats, perinatal exposure to EFV led in the offspring to a 
delay in motor development as well as disturbances within the 
cytoarchitecture of the motor cortex17.  
 EFV can bind as an agonist or antagonist to vesicular monoamine 
transporters, dopamine and serotonin (5-HT) transporters, and glutamate, 
GABA, muscarinic, and the 5-HT receptors 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C 
and 5-HT6
18,19. EFV’s effect on 5-HT receptors and transporter is of particular 
relevance for brain development, since 5-HT functions as a neurotrophic 
factor responsible for controlling the events of proliferation, migration, 
differentiation and cell death during fetal and early postnatal brain 
development20-24. Before the serotonergic raphe nucleus in the embryonic 
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brain starts to produce 5-HT around embryonic day (E)10.5, the embryo 
receives 5-HT from the placenta25,26. In rats, the dorsal and medial raphe 
nucleus, located in the brain stem, start to develop and send their fibers to the 
forebrain which at around E16.5 reach the medial prefrontal cortex (mPFC). 
Once the serotonergic fibers are able to supply 5-HT to all brain regions 
(around E18.5), the placenta stops the production of 5-HT25,26. It is known 
that selective pharmacological or genetic interference with components of the 
5-HT signaling pathway in pregnant rodents leads to a variety of behavioural 
changes, including increased anxiety, depression-related behavior in the 
context of stress, decreased behavioral flexibility and deficits in social 
behavior27,28,29. Furthermore, a prenatal pharmacological/genetic block of the 
5-HT transporter (5-HTT) has been associated with an increase in 5-HT and 
dopamine innervation in the mPFC of embryos and pups, a disorganization 
of the cytoarchitecture of cortical layers30,24 as well as a down/up-regulation 
of numerous serotonergic receptors in various cortical areas including the 
mPFC31,32,33. Thus, a critical question is whether perinatal EFV exposure 
affects the cytoarchitecture of the mPFC as well. 
 Here, our objective was to explore the effects of EFV-exposure 
throughout the gestational period and during the first postnatal week on the 
infralimbic, prelimbic and cingulate cortex subareas of the rat mPFC, and to 
determine if any changes were maintained during adult life. We found that 
perinatal EFV exposure decreased the number of cells, in particular mature 
neurons, in all mPFC subareas studied and increased the expression of the 
apoptotic marker cleaved-Caspase-3. We furthermore observed differences in 
the expression of layer markers and increased serotonergic and dopaminergic 
innervations of the mPFC. Because in mPFC subareas EFV causes significant 
disturbances in cortical cytoarchitecture, our results are important when 
considering EFV-treatment of HIV-positive women during their pregnancy 
and lactating period. 
 
Material and methods 
 
Animals 
 
 All experiments were approved by the Animal Experimentation 
Committee of the Radboud University Medical Center Nijmegen, The 
Netherlands (ref no. 2012-236) and carried out in accordance with the 
Directive of the Council of European Communities (2010/63/EU). Male and 
female nulliparous Wistar rats weighing 185-215g (Charles River, Cologne, 
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Germany) were acclimated and housed together. After detection of the 
vaginal plug, at the first gestational day (GD1), pregnant females were 
randomly housed in pairs in Macrolon® type 3 standard cages in temperature-
controlled rooms (21°C ± 1°C) under a 12-hour standard light/dark cycle 
(lights on at 7:00 a.m.) with food and water available ad libitum. 
 
Drug treatment 
 
 Pregnant rats were randomly assigned to daily treatment with either 
EFV or vehicle from GD1 until postnatal day 7 (PND7). The drug solution 
was prepared by diluting the oral suspension of EFV (Stocrin suspension 30 
mg/ml, Merck Sharp & Dohme, Haarlem, The Netherlands) with distilled 
water. As a vehicle, we used a 1% cellulose suspension (Genfarma BV, 
Maarssen, The Netherlands), enriched with additives from the EFV solution, 
consisting of medium chain triglyceride oil (Newpharma, Liège, Belgium) 
and strawberry and mint flavors (Lecocq NV/SA, Zonhoven, Belgium). The 
EFV or vehicle was given blindly by oral gavage in a volume of 5 ml/kg. A 
dose of 100 mg/kg was used, based on unpublished pilot work and previous 
work demonstrating plasma levels within the human therapeutic range (1.0-
4.0 mg/l)2. Plasma EFV levels were measured on the fourth gestational day 
(GD4) 90 minutes after drug administration in a blood sample obtained via 
the tail and collected in Microvette CB 300 tubes (containing EDTA, Sarstedt, 
Germany), and the sample was processed as described by Wijer et al.36. At 
PND70, male offspring were sacrificed, and their brains removed for 
immunohistochemical studies. 
 
Immunohistochemistry 
 
 The animals received a single intraperitoneal (IP) injection of sodium 
pentobarbital (200 mg/kg), causing deep anesthesia. They were perfused 
transcardially with cold phosphate buffered saline (PBS, pH 7.4), followed 
by 4% paraformaldehyde (PFA) in PBS. Brains were rapidly removed and 
immersed in 4% PFA in PBS for 48 hours at 4°C. After 2 days, the brains 
were immersed in a 30% sucrose solution in PBS until they sunk, frozen and 
stored at -80°C. 16 μm sections were cut on a Microm Cryostat, mounted on 
Superfrost® Plus slides (Thermo Fisher Scientific, Waltham, MA, USA), air 
dried and stored desiccated at -20°C. After one hour in blocking buffer (BB, 
1.7% normal goat serum (NGS), 1.7% normal donkey serum (NDS), normal 
horse serum (NHS), 0.1% lysine, 1% BSA, 1% glycine and 0.4% Triton X-
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100), the cryosections were stained immunohistochemically using the 
following primary antibodies: mouse anti-Cux1 (1:300, Abcam, ab242194, 
Cambridge, United Kingdom), rabbit anti-Tbr1 (1:500, Abcam, ab31940, 
Cambridge, United Kingdom), mouse anti-NeuN (1:500, Merck Millipore, 
Bedford, MA, USA; MAB377), rabbit anti-cleaved-Caspase-3  (cl-Casp3, 
1:500, Cell Signaling Technologies, Danvers, MA, USA, ASP175), rabbit 
anti-hydroxytryptamine (5-HT) (1:500, Sigma-Aldrich, Zwijndrecht, The 
Netherlands, S5545) and rabbit anti-tyrosine hydroxylase (TH) (1:500, Merck 
Millipore, Bedford, MA, USA; AB152), all diluted in blocking buffer. After 
overnight incubation, the slides were washed in PBS and incubated with the 
corresponding species-specific Alexa-conjugated secondary antibody (1:500, 
Thermo Fisher Scientific) in blocking buffer for 30 minutes at room 
temperature. After washing in PBS, the sections were contrasted with DAPI 
diluted in PBS (1:1000, Thermo Fisher Scientific) for 15 minutes, washed 
extensively in PBS and embedded in 90% glycerol in PBS. For visualization, 
a Leica DMI6000B Automated high-content fluorescence microscope was 
used. 
 
Quantification and analysis 
 
 All analyses were performed in a blind fashion on at least six 
sequential coronal sections of each mPFC subarea (infralimbic, prelimbic and 
cingulate), which were scanned for cell and fiber quantification. The counting 
area in the mPFC was obtained using a rectangle of 0.1 mm wide extending 
from the ventricular zone to the marginal zone, using Photoshop CS6 
(Adobe). This rectangle was subdivided into 10 equal bins, in which bin 1 
represents the deepest layer and bin 10 the most superficial layer. For 
counting of the cells, Photoshop CS6 (Adobe) tools were used and fiber 
lengths were measured using ImageJ software, including the NeuronJ plugin 
(National Institutes of Health, Bethesda, USA). Data were statistically 
analyzed by one-way ANOVA (α = 5%) using GraphPad Prism 6/Excel data 
analysis toolkit and expressed as mean ± SEM. 
 
Results 
 
Perinatal EFV exposure affects the architecture of mPFC subareas 
 
 In a previous study, we found a clear effect of EFV on the maturation 
of the motor cortex and correlated behavior. However, it was unclear whether 
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this effect also occurs in other cortical structures that direct complex 
behavior36. In order to investigate the effect of perinatal EFV exposure on 
prefrontal development, the cytoarchitecture of various subdomains 
(infralimbic, prelimbic and cingulate) of adult (PND75) mPFC was studied. 
In rats perinatally exposed to EFV, we observed a significant reduction in the 
total number of DAPI+ cells in the adult infralimbic (p = 0.00065; Fig. 1B and 
C), prelimbic (p = 0.034; Fig. 1B and D), and cingulate cortex (p = 0.00085; 
Fig. 1B and E) when compared to the control group. This cellular reduction 
was distributed over the cortical swatch of all subdomains, but most apparent 
in the deeper layers (Fig. 1F, G, H).  
  To search for the identity of this reduced number of cells in the mPFC, 
we quantified the number of cells positive for the neuronal marker NeuN in 
the mPFC subareas. We found a significant reduction in the total number of 
NeuN+ cells per area in the deep as well as superficial cortical layers of the 
infralimbic (bin1, p = 0.0071; bin2, p = 0.025; Fig. 1B and I), prelimbic (bin1, 
p = 0.0063; bin2, p = 0.012; bin3, p = 0.0060; bin4, p = 0.013; bin5, p = 0.016; 
bin6, p = 0.019; Fig. 1B and J) and cingulate cortex (bin1, p = 0.0022; bin2, 
p = 0.00091; bin3, p = 0.0018; bin4, p = 0.0016; bin5, p = 0.0011; bin6, p = 
0.00016; bin7, p = 0.00014; bin8, p = 0.0060; bin9, p = 0.00044; Fig. 1B and 
K) of animals perinatally exposed to EFV compared to the control group. 
Using neocortex laminar/identity markers, we detected a significantly lower 
number of cells immunoreactive for the deep layer marker Tbr1 in all 
subareas of the mPFC of the EFV-exposed rats compared to control animals 
(infralimbic, p = 0.0019; prelimbic, p = 0.017; cingulate cortex, p = 0.014; 
Fig. 2A-G; Supplemental Fig. 1A, B, C). In addition, we found a significantly 
lower number of cells positive for the superficial layer marker Cux1 in all 
cortical layers of the infralimbic (p = 0.0083; Fig. 3A, B, E; Supplemental 
Fig. 1D), prelimbic (p = 0.0013; Fig. 3A, C, F, Supplemental Fig. 1E), and 
cingulate cortex (p = 0.0066; Fig. 3A, D, G; Supplemental Fig. 1F) of animals 
exposed to EFV compared to controls. In a small population of cells in the 
upper and deep layers, we identified double-positive Tbr1+/Cux1+ cells37 
which showed a significant decrease in the deeper aspects of laminar 
distribution of mPFC prelimbic (bin2, p = 0.033; Fig. 4C, F; Supplemental 
Fig. 1H) and cingulate cortex (bin1, p = 0.029; bin2, p = 0.030; bin3, p = 
0.019; bin4, p = 0.030; bin5, p = 0.035; Fig. D and G; Supplemental Fig. 1I) 
of the EFV-treated group compared to the controls. However, in the 
infralimbic cortex, a significant reduction of these double-labeled cells was 
found in not only deep but also in superficial layers (bin2, p = 0.029; bin5, p 
= 0.048; bin6, p = 0.0085; bin7, p = 0.00081; Fig. 4A, B, E; Supplemental 
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Fig. 1G). Even with cell loss, the cortical thickness between mPFC domains 
was not affected (Supplemental Fig. 1A-C). Together, the data suggest that 
perinatal EFV exposure alters the cytoarchitecture of mPFC subareas by 
reducing the number of neurons, along with an altered expression of deep and 
superficial cortical layer markers. 
 
Perinatal EFV exposure results in neuron death in mPFC subareas 
  
 Programmed cell death is a natural and critical process during brain 
development38. Various apoptotic signaling pathways are mediated by 
activation of, among others, serotonergic signaling38,39,40,41. We observed a 
significant increase in cells positive for the apoptotic marker cleaved-
Caspase-3  in the prelimbic (bin4, p = 0.040; bin5, p = 0.049; Fig. 5F) and 
cingulate cortex (bin1, p = 0.011; bin2, p = 0.048; bin4, p = 0.015; bin6, p = 
0.023; bin8, p = 0.0039; bin9, p = 0.039; Fig. 5G) of adult (PND75) animals 
exposed to EFV when compared to control animals. No differences were 
identified in the infralimbic cortex (p = 0.16; Fig. 5E). Interestingly, not all 
cleaved-Caspase-3+ cells co-expressed NeuN (Fig. 5A). Only in the cingulate 
cortex, we found a significant difference in the total number of mature 
apoptotic neurons between the EFV and control groups (p = 0.027; Fig. 5D). 
We conclude that perinatal EFV exposure results in cellular apoptosis of 
mature neurons in mPFC subareas of adult animals. 
 
Perinatal EFV exposure causes disturbances in serotonergic and 
dopaminergic innervations of mPFC subareas 
  
 Disturbances of serotonergic and dopaminergic innervations during 
the critical period of brain development are associated with various brain 
diseases42,43. Both neurotransmitters are able to control important 
neurodevelopmental processes such as proliferation, migration, 
differentiation, programmed cell death and synaptic organization during the 
embryonic period and adolescence, up to adulthood44,39. Therefore, we next 
quantified the lengths of the 5-HT+ and TH+ fibers in the infralimbic, 
prelimbic and cingulate cortex of adult (PND75) animals exposed to EFV 
perinatally. We found a significant increase in 5-HT+ fiber lengths in the deep 
layers of the infralimbic (bin2, p = 0.033; bin3, p = 0.021; bin4, p = 0.017; 
Fig. 6A, B, E), prelimbic (bin1, p = 0.016; bin2, p = 0.027; bin3, p = 0.037; 
Fig. 6C and F) and cingulate cortex (bin2, p = 0.031; bin3, p = 0.022; Fig. 6D 
and G) of rats perinatally exposed to EFV compared to control animals. We 
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furthermore observed a significant increase in TH+ fiber lengths in the deeper 
layers of the infralimbic (bin3, p = 0.045; Fig. 7A, B, G), prelimbic (bin6, p 
= 0.039; Fig. 7C, D, H) and cingulate cortex (bin1, p = 0.010; bin2, p = 0.011; 
bin5, p = 0.0054; bin6, p = 0.018; Fig. 7E, F, I). Together, the data suggest 
that changes in serotonergic and catecholaminergic systems occur in animals 
perinatally exposed to EFV and that these changes persist into adulthood. 
 
Discussion 
 
 We have explored the question whether exposure of rats to EFV 
during the embryonic period and the first postnatal week results in adverse 
effects on mPFC development. Our results demonstrate that perinatal EFV 
exposure causes a significant decrease in the total number of cells, including 
mature neurons, in all subareas of the mPFC without affecting cortical 
thickness. Furthermore, EFV exposure results in disturbances in the 
cytoarchitecture as evidenced by a significantly reduced number of cells 
expressing Cux1 and Tbr1, markers of superficial and deep cortical layers, 
respectively. This may be due to the increased activation of apoptotic 
pathways as demonstrated by the increase of cleaved-Caspase-3+ cells in all 
mPFC subdomains or an altered or delayed expression of the markers. In 
addition, we observed a significant increase in serotonergic and 
catecholaminergic innervations of the infralimbic, prelimbic and cingulate 
cortex of EFV-exposed rats. Together, the data suggest that perinatal EFV 
exposure causes prefrontal alterations at the cellular level in all subdomains 
of the mPFC and that these changes persist into adulthood. 
 The development of the PFC undergoes a number of stages. Following 
proliferation, cells progress to stages of neural migration, maturation, synapse 
formation, cell death, and network maturation34,45-48. All of these events are 
mediated by local neurotrophic factors and other external afferents, including 
serotoninergic and catecholaminergic ones24. It has been demonstrated that 5-
HT, via various receptors present on different neural progenitor cells, glial 
cells and Cajal-Retzius cells, can regulate specific events during cortical 
development, including neuronal maturation, excitability and programmed 
cell death20,21,22. The effects of EFV on the immature brain may be broad, 
since this drug binds as an agonist or antagonist to a number of receptors and 
transporters of the 5-HT signaling pathway as well as of other 
neurotransmitter systems19,18. This interaction of EFV with different 
serotonergic receptors and transporter could be behind disturbances in 
neuronal migration and increased programmed neuronal death found by us. 
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Which together resulted in disorganized layers of the mPFC in the face of 
increased serotonergic and dopaminergic innervation. Recently, we found 
that rats exposed perinatally to EFV showed an increase in serotonergic 
innervation of the motor cortex17, and a similar effect was found in the 
absence of the 5-HTT in knockout rats with increased serotonergic 
innervation of mPFC subdomains24,30. In addition, a disorganised cortical 
cytoarchitecture demonstrated by the Satb2, Cux1 and Tbr1 layers markers in 
mPFC from young 5-HTT-/- rats was found24,30. Interference of EFV with the 
5-HT signaling pathway may explain the increase we found in serotonergic 
axonal length in the mPFC. Thus, the serotonergic system may well have been 
the major target for the effects of EFV we observed. Previous studies 
demonstrated that the 5-HTT-/- rats display a delay in motor development55, 
comparable to the effects of perinatal EFV exposure in rats17. The knockout 
rats furthermore display increases in affective behaviour56, lower levels of 
social interaction57, and a decrease in memory for neutral information but an 
increase in memory for valenced (rewarding, aversive) information58,59. 
Whether perinatal EFV exposure causes a similar behavioural profile remains 
to be investigated.  
 The increase in 5-HT and catecholaminergic fibers in response to 
perinatal EFV exposure corresponds to our previous observation of increases 
in these fibers in the mPFC in rats lacking the 5-HTT24. This similarity 
suggests that the 5-HT system was the major target for the effects of EFV we 
observed. Previous studies demonstrated that these rats display a delay in 
motor development55, comparable to the effects of perinatal EFV exposure in 
rats17. These rats furthermore display increases in affective behaviour56, lower 
levels of social interaction57, and a decrease in memory for neutral 
information but an increase in memory for valenced (rewarding, aversive) 
information58,59. Whether perinatal EFV exposure causes a similar 
behavioural profile remains to be investigated.  
 A limitation of this study is that we used a daily concentration of EFV 
(100 mg/kg) that produced plasma levels lower than the therapeutic range in 
humans60. However, such a dose has led to neurotoxic effects in rats61,62 to the 
same extent as in humans63, because the neurotoxic metabolite accumulates 
in brain tissue, giving our study a high translational impact. Further, our 
animals were exposed during the perinatal period and first postnatal week, 
and the analyses were performed in adult life, allowing compensatory 
changes to take place during this developmental period, such as reduction of 
cell death or induction of proliferation. 
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 The high efficacy of EFV in inhibiting cross-infection between mother 
and embryo together with its low cost still makes EFV the first drug of choice 
for the treatment of HIV in pregnant women1,2,3,4. However, this may come at 
a cost. In rats, perinatal exposure to EFV caused a developmental delay and 
a clear loss of neurons in the motor cortex17. Our results also point to a 
significant neuronal loss and a disorganized cytoarchitecture in the mPFC. 
These findings are in line with preliminary data from the first study on EFV-
exposed children in Botswana (Southern Africa), which demonstrated a 
compromised motor and cognitive development15.   
 In conclusion, exposure of rats to EFV during pregnancy and the first 
week of postnatal life leads to a perturbed cytoarchitecture, and altered 
serotonergic and dopaminergic innervations of the infralimbic, prelimbic and 
cingulate cortices of their offspring. Given that the mPFC is responsible for 
cognitive functions, language, comprehension, decision making, planning, 
memory and attention, these findings may have implications for the social 
and cognitive functioning of adult offspring of expectant women exposed to 
EFV. This is of great importance when considering EFV as the drug of choice 
for treating pregnant, HIV-infected women.  
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Fig. 1. Perinatal EFV exposure decreases the total number of cells and mature 
neurons in mPFC subareas. (A) Schematic of a sagittal and coronal section of the 
forebrain with the mPFC. (B) Immunostaining marking mature neurons (NeuN, 
green) counterstained with DAPI (blue) in coronal slices in infralimbic, prelimbic 
and cingulate subareas of the mPFC in EFV-exposed (n = 5) and control (Ctrl, n = 
5) rats. Quantification of the number of DAPI+ cells per total area in (C-E) mPFC 
subareas over the superficial and deep cortical layers (F-H) of the EFV–exposed 
group when compared with controls. (I-K) Quantification of mature neurons 
(NeuN+) showing a significant decrease in NeuN+ cells in deep and superficial layers 
in EFV–exposed and control group in the infralimbic, prelimbic and cingulate cortex. 
Schema adapted from McKlveen et al64. Data show mean (± SEM) number of cells, 
*p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (α = 5%). 
EFV: efavirenz; Ctrl: vehicle. 
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Fig. 2. Perinatal EFV exposure affects the expression of deep layer marker Tbr1 
in mPFC subareas. (A) Immunostaining for the deep layer marker Tbr1 (red) in the 
prelimbic subarea of mPFC of EFV-exposed (n = 5) and control (n = 5) rats. (B-D) 
Significant decrease of Tbr1+ cells in all subdomains of the mPFC cortex of the 
EFV–exposed group compared to controls. (E-G) Significant decrease in the number 
of Tbr1+ cells in cortical deep layers of the infra-, pre- and cingulate cortex of EFV-
exposed versus control rats. Data show mean (± SEM) number of cells, *p < 0.05, 
**p < 0.01, ***p < 0.001, analyzed using One-way ANOVA (α = 5%). EFV: 
efavirenz; Ctrl: vehicle. 
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Fig. 3. Perinatal EFV exposure affects the expression of superficial layer marker 
Cux1 in mPFC subareas. (A) Immunostaining for the superficial layer marker Cux1 
in infralimbic cortical subarea of the mPFC of EFV-exposed (n = 5) and control (n 
= 5) rats. (B-D) Significant decrease in number of Cux1+ cells in the total area of the 
infralimbic, prelimbic and cingulate cortices of EFV–exposed rats compared to 
controls. (E-G) Significant decrease in the number of Cux1+ cells in both cortical 
superficial as well as deep layers of mPFC subdomains of the EFV-exposed rats 
compared to controls. Data show mean (± SEM) number of cells, *p < 0.05, **p < 
0.01, ***p < 0.001, analyzed using One-way ANOVA (α = 5%). EFV: efavirenz; 
Ctrl: vehicle. 
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Fig. 4. Perinatal EFV exposure affects specific subsets of neurons in mPFC 
subareas. (A) Co-immunostaining for Tbr1 and Cux1 in the infralimbic subarea of 
mPFC of EFV-exposed (n = 5) and control (n = 5) rats. (B-D) Significant decrease 
in total number of Tbr1+/Cux1+ cells in the infralimbic and cingulate, but not 
prelimbic cortices in EFV-exposed versus control rats. Differences in the total 
number of Tbr1+/Cux1+ cells in the superficial and deep cortical layers of infralimbic 
(E), prelimbic (F) and cingulate (G) cortex of EFV-exposed rats compared to 
controls. Data show mean (± SEM) number of cells, *p < 0.05, **p < 0.01, ***p < 
0.001, analyzed using One-way ANOVA.  
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Fig. 5. Perinatal EFV exposure results in cell death in subareas of the mPFC. (A) 
Immunostaining for NeuN (green), cleaved-Caspase-3 (red) and counterstained with 
DAPI (blue) in the infralimbic subarea of mPFC of EFV-exposed (n = 5) and control 
(n = 5) rats. (B-D) Quantification of the number of cleaved-Caspase-3+ neurons 
mPFC subdomains in EFV-exposed rats compared to controls. (E-G) Significant 
increase in cleaved-Caspase-3+ cells per area in superficial and deep layers of the 
prelimbic and cingulate cortices, but not in the infralimbic cortex of EFV exposed 
versus control rats. Data show mean (± SEM) number of cells, *p < 0.05, **p < 0.01, 
***p < 0.001, analyzed using One-way ANOVA (α = 5%). EFV: efavirenz; Ctrl: 
vehicle. 
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Fig. 6. Perinatal EFV exposure causes disturbances in serotonergic innervation 
of mPFC subareas. (A) Immunostaining showing 5-HT+ fibers (white) in deep and 
superficial layers of the infralimbic cortex in EFV-exposed (n = 5) and control (n = 
5) rats. (B-D) Quantification of serotonergic fiber length in total swatch area in all 
mPFC subareas in EFV-exposed animals compared to control areas. (E-G) A 
significant increase in 5-HT+ fiber length in deep layers of the infralimbic, prelimbic 
and cingulate cortex area of EFV-exposed group compared to the controls. Data 
show mean (± SEM) length, *p < 0.05 analyzed using One-way ANOVA (α = 5%). 
EFV: efavirenz; Ctrl: vehicle; 5-HT: serotonin. 
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Fig. 7. Perinatal EFV exposure causes disturbances in dopaminergic innervation 
of mPFC subareas. (A-F) Immunostaining showing TH+ fibers in infralimbic, 
prelimbic and cingulate cortex in EFV-exposed (n = 5) and control (n = 5) rats. (G-
I) No significant differences in total fiber length in mPFC subareas in the EFV group 
compared to the control group. (J-L) A significant increase in TH+ fiber length in 
deep layers of the infralimbic, prelimbic and cingulate cortex of EFV-exposed versus 
control rats. Data show mean (± SEM) length, *p < 0.05 analyzed using One-way 
ANOVA (α = 5%). EFV: efavirenz; Ctrl: vehicle; TH: tyrosine hydroxylase.  
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Supplemental Fig. 1. Quantification of cortical thickness and reduction in cortical 
layer markers expression in mPFC subareas. (A, C) Quantification of cortical 
thickness of mPFC subareas. (D, F) Quantification of total number of Tbr1+ cells in 
mPFC subareas in EFV–exposed group compared to controls. (G, I) Quantification 
of total number of Cux1+ cells in mPFC subareas in EFV–exposed group compared 
to controls. (J, L) Quantification of total number of Tbr1+/Cux1+ cells showing a 
significant decrease in Tbr1+/Cux1+ cells in the infralimbic and cingulate but not 
prelimbic cortex in EFV–exposed versus control rats. Data show mean (± SEM) 
number of cells, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using One-way 
ANOVA (α = 5%). EFV: efavirenz; Ctrl: vehicle. 
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The dynamic course of brain development involves vital processes 
and adaptations that begin during the embryonic period and last a lifetime. 
The prenatal and early-postnatal stages of development appear to be the most 
vulnerable stages for aberrations1-5. The development of the cerebral cortex, 
including the evolutionarily more recent prefrontal part, starts during the 
embryonic period via a highly organized sequence of events, including cell 
proliferation, migration, differentiation, and formation of connections5,6,7. 
After birth, the cortex continues to develop and specializes into increasingly 
complex functions based on a precise genetic program with modulations 
influenced by the environment8,9,10. Furthermore, these events can be fine-
tuned by neurotrophic factors such as serotonin (5-HT)5,6. 5-HT is a regulator 
of corticogenesis during brain development and as such a potent regulator of 
behavior8. 
 In this thesis, prefrontal neurodevelopment was studied using wild-
type animals as well as genetically modified or pharmacologically treated 
rodents, with a focus on the serotonergic system during embryonic 
development and around birth. In Chapter 2, mice were used to describe in 
detail the development of the medial prefrontal cortex (mPFC) at different 
developmental time points, in addition to comparing its development to that 
of the more dorsal somatosensory cortex. Once we understood the default 
mechanism of prefrontal development and its relationship to the serotonergic 
system, we used the serotonin transporter knockout (5-HTT-/-) rat in Chapter 
3 to study the role of the 5-HTT and the effect of the resulting increased 5-
HT levels on the development of the mPFC at the cellular level. Additionally, 
we examined the interaction between the catecholaminergic and serotonergic 
systems during mPFC development. Chapter 4 describes increased anxiety in 
adolescent compared to juvenile 5-HTT-/- rats, which was associated with an 
increased 5-HT innervation of the mPFC and cell loss in deep as well as 
superficial layers, including mature neurons. Chapters 5 and 6 tested the 
effect of perinatal exposure of pregnant rats to the antiviral drug efavirenz on 
behavior and cortical morphology. We found a delay in motor development, 
reduced body weight and increased neuronal cell death in the M1 motor 
cortex and all subdomains of the mPFC. In this last chapter, the findings 
reported in chapters 2-6 and their main conclusions will be discussed and put 
into a broader perspective. 
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The role of 5-HT during cortical development 
 
 The timing of cortex development depends on the function exerted11. 
The areas responsible for higher cognitive functions develop later relative to 
the areas of primary functions such as visual, sensory and motor cortices11,12. 
Because of its superior and integrative functioning, the mPFC is the last area 
to evolve, and its development has recently been documented by magnetic 
resonance imaging12. In mice, mPFC development seems to be delayed 
relative to the development of more dorsal regions such as the somatosensory 
cortex (S1). This delay in maturation may in part be due to its serotonergic 
innervation. Indeed, serotonergic axons travel from the dorsal raphe nucleus 
in the brainstem to the mPFC at the same time as corticogenesis begins in this 
frontal area4,5,6,7 (Chapters 2 and 3). Once serotonergic axons reach their 
frontal targets the serotonergic contribution increases, leading to a higher 
cellular innervation. It is important to note that the serotonergic fibers first 
arrive in the infralimbic areas, followed by prelimbic and cingulate cortex8. 
The compartmentalization and stratification of these mPFC subdomains 
occur differently when compared to the S1, with the cingulate cortex being 
the last area to be reached by serotonergic fibers (Chapter 2). This may 
explain the behavioral changes in adulthood when the connections of the 
cingulate cortex with other areas of the limbic system develop and these 
connections are associated with the control of emotions and behavior13,14,15. 
Once developed, the prelimbic and infralimbic cortices send projections back 
to the raphe nucleus16,17, and create a feedback system18,19.  
 The 5-HTT is expressed in cortical areas even before 5-HT projections 
arrive20. This suggesting that there must be an alternate source of 5-HT during 
early development. Indeed, maternal-derived 5-HT from the placenta is 
already present at early stages of corticogenesis21. Therefore, a correct 
cortical maturation, and appropriate 5-HT levels and innervation are 
necessary for the proper functioning of this circuit. 
 
Damages caused by increased 5-HT levels during mPFC development 
 
 Changes in 5-HT levels are the basis of neuropsychiatric disorders 
such as schizophrenia, bipolar disorder, depression, anxiety and autism. 5-HT 
should be kept at appropriate levels because it is an important regulator of 
cortical development and emotional control22,23. As mentioned, one  
important regulator of 5-HT levels is the 5-HTT, which promotes the re-
uptake of this neurotransmitter and as such regulates its extracellular 
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levels23,24,25. Alterations in the promoter of the human gene encoding 5-HTT 
are associated with an increase of extracellular 5-HT. Carriers of the short 
allele (s) of this gene initially present depressive episodes, followed by an 
increase of anxiety25-30. This circumstance in human is mimicked in the 5-
HTT-/- rat and through selective or non-selective pharmacological animal 
models33. Altered 5-HT levels during prenatal and postnatal development 
affect cortical development because during this period the cortex is still at its 
peak of development and an excess of 5-HT leads to specific changes in 
mPFC gene expression31,32,33 (Chapters 3-6). In the knockout animals, the 
absence of the transporter causes an increase in extracellular 5-HT31,32, and 
this increase causes aberrations in the development of the serotonergic system 
with a lower cell density in the raphe nucleus, the origin of the serotonergic 
system (Chapter 3). This may result in a compensation mechanism, namely 
an increase of axonal projections of this system towards frontal regions 
(Chapter 3). At the level of the mPFC, excess of 5-HT during development 
caused a decrease in the number of CR cells. Furthermore, the organization 
of the layers was disturbed with a delay in the expression of the subcerebral 
projection neuron marker Satb2, i.e. a decrease at early postnatal days 
(Chapter 3) and an increase in early adolescence (Chapter 4). In addition, 
neuronal maturation was affected, and neuronal loss was provoked through 
activation of apoptosis (Chapters 3 and 4). This neuronal loss and a delay in 
cell specification, associated with an increase in serotonergic innervation in 
the cingulate cortex, may explain the increased anxiety identified during early 
adulthood of the 5-HTT-/- rats (Chapter 4).  
 Anxiety is a physiological defense mechanism and is associated with 
the activation of different brain areas, which mobilize the organism for an 
anticipatory and aversive reaction34. When a certain level of stress is 
exceeded, anxiety ceases to be adaptive and becomes pathological35,36,37. The 
mPFC plays an important role in the coordination of behavioral and 
physiological stress responses38,39, especially the cingulate cortex, most likely 
through its reciprocal connections with the amygdala and other parts of the 
limbic system17,40,41,42. In systems with an affected 5-HTT these structures are 
also disturbed and characterized by cell loss (Chapter 3)45. Interestingly, 
anxiety emerges only between PND25 and PND35 in 5-HTT-/- rats and not 
earlier (Chapter 4). This may be due to the relatively late maturation of the 
mPFC. Apparently, connections between the mPFC and limbic areas seem to 
depend on proper mPFC maturation which begins during the embryonic 
period and lasts until adulthood43,44,45 (Chapters 2 and 4).  
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 Emerging compensatory mechanisms, such as dynamic modulation of 
the expression of 5-HT receptors in different cortical areas, can be key to the 
eventual effects of excess 5-HT46. These receptors may stimulate cell 
proliferation or activate apoptotic pathways47. The serotonergic receptors 5-
HT1A, 5HT2A, 5-HT2C and 5-HT3A have been associated with depressive 
behavior and increased anxiety when 5-HT levels are increased 46,47. For 
example, the selective pharmacological block of the transporter during the 
embryonic period, via fluoxetine, increases expression of the 5-HT3A 
receptor, which has been associated with the occurrence of autism48,49. 
Studies have focused on avoiding these compensatory effects of the blockade 
or absence of 5-HTT. Specific blockers of 5-HT2A/C receptors administered at 
early-postnatal periods were able to prevent the pharmacologically induced 
alterations in cortical areas, and as such inhibited depression and anxious 
behavior in adult life50. 
 The change in 5-HT levels not only caused alterations in cortical 
development and in the serotonergic system itself, but also interfered with the 
development of another system, the dopaminergic system (Chapters 3, 5 and 
6). Following the increase in 5-HT levels, the loss of cells in the ventral 
tegmental area (VTA) and in the substantia nigra compact (SNc) promoted an 
increase of the dopaminergic axon projections to the mPFC, possibly as a 
compensatory mechanism (Chapter 3). Since there are contacts between 
dopaminergic fibers and CR cells, the increased dopaminergic mPFC 
innervation may lead to even more disturbances in cortical development 
(Chapter 3). This is interesting because also during corticogenesis dopamine 
(DA) participates in several developmental processes51,52,53. Such an 
interaction between systems has previously been demonstrated only through 
pharmacological blocks of dopaminergic, noradrenergic or serotonergic 
levels, receptors and transporters54,55. The addition of methylphenidate, an 
inhibitor of DA and noradrenaline transporters, together with the 5-HTT 
inhibitor citalopram led to a decrease in extracellular 5-HT levels and 
increased levels of DA in the PFC of rats55. The integration of different 
systems, as exemplified by a loss of cells in the dopaminergic system in the 
absence of 5-HTT (Chapters 3 and 4), should be carefully monitored when 
perinatally administering drugs (Chapters 5 and 6). The interaction of various 
transmitter systems during development could cause even more cortical 
damage than initially thought and can last into adulthood (Chapters 5 and 6). 
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Effects of pharmacological agents on cortical development  
 
 In many cases the use of medication during pregnancy cannot be 
avoided, for example when trying to prevent cross-infection between mother 
and child by HIV during the pre- and perinatal periods. The drug most 
commonly used in this respect, efavirenz (EFV)57,58, is a non-nucleoside 
reverse transcriptase inhibitor that blocks HIV replication. Additionally, EFV 
interacts with the serotonergic system through not only the 5-HTT but also 
via stimulation or inhibition of various 5-HT receptors59,60. These 
pharmacological targets can be the basis of the side effects presented by 
patients (or their offspring) and found in animal models, such as increased 
levels of anxiety, depression, hallucinations and aggressiveness61-66. 
 Previous studies on possible damage caused by EFV in the immature 
brains of humans and nonhuman primates have given inconclusive results67. 
In vitro studies have demonstrated a clear effect of EFV on the death of 
progenitor cells from different brain areas, and in vivo EFV-induced brain 
toxicity has been found in adult animals68-72. We exposed animals to EFV 
throughout the prenatal and lactation periods and evaluated the side effects of 
the drug on the adult brain. Behavioral tests during early postnatal ages, 
adolescence and adulthood showed a delay in motor and reflex development 
(Chapter 5). A similar outcome was obtained in a large-scale study on African 
children exposed to EFV. These children had a worse motor development 
when compared to children not exposed to EFV73. 
 At the cellular level, EFV intake during prenatal and early postnatal 
periods elicited cellular apoptosis in all cortical layers of the mice. In the adult 
primary motor cortex (Chapter 5) and mPFC (Chapter 6), these cells were 
mature neurons or astrocytes, which also regulate neuronal survival through 
the secretion of neurotrophic factors69,72. At the same time, the excess of 
serotonergic innervation, associated with EFV cell toxicity, caused 
disturbances in the cortical organization and promoted an increase in 
dopaminergic innervation, which was evaluated in the M1 (Chapter 5) and 
mPFC (Chapter 6).  
 Interestingly, the observed behavioral effects of EFV resemble those 
previously found in response to perinatal exposure of rats to selective 
serotonin reuptake inhibitors (SSRIs) and in 5-HTT-/- rats33, albeit milder. 
This, in combination with the increased serotonergic innervation of the mPFC 
as also observed in the 5-HTT-/- rats (Chapter 3), implies that the effects of 
EFV are mainly mediated through the serotonergic system. The milder 
behavioral consequences of perinatal EFV exposure compared to perinatal 
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SSRI exposure may relate to the fact that SSRIs increase 5-HT levels that can 
bind to all 15 5-HT receptors, whereas EFV more specifically targets the 
postsynaptic 5-HT2A receptor
59,60. In support, a 5-HT2A receptor antagonist 
treatment was found to partially block the effects of perinatal SSRI exposure 
on behavior in offspring50. 
 These data demonstrate an important role of 5-HT in cortical 
development and control of behavior, and especially point to the danger such 
drugs can pose during brain development. Such a risk factor should be 
considered when prescribing or using these types of medication perinatally. 
 In conclusion, events occurring during early stages of cortical 
development determine the basic neurobiological architecture and function of 
the brain, and eventually define behavior in adult life. For proper brain 
functioning, these events require adequate levels of 5-HT. Identifying when 
and where developmental events occur, offers a broadening of our 
understanding of brain development and highlights the mechanisms 
underlying neurodevelopmental disorders. The stimuli transmitted to the 
brain during the pre- and postnatal periods, and also during the other stages 
of life, affect the functioning of neurons and neural circuits. In addition, the 
mechanisms of brain plasticity induced by environmental stimuli during the 
pre- and postnatal periods add to the understanding of how the cortex 
develops and how prenatal events are reflected in adult behavior. The ultimate 
goal of this thesis was to identify some of these neurodevelopmental 
mechanisms in the maturation of the mPFC, and to study the effects of the 
serotonergic system on these mechanisms and how disturbances in this 
system are translated into various diseases in which the PFC plays a major 
role.  As such, we hope to have contributed to the understanding of how the 
structure of the PFC develops and how these developmental events are subject 
to various risk factors like increased 5-HT levels, either via genetic or 
pharmacological influence, causing structural damage that will persist 
throughout adult life and become apparent as perturbed behavior. To provide 
a graphical overview, the results of the studies reported in this thesis are 
summarized in Fig. 1. 
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Fig. 1. Effects of 5-HT increase on brain development. (A) - The increase of 
extracellular 5-HT causes an increase in serotonergic and dopaminergic innervation 
in cortical areas especially the MZ, where they contact with CR cells in the 
embryonic mPFC. (B) - Already in the postnatal mPFC, the increase of 5-HT induces 
a neuronal cell death program, and altered organization of the cortical layers, 
demonstrated by decreasing levels of the transcription factor layer markers Cux1 
(superficial), Satb2 (superficial and deep) and Tbr1 (deep). The increase of 
serotonergic and dopaminergic innervation remains. These changes lead to an 
increase in anxious behavior in adulthood. (C) - During the development of the 
motor cortex, the increase in 5-HT levels, via EFV, caused an increase in 
dopaminergic innervation, and neuronal and astrocyte death, which was reflected by 
a delay in motor and reflex development. (D) - The increase in 5-HT levels in the 
medial forebrain bundle was established by the increase in the number and thickness 
of serotonergic and dopaminergic fascicles in this region early postnatally (P6). (E) 
- The increase in 5-HT levels during embryonic development caused a decrease in 
the number of dopaminergic neurons in the midbrain, which were identified at P6. 
(F) - Finally, the increase in 5-HT levels during the embryonic period causes a 
significant decrease in cell density in the dorsal and medial raphe nuclei, being the 
origin of the serotonergic system at P6. 5-HT, serotonin; nl 5-HT, normal levels of 
serotonin; DA, dopamine; MZ, marginal zone; CP, cortical plate; SP, subplate; IZ, 
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intermediate zone; SVZ, subventricular zone; VZ, ventricular zone; WM, white 
matter; CR, Cajal-Retzius cells; RN, rape nucleus; SN, substantia nigra; VTA, 
ventral tegmental area; DRN, dorsal raphe nucleus; MRN, medial raphe nucleus; Str, 
striatum; Mid, midbrain; Di, diencephalon, Ctx, cortex.  
 
Future prospects 
 
 The early years of human development establish the basic 
neurobiological architecture and function of the brain. This initial period of 
development, from conception to the first years of age, is crucial as it defines 
physical and mental health in later life. The stimuli transmitted to the brain 
by sensory circuits during pre- and postnatal periods, and also in later stages 
of life, shape the function of neurons and neural circuits. For instance, altered 
levels of 5-HT are a risk factor for disorders such as depression and anxiety. 
Currently, the treatment of these disorders involves only a standardized 
treatment with mostly symptom management, rather than taking the cause 
and/or other transmitter systems into consideration. Timely preventing 
cortical aberrations, e.g. caused by deviations in 5-HT levels, may provide a 
more attractive therapy. Therefore, knowledge of the biological framework 
that underpins these disorders is essential. Longitudinal studies that describe 
all aspects of (human) brain development are crucial for the understanding of 
the defects that occur in neurological disease, but maybe more so in 
neurodevelopmental disorders. The exact timing of the occurrence of deficits 
and the establishment of the precise critical developmental window in which 
these deficits start to manifest themselves is vital for determining the best 
treatment strategy. In this thesis, we focused on the role of 5-HT in cortical 
development and the effects of alterations in 5-HT levels during development 
on behavior. However, as described in Chapter 3, during development 5-HT 
interacts with the catecholaminergic system and most likely also with other 
systems. We therefore have to be careful with choosing perinatal treatment 
regimens since pharmacologic agents are likely to perturb multiple systems 
and may thereby alter fundamental biological processes at a systems level. 
Although animal models have their limitations, they allow us to test these 
hypotheses and have high translational value. Future studies on human as well 
as animal models will hopefully shed more light on the mechanisms 
underlying PFC development in health and disease, and more specifically on 
the role of 5-HT and other transmitters in these processes. By performing 
basic research in animal models with high translational value, we hope to have 
contributed to the understanding of the (serotonergic) mechanisms underlying 
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PFC development that when disturbed are known to play an important role in 
the etiology of many brain disorders. 
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Summary 
 
 The prefrontal cortex is the area of the brain responsible for the 
complex control of higher cognitive functions. Correct cortical development 
depends on a series of orchestrated events that begin in the embryonic period, 
linger during the adolescent phase and result in an intricate six-layered 
structure in adulthood. The sequence of events occurring during cortical 
development covers cell proliferation, migration, differentiation, formation of 
various connections and synaptic pruning. All of these events are timely 
controlled by intrinsic and extrinsic factors, including serotonergic 
neuromodulation. Serotonin is an important neurotrophic factor during 
development that has its origin in the brainstem and serotonergic neurons 
project to diverse regions in the brain, among them the prefrontal cortex. 
Serotonin participates in the regulation of neurodevelopmental processes 
such as cell proliferation and maturation, and programmed cell death. 
Therefore, appropriate levels of serotonin should be maintained for correct 
cortical development and disturbances in serotonin levels are associated with 
a number of disorders. 
 
 Chapter 2 presents the cortical events occurring during normal 
development of the mouse brain and compares the development of various 
cortical areas. Events such as cell proliferation and the appearance of the 
cortical layers appear to coincide with the development of the serotonergic 
and dopaminergic systems and their arrival in prefrontal and somatosensory 
areas. However, frontal development was delayed when compared to the 
more dorsally located somatosensory cortex. This shows that the prefrontal 
cortex needs a longer time to develop than the somatosensory cortex, perhaps 
due to the large number of connections that the prefrontal cortex has to 
establish with other brain areas. 
  
 After examining how events normally occur during prefrontal cortical 
development, we next studied how increased cortical serotonin levels would 
affect normal development. In Chapter 3, we used rats lacking the serotonin 
transporter (5-HTT-/- rats), and found that these rats exhibited an increase in 
serotonergic innervation of the prefrontal cortex and changes in prefrontal 
cortical differentiation. Furthermore, we observed that the number of cells 
was decreased in the dorsal raphe nucleus in the brainstem, the origin of the 
serotonergic system. We further demonstrated an interrelationship between 
the serotonergic system and the dopaminergic system, since an increase in 
 
 
273 
 
also dopaminergic innervation was found in the prefrontal areas of the 5-HTT-
/- rats, in addition to a loss of cells in the origins of the dopaminergic system, 
the ventral tegmental area and substantia nigra. The cortical changes induced 
by elevated levels of serotonin were further explored in Chapter 4. Excessive 
serotonin levels were found to be associated with altered cellular migration 
and neuronal maturation, and active apoptotic pathways. These 
developmental changes caused a disorganized cortical structure at early 
postnatal age, which remained during adolescence. This was paralleled by an 
increase in anxious behavior during adolescence that persisted into adulthood. 
Together, the results demonstrate that serotonin plays a key role in embryonic 
cortical development and the need to maintain adequate levels of this 
neuromodulator.  
 
 Chapters 5 and 6 show how perinatal serotonergic drug exposure can 
alter brain development in the offspring. We tested the medication most 
commonly used to treat HIV-positive pregnant women, efavirenz (EFV). 
EFV blocks viral replication and decreases the chance of cross-infection 
between mother and child during the pre- and perinatal period to 5%. EFV 
acts as an agonist or antagonist of several receptors and transporters, 
including serotonergic ones. This medication was administered to pregnant 
rats throughout the embryonic and lactation periods, and the offspring was 
studied across a number of developmental stages. EFV exposure was 
associated with a delay in motor and reflex development, and increased 
serotonergic innervation as well as  cell death in the motor cortex. Similar 
findings were obtained in the prefrontal cortex, namely an increase in 
serotonergic and dopaminergic innervation, and a marked loss of neurons. 
Additionally, the cytoarchitectural organization of the prefrontal cortex was 
altered. Together, these chapters demonstrate that EFV changes the 
development of the immature cortex, and that these changes remain until 
adulthood and are reflected by a delay in reflex and motor development. 
Further studies are needed to fully elucidate the cellular and behavioral side 
effects caused by EFV toxicity in the immature brain. In the meantime, 
caution is required when prescribing this type of medication for pregnant 
women. 
 
 The main purpose of this thesis was to demonstrate the importance of 
serotonin for embryonic cortical development, and in what sense 
corticogenesis is vulnerable to genetically- or pharmacologically-induced 
alterations in the levels of this neurotrophic factor. Excess serotonin may 
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cause damage to the formation and correct organization of the cortex, and this 
is reflected by altered (aggressive, depressed, anxious) behavior in adulthood. 
With our studies we hope to have contributed to the understanding of the 
development of the prefrontal cortex and highlighted the care that should be 
taken when prescribing or using drugs during cortical development, 
especially in the gestational period. 
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Samenvatting 
 
 De prefrontale cortex is het gebied van de hersenen dat 
verantwoordelijk is voor de complexe controle van hogere cognitieve 
functies. Een juiste corticale ontwikkeling is afhankelijk van een reeks 
samenhangende gebeurtenissen die beginnen in de embryonale periode, 
verder veranderen tijdens de adolescente fase en resulteren in een 
ingewikkelde, zes-laagse structuur op volwassen leeftijd. De volgorde van de 
gebeurtenissen die zich voordoen tijdens de corticale ontwikkeling omvatten 
achtereenvolgens celproliferatie, -migratie, -differentiatie en -rijping, en 
vorming en snoeien van synaptische verbindingen. Al deze gebeurtenissen 
worden op de juiste tijd gereguleerd door intrinsieke en extrinsieke factoren, 
waaronder serotonerge neuromodulatie. Serotonine is een belangrijke 
neurotrofische factor in ontwikkeling die zijn oorsprong in de hersenstam 
heeft en van waaruit projecties naar verschillende regio's in de hersenen gaan, 
waaronder de prefrontale cortex. Serotonine neemt deel aan de regulatie van 
neuro-ontwikkelingsprocessen zoals celproliferatie en -rijping, en 
geprogrammeerde celdood. De juiste niveaus van serotonine zijn belangrijk 
voor een correcte corticale ontwikkeling en verstoringen in serotonineniveaus 
zijn geassocieerd met een aantal aandoeningen. 
 
 Hoofdstuk 2 laat zien hoe corticale gebeurtenissen optreden tijdens 
de normale ontwikkeling van de hersenen van de muis en vergelijkt de 
ontwikkeling van verschillende corticale gebieden. Gebeurtenissen zoals 
celproliferatie en het verschijnen van de corticale lagen lijken samen te vallen 
met de ontwikkeling van de serotonerge en dopaminerge systemen en hun 
aankomst in prefrontale en somatosensorische gebieden. Echter, de 
ontwikkeling van de prefrontale cortex was vertraagd ten opzichte van de 
meer dorsaal gelegen somatosensorische cortex. Dit geeft aan dat de 
prefrontale cortex een langere tijd nodig heeft om zich te ontwikkelen dan de 
somatosensorische cortex, misschien vanwege het grote aantal verbindingen 
die de prefrontale cortex moet maken met andere hersengebieden. 
  
 Na het onderzoek naar de processem die optreden tijdens de normale 
ontwikkeling van de prefrontale cortex, hebben we vervolgens het effect van 
verhoogde corticale serotonineniveaus op dit proces bestudeerd. In 
Hoofdstuk 3 hebben we ratten zonder de serotonine transporter (5-HTT-/- 
ratten) gebruikt, welke worden gekenmerkt door hoge extracellulaire 
serotonineniveaus in de hersenen. We vonden dat deze ratten een toename 
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van serotonerge innervatie van de prefrontale cortex en veranderingen in 
prefrontale corticale differentiatie vertoonden. Verder stelden we vast dat het 
aantal cellen was afgenomen in de dorsale raphekern in de hersenstam, waar 
de serotonerge neuronen zijn gelokaliseerd. Tevens toonden we een verband 
aan tussen het serotonerge systeem en het dopaminerge systeem, aangezien 
er ook een toename van dopaminerge innervatie werd gevonden in de 
prefrontale gebieden van de 5-HTT-/- ratten, naast een verlies van cellen in de 
gebieden waar het dopaminerge systeem is gelokaliseerd, namelijk het 
ventrale tegmentale gebied en de substantia nigra. De corticale veranderingen 
veroorzaakt door de verhoogde niveaus van serotonine werden verder 
onderzocht in Hoofdstuk 4. We vonden dat de overmaat aan serotonine de 
celmigratie, neuronale rijping en actieve apoptotische paden veranderden, wat 
vervolgens leidde tot een ongeorganiseerde corticale structuur vanaf jonge 
leeftijd tot aan volwassenheid. Dit ging gepaard met een toename van angstig 
gedrag vanaf adolescente leeftijd tot aan volwassenheid. Deze resultaten 
tonen aan dat serotonine een belangrijke rol speelt tijdens de embryonale 
neuronale ontwikkeling en geven de noodzaak aan om een adequaat 
serotonineniveau te handhaven . 
 
De Hoofdstukken 5 en 6 laten zien hoe perinatale blootstelling aan 
serotonerge geneesmiddelen de hersenontwikkeling bij de nakomelingen kan 
veranderen. We hebben het medicijn getest dat het meest wordt gebruikt om 
HIV-positieve, zwangere vrouwen te behandelen, te weten efavirenz (EFV). 
EFV blokkeert virale replicatie en vermindert de kans op kruisbesmetting 
tussen moeder en kind tijdens de pre- en perinatale periode tot 5%. EFV werkt 
als een agonist of antagonist van verschillende receptoren en transporteurs, 
waaronder serotonerge. Deze medicatie werd toegediend aan zwangere ratten 
gedurende de embryonale- en lactatieperiode, en de nakomelingen werden in 
een aantal ontwikkelingsstadia bestudeerd. Blootstelling aan EFV ging 
gepaard met een vertraging in de ontwikkeling van reflexen en motorgedrag, 
en verhoogde serotonerge innervatie en celdood in de motorische cortex. 
Vergelijkbare bevindingen werden verkregen in de prefrontale cortex, 
namelijk een toename van serotonerge en dopaminerge innervatie, en een 
duidelijk verlies van neuronen. Bovendien was de cytoarchitectonische 
organisatie van de prefrontale cortex veranderd. Tezamen tonen deze 
hoofdstukken aan dat EFV de ontwikkeling van de onvolwassen cortex 
verandert, en dat deze veranderingen aanhouden tot aan volwassen leeftijd en 
gepaard gaan met een vertraging in reflex- en motorische ontwikkeling. 
Verdere studies zijn nodig om de cellulaire en gedragsmatige bijwerkingen 
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veroorzaakt door vroege blootstelling aan EFV op te helderen. Tot die tijd is 
voorzichtigheid geboden bij het voorschrijven van dit soort medicatie voor 
zwangere vrouwen. 
 
 Het belangrijkste doel van dit proefschrift was om het belang van 
serotonine voor embryonale corticale ontwikkeling aan te tonen, en in welke 
zin corticogenese kwetsbaar is voor genetisch- of farmacologisch-
geïnduceerde veranderingen in de niveaus van deze neurotrofe factor. 
Overtollige serotonine kan de vorming en de juiste organisatie van de cortex 
beïnvloeden, en dit wordt op volwassen leeftijd weerspiegeld in veranderd 
(agressief, depressief, angstig) gedrag. Met onze studies hopen we een 
bijdrage te hebben geleverd aan het begrip van de ontwikkeling van de 
prefrontale cortex en hebben we de aandacht gevestigd op de zorg die moet 
worden besteed aan het voorschrijven of het gebruik van geneesmiddelen 
tijdens de corticale ontwikkeling, met name in de zwangerschapsperiode. 
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A smaller percentage enters business as research consultants, analysts 
or head of research and development. Fewer graduates stay in a research 
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